Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-ones and derivatives thereof as kinase inhibitors

ABSTRACT

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 11/652,852, filed Jan. 23, 2007, which claims priority to U.S. Provisional Application No. 60/761,660, filed Jan. 24, 2006, which is expressly incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to novel compounds capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction. The present invention is also directed to methods of regulating, modulating or inhibiting tyrosine kinases, whether of the receptor or non-receptor class, for the prevention and/or treatment of disorders related to unregulated tyrosine kinase signal transduction, including cell growth, metabolic, and blood vessel proliferative disorders.

2. Description of the Related Art

Protein tyrosine kinases (PTKs) comprise a large and diverse class of proteins having enzymatic activity. The PTKs play an important role in the control of cell growth and differentiation.

For example, receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response (e.g., cell division, metabolic homeostasis, and responses to the extracellular microenvironment).

With respect to receptor tyrosine kinases, it has been shown also that tyrosine phosphorylation sites function as high-affinity binding sites for SH2 (src homology) domains of signaling molecules. Several intracellular substrate proteins that associate with receptor tyrosine kinases (RTKs) have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such domain but serve as adapters and associate with catalytically active molecules. The specificity of the interactions between receptors or proteins and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. These observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

Aberrant expression or mutations in the PTKs have been shown to lead to either uncontrolled cell proliferation (e.g. malignant tumor growth) or to defects in key developmental processes. Consequently, the biomedical community has expended significant resources to discover the specific biological role of members of the PTK family, their function in differentiation processes, their involvement in tumorigenesis and in other diseases, the biochemical mechanisms underlying their signal transduction pathways activated upon ligand stimulation and the development of novel drugs.

Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular).

The RTKs comprise a large family of transmembrane receptors with diverse biological activities. The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses.

At present, at least nineteen (19) distinct RTK subfamilies have been identified. One RTK subfamily, designated the HER subfamily, is believed to be comprised of EGFR, HER2, HER3 and HER4. Ligands to the Her subfamily of receptors include epithelial growth factor (EGF), TGF-α, amphiregulin, HB-EGF, betacellulin and heregulin.

A second family of RTKs, designated the insulin subfamily, is comprised of the INS-R, the IGF-1R and the IR-R. A third family, the “PDGF” subfamily includes the PDGF α and β receptors, CSFIR, c-kit and FLK-II. Another subfamily of RTKs, identified as the FLK family, is believed to be comprised of the Kinase insert Domain-Receptor fetal liver kinase-1 (KDR/FLK-1), the fetal liver kinase 4 (FLK-4) and the fms-like tyrosine kinase 1 (flt-1). Each of these receptors was initially believed to be receptors for hematopoietic growth factors. Two other subfamilies of RTKs have been designated as the FGF receptor family (FGFR1, FGFR2, FGFR3 and FGFR4) and the Met subfamily (c-met and Ron).

Because of the similarities between the PDGF and FLK subfamilies, the two subfamilies are often considered together. The known RTK subfamilies are identified in Plowman et al, 1994, DN&P 7(6): 334-339, which is incorporated herein by reference.

The non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. At present, over twenty-four individual non-receptor tyrosine kinases, comprising eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified. At present, the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis. A more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, 1993, Oncogen 8: 2025-2031, which is incorporated herein by reference.

Many of the tyrosine kinases, whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways leading to cellular signal cascades leading to pathogenic conditions, including cancer, psoriasis and hyper immune response.

In view of the surmised importance of PTKs to the control, regulation and modulation of cell proliferation the diseases and disorders associated with abnormal cell proliferation, many attempts have been made to identify receptor and non-receptor tyrosine kinase “inhibitors” using a variety of approaches, including the use of mutant ligands (U.S. Pat. No. 4,966,849), soluble receptors and antibodies (PCT Application No. WO 94/10202; Kendall & Thomas, 1994, Proc. Nat'l Acad. Sci. 90: 10705-09; Kim, et al, 1993, Nature 362: 841-844), RNA ligands (Jellinek, et al, Biochemistry 33: 10450-56); Takano, et al, 1993, Mol. Bio. Cell 4:358 A; Kinsella, et al, 1992, Exp. Cell Res. 199: 56-62; Wright, et al, 1992, J. Cellular Phys. 152: 448-57) and tyrosine kinase inhibitors (PCT Application Nos. WO 94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Pat. No. 5,330,992; Mariani, et al, 1994, Proc. Am. Assoc. Cancer Res. 35: 2268).

More recently, attempts have been made to identify small molecules which act as tyrosine kinase inhibitors. For example, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT Application No. WO 92/20642), vinylene-azaindole derivatives (PCT Application No. WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (U.S. Pat. No. 5,330,992) have been described generally as tyrosine kinase inhibitors. Styryl compounds (U.S. Pat. No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Pat. No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT Application No. WO 94/03427), tricyclic polyhydroxylic compounds (PCT Application No. WO 92/21660) and benzylphosphonic acid compounds (PCT Application No. WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer.

The identification of effective small compounds which specifically inhibit signal transduction by modulating the activity of receptor and non-receptor tyrosine kinases to regulate and modulate abnormal or inappropriate cell proliferation is therefore desirable and one object of this invention.

In addition, certain small compounds are disclosed in U.S. Pat. Nos. 5,792,783; 5,834,504; 5,883,113; 5,883,116 and 5,886,020 as useful for the treatment of diseases related to unregulated TKS transduction. See also U.S. patent application Ser. No. 10/256,381; WO 02/29630; U.S. Pat. No. 6,765,012, Ser. No. 10/886,213; U.S. Pat. No. 6,541,504 and U.S. Pat. No. 6,747,025. These patents are hereby incorporated by reference in its entirety for the purpose of disclosing starting materials and methods for the preparation thereof, screens and assays to determine a claimed compound's ability to modulate, regulate and/or inhibit cell proliferation, indications which are treatable with said compounds, formulations and routes of administration, effective dosages, etc.

BRIEF SUMMARY OF THE INVENTION

The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated TKS transduction, including cell proliferative diseases such as cancer, atherosclerosis, restenosis, metabolic diseases such as diabetes, inflammatory diseases such as psoriasis and chronic obstructive pulmonary disease, vascular proliferative disorders such as diabetic retinopathy, age-related macular degeneration and retinopathy of prematurity, autoimmune diseases and transplant rejection.

In one illustrative embodiment, the compounds of the present invention have the following general formulae:

-   -   wherein     -   X is O or S;     -   Y is selected from the group consisting of O, S, NR³ and CR³R⁴;         and wherein the ring system represented by A in formula V below,         is a 5 or 6 membered aryl group, e.g. a carbocyclic aryl or a         heterocyclic aryl

wherein said aryl group is selected from the group consisting of:

and wherein the ring system represented by B in formula VI, above, is a five membered unsaturated heterocyclic ring wherein said unsaturated heterocyclic ring is selected from the group consisting of:

wherein Z is selected from the group consisting of [C(R²)₂]_(c), O, NR³ and S;

and wherein the ring system represented by C in formula VII, above, is a 5 or 6 membered aryl group e.g. a carbocyclic aryl or heterocyclic aryl, wherein said aryl group is selected from the group consisting of:

wherein R¹ is selected from the group consisting of halogen, aryl, e,g, carbocyclic and heterocyclic aryl, C₁ to C₈ alkyl, C₂ to C₈ alkenyl; CF₃, OCF₃, OCF₂H, S(O)_(f)R², (CR³R⁴)_(d)C(O)OR², O(CR³R⁴)_(e)C(O)OR², NR²(CR³R⁴)_(d)C(O)R², NR²(CR³R⁴)_(d)C(O)OR², OP(O)(OR²)₂, OC(O)OR², OCH₂O, NR²(CH₂)_(e)N(R²)₂, O(CH₂)_(e)N(R²)₂, (CR³R⁴)_(d)CN, O(CR³R⁴)_(e)CN, (CR³R⁴)_(d)Ar, NR²(CR³R⁴)_(d)Ar, O(CR³R⁴)_(d)Ar, S(O)_(f)(CR³R⁴)_(d)Ar, (CR³R⁴)_(d)SO₂R², (CR³R⁴)_(d)C(O)N(R²)₂, NR²(CR³R⁴)_(d)C(O)N(R²)₂, O(CR³R⁴)_(d)C(O)N(R²)₂, C(O)(CR²CR³)_(d)Ar, S(O)_(f)(CR³R⁴)_(e)C(O)N(R²)₂, (CR³R⁴)_(d)OR², NR²(CR³R⁴)_(e)OR², O(CR³, R⁴)_(e)OR², S(O)_(f)(CR³R⁴)_(d)OR², C(O)(CR³R⁴)_(d)R³, NR²C(O)(CR³R⁴)_(d)R³, OC(O)(CR³R⁴)_(d)N(R²)₂, C(O)(CR³R⁴)_(d)N(R²)₂′NR²C(O)(CR³R⁴)_(d)N(R²)₂, OC(O)(CR³R⁴)_(d)N(R²)₂, (CR³R⁴)_(d)R³, NR²(CR³R⁴)_(d)R³, O(CR³R⁴)_(d)R³, S(O)_(f)(CR³R⁴)_(d)R³, (CR³R⁴)_(d)N(R²)₂, NR²(CR³R⁴)_(e)N(R²)₂, O(CR³R⁴)_(e)N(R²)₂, S(O)_(f)(CR³R⁴)_(d)N(R²)₂, N(R⁵)₂, OR⁵, C(O)R⁵ and S(O)_(f)R⁵; R² is selected from the group consisting of hydrogen, C₁ to C₈ alkyl, C₁ to C₈ alkenyl, C₁ to C₈ alkynyl, C₁ to C₄ alkylol, lower alkylphenyl, phenyl, (CR³R⁴)_(d)Ar, (CR³R⁴)_(d)C(O)OR⁶, (CR³R⁴)_(d)SO₂R⁶, (CR³R⁴)_(d)OR⁶, (CR³R⁴)_(d)OSO₂R⁶, (CR³R⁴)_(d)P(O)(OR⁶)₂, (CR³R⁴)_(d)R⁶, (CR³R⁴)_(e)N(R⁶)₂ and (CR³R⁴)_(e)NR⁶C(O)N(R⁶)₂; wherein N(R⁶)₂ may form a 3-7 membered heterocyclic ring, for example, pyrrolidine, 3-fluoropyrrolidine, piperidine, 4-fluoropiperidine, N-methylpiperazine, morpholine, 2,6-dimethylmorpholine, thiomorpholine, and wherein said heterocyclic ring may be substituted with one or more of R³; and [C(R²)₂]_(c) may form a 3-7 membered carbocyclic or heterocyclic ring; R is selected from the group consisting of halogen, C₁ to C₈ alkyl, C₂ to C₈ conjugated alkenyl, (CR²═CR²)_(d)CON(R²)₂, CF₃, OCF₃, OCF₂H, (CR³R⁴)_(d)CN, NR²(CR³R⁴)_(e)CN, O(CR³R⁴)_(e)CN, S(O)_(f)R², (CR³R⁴)_(d)C(O)OR², NR²(CR³R⁴)_(d)C(O)OR², O(CR³R⁴)_(d)C(O)OR², S(O)_(f)(CR³R⁴)_(d)C(O)OR², (CR³R⁴)_(d)Ar, NR²(CR³R⁴)_(d)Ar, O(CR³R⁴)_(d)Ar, S(O)_(f)(CR³R⁴)_(d)Ar, (CR³R⁴)_(d)SO₂R², NR²(CR³R⁴)_(d)S(O)_(f)R², O(CR³R⁴)_(d)S(O)_(f)R², S(O)_(f)(CR³R⁴)_(e)S(O)_(f)R², (CR³R⁴)_(d)C(O)N(R²)₂, NR²(CR³R⁴)_(d)C(O)N(R²)₂, O(CR³R⁴)_(d)C(O)N(R²)₂, S(O)_(f)(CR³R⁴)_(e)C(O)N(R²)₂, (CR³R⁴)_(d)OR², NR² (CR³R⁴)_(e)OR², O(CR³R⁴)_(e)OR², S(O)_(f)(CR³R⁴)_(d)OR², (CR³R⁴)_(d)OSO₂R², NR² (CR³R⁴)_(e)OSO₂R², O(CR³R⁴)_(e)OSO₂R², S(O)_(f)(CR³R⁴)_(e)OSO₂R²(CR³R⁴)_(d)P(O)(OR²)₂, NR² (CR³O_(d)P(O)(OR²)₂, O(CR³R⁴)_(d)P(O)(OR²)₂, S(O)_(f)(CR³R⁴)_(e)P(O)(OR²)₂, C(O)(CR³R⁴)_(d)R³, NR²C(O)(CR³R⁴)_(d)R³, OC(O)(CR³R⁴)_(d)N(R²)₂, C(O)(CR³R⁴)_(d)N(R²)₂, NR²C(O)(CR³R⁴)_(d)N(R²)₂, OC(O)(CR³R⁴)_(d)N(R²)₂, (CR³R⁴)_(d)R³, NR²(CR³R⁴)_(d)R³, O(CR³R⁴)_(d)R³, S(O)_(f)(CR³R⁴)_(d)R³, HNC(O)R², HN—C(O)OR², (CR³R⁴)_(d)N(R²)₂, NR²(CR³R⁴)_(e)N(R²)₂, O(CR³R⁴)_(e)N(R²)₂, S(O)_(f) (CR³R⁴)_(d)N(R²)₂, OP(O)(OR²)₂, OC(O)OR², OCH₂O, HN—CH═CH, —N(COR²)CH₂CH₂, HC═N—NH, N═CH—S, (CR³R⁴)_(d)C═C(CR³R⁴)_(d)R², (CR³R⁴)_(d)C═C(CR³R⁴)_(d)OR², (CR³R⁴)_(d)C═C(CR³R⁴)_(d)N(R²)₂, (CR³R⁴)_(d)CC(CR³R⁴)_(d)R², (CR³R⁴)_(d)CC(CR³R⁴)_(e)OR², (CR³R⁴)_(d)CC(CR³R⁴)_(e)N(R²)₂, (CR³R⁴)_(d)C(O)(CR³R⁴)_(d)R², (CR³R⁴)_(d)C(O)(CR³R⁴)_(d)OR² and (CR³R⁴)_(d)C(O)(CR³R⁴)_(d)N(R²)₂; R³ and R⁴ may be selected from the group consisting of H, F, hydroxy, and C₁-C₄ alkyl or CR³R⁴ may represent a carbocyclic or heterocyclic ring of from 3 to 6 carbons or alternatively, (CR³R⁴)_(d) and (CR³R⁴)_(e) may form a 3-7 membered carbocyclic or heterocyclic ring, preferably R³ and R⁴ are H, F, CH₃ or hydroxy; R⁵ is Ar—R¹ _(b), wherein Ar is 5-7 membered carbocyclic aryl or 5-7 membered heterocyclic aryl; R⁶ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, hydroxylmethyl and phenyl; R⁷ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, (R²CCR²)_(a)CN and aryl; a is 0 or an integer of from 1 to 3; b is 0 or an integer of from 1 to 2; c is an integer of from 1 to 2; d is 0 or an integer of from 1 to 5; e is an integer of from 1 to 4; f is 0 or an integer of from 1 to 2; g is an integer of from 2 to 5, and further provided said alkyl or aryl radicals may be substituted with one or two halo, hydroxy, lower alkyloxy, lower alkyl amino or cycloalkylamino radicals wherein the cycloalkyl ring can include an enchained oxygen, sulfur or additional nitrogen atom and may be substituted with one or two halo or lower alkyl radicals; and pharmaceutically acceptable salts thereof.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

Illustrative routes to compounds of the present invention are illustrated in Schemes 1 through 11 set forth in the Drawing Figures and are not intended to limit the scope of the invention.

DETAILED DESCRIPTION OF THE INVENTION

In particular, the compounds of the present invention may be selected from the group of compounds set forth in the Tables below.

TABLE 1 3-[4-amino-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one derivatives Example # Chemical Structure Chemical Name FW 1

6-Fluoro-3-{4-[(2-methoxy-ethyl)- methyl-amino]-5H-furan-2-ylidene}- 1,3-dihydro-indol-2-one 304.319 2

6-Fluoro-3-[4-(4-methyl-piperazin- 1-yl)-5H-furan-2-ylidene]-1,3- dihydro-indol-2-one 315.346 3

6-Fluoro-3-(4-{4-[2-(2-hydroxy- ethoxy)-ethyl]-piperazin-1-yl}-5H- furan-2-ylidene)-1,3-dihydro- indole-2-one 389.425 4

6-Fluoro-3-[4-(3-hydroxy- piperidin-1-yl)-5H-furan-2- ylidene]-1,3-dihydro-indol-2-one 316.33  5

6-Fluoro-3-[4-(4-hydroxy- piperidin-1-yl)-5H-furan-2- ylidene]-1,3-dihydro-indol-2-one 316.33  6

6-Fluoro-3-{4-[2-(2-hydroxy- ethoxy)-ethylamino]-5H-furan-2- ylidene}-1,3-dihydro-indol-2-one 320.318 7

3-[4-(3-Diethylamino- propylamino)-5H-furan-2- ylidene]-6-fluoro-1,3-dihydro- indol-2-one 345.416 8

6-Fluoro-3-[4-(2-morpholin-4-yl- ethylamino)-5H-furan-2-ylidene]- 1,3-dihydro-indol-2-one 345.372 9

6-Fluoro-3-(4-morpholin-4-yl-5H- furan-2-ylidene)-1,3-dihydro- indol-2-one 302.303 10 

6-Fluoro-3-[4-(3-morpholin-4-yl- propylamino)-5H-furan-2- ylidene]-1,3-dihydro-indol-2-one 359.399

TABLE 2 3-[4-amino-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one derivatives Example # Chemical Structure Chemical Name FW 11

3-{4-[4-(3-Diethylamino-propoxy)- 3-fluoro-phenylamino]-5H-furan-2- ylidene}-6-fluoro-1,3-dihydro-indol- 2-one 455.502 12

3-{4-[4-(2-Diethylamino-ethoxy)- phenyl-amino]-5H-furan-2-ylidene}- 6-fluoro-1,3-dihydro-indol-2-one 423.485

TABLE 3 3-[5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one derivatives Example # Chemical Structure Chemical Name FW 13

3-{3-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,5- dihydrofuran-3-yl]-1H-pyrrol-1- yl}propyl methanesulfonate 418.443 14

(3E)-6-fluoro-3-{4-[1-(3-morpholin- 4-ylpropyl)-1H-pyrrol-3-yl]furan- 2(5H)-ylidene)-1,3-dihydro-2H- indol-2-one 409.459 15

(3E)-6-fluoro-3-{4-[1-(3- hydroxypropyl)-1H-pyrrol-3- yl]furan-2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 340.352 16

(3E)-3-{4-[1-(3-{[tert- butyl(dimethyl)silyl)oxy}propyl)-1H- pyrrol-3-yl]furan-2(5H)-ylidene}-6- fluoro-1,3-dihydro-2H-indol-2-one 454.615 17

(3E)-3-[4-(1-benzothien-3-yl)furan- 2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 349.384 18

(3E)-6-fluoro-3-{4-[4-(3- hydroxypropyl)phenyl]furan-2(5H)- ylidene}-1,3-dihydro-2H-indol-2- one 351.375 19

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,5- dihydrofuran-3-yl]-N-methoxy-N- methylbenzamide 380.373 20

methyl 3-{4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,5-dihydrofuran-3- yl]phenyl}propanoate 379.385 21

(3E)-6-fluoro-3-{4-[4- (methoxymethyl)phenyl]furan- 2(5H)-ylidene}-1,3-dihydro-2H- indol-2-one 337.348 22

(3E)-6-fluoro-3-[4-(1-methyl-1H- indol-5-yl)furan-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 346.359 23

methyl (2E)-3-{4-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro-3H-indol-3- ylidene)-2,5-dihydrofuran-3- yl]phenyl}acrylate 377.369 24

N-{4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,5- dihydrofuran-3- yl]phenyl}methanesulfonamide 386.401 25

N-{4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,5- dihydrofuran-3-yl]phenyl}acetamide 350.348 26

(3E)-6-fluoro-3-[4-(1H-indol-5- yl)furan-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 332.333 27

(3E)-3-[4-(1,3-benzodioxol-5- yl)furan-2(5H)-ylidene]-6-fluoro- 1,3-dihydro-2H-indol-2-one 337.305 28

N-{3-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,5- dihydrofuran-3-yl]phenyl}acetamide 350.348 29

(3E)-3-[4-(4-chlorophenyl)furan- 2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 327.741 30

(3E)-6-fluoro-3-[4-(4- fluorophenyl)furan-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 311.286 31

methyl 4-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,5-dihydrofuran-3-yl]-1H-pyrrole- 2-carboxylate 340.309 32

1-tert-butyl 2-methyl 4-[(5E)-5-(6- fluoro-2-oxo-1,2-dihydro-3H-indol- 3-ylidene)-2,5-dihydrofuran-3-yl]- 1H-pyrrole-1,2-dicarboxylate 440.425 33

(3E)-3-(3,3′-bifuran-5(2H)- ylidene)-6-fluoro-1,3-dihydro-2H- indol-2-one 283.257 34

(3E)-6-fluoro-3-[4-(1H-pyrrol-3- yl)furan-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 282.273 35

(3E)-6-fluoro-3-{4-[1- (triisopropylsilyl)-1H-pyrrol-3- yl]furan-2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 438.616 36

(3E)-6-fluoro-3-[4-(1H-pyrrol-2- yl)furan-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 282.273 37

tert-butyl 2-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,5-dihydrofuran-3-yl]-1H-pyrrole- 1-carboxylate 382.389 38

(3E)-6-fluoro-3-[4-(3-thienyl)furan- 2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 299.324 39

3-{4-[5-(6-Fluoro-2-oxo-1,2- dihydro-indol-3-ylidene)-2,5-dihydro- furan-3-yl]-phenyl}propionic acid 365.358 40

4-[5-(6-Fluoro-2-oxo-1,2-dihydro- indol-3-ylidene)-2,5-dihydro-furan-3- yl]-benzoic acid methyl ester 351.332 41

6-Fluoro-3-(4-styryl-5H-furan-2- ylidene)-1,3-dihydro-indol-2-one 319.334 42

3-[4-(4-Bromo-phenyl)-5H-furan-2- ylidene]-6-fluoro-1,3-dihydro-indol- 2-one 372.192 43

6-Fluoro-3-[4-(3-methoxy-phenyl)- 5H-furan-2-ylidene]-1,3-dihydro- indol-2-one 323.322 44

6-Fluoro-3-{4-[4-(2-morpholin-4-yl- ethoxy)-phenyl]-5H-furan-2- ylidene}-1,3-dihydro-indol-2-one 422.454 45

3-[4-(4-Dimethylmaino-phenyl)- 5H-furan-2-ylidene]-6-fluoro-1,3- dihydro-indol-2-one 336.364 46

6-Fluoro-3-[4-(4-methoxy-phenyl)- 5H-furan-2-ylidene]-1,3-dihydro- indol-2-one 323.322

TABLE 4 [5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one derivatives Example # Chemical Structure Chemical name FW 47

(3E)-6-bromo-3-[5,5-dimethyl-4- (1H-pyrrol-3-yl)furan-2(5H)- ylidene]-1,3-dihydro-2H-indol-2- one 371.233 48

(3E)-6-bromo-3-{5,5-dimethyl-4-[1- (triisopropylsilyl)-1H-pyrrol-3- yl]furan-2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 527.576 49

(3E)-6-fluoro-3-(2′,2′,5-trimethyl- 2,3′-bifuran-5′(2′H)-ylidene)-1,3- dihydro-2H-indol-2-one 325.337 50

(3E)-3-[5,5-dimethyl-4-(4-methyl- 2-phenyl-1,3-thiazol-5-yl)furan- 2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 418.49 51

(3E)-3-{5,5-dimethyl-4-[2-(4- methylpiperazin-1-yl)pyridin-4- yl]furan-2(5H)-ylidene}-6-fluoro- 1,3-dihydro-2H-indol-2-one 420.486 52

(3E)-3-[4-(6-aminopyridin-3-yl)- 5,5-dimethylfuran-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol-2- one 337.352 53

ethyl 5-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]nicotinate 394.4 54

(3E)-6-fluoro-3-[4-(5- methoxypyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 352.363 55

methyl 5-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]-1-benzothiophene-2- carboxylate 435.473 56

N-[2-(dimethylamino)ethyl]-3- [(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]benzamide 435.496 57

(3E)-3-[5,5-dimethyl-4-{4-[(4- methylpiperazin-1- yl)carbonyl]phenyl}furan-2(5H)- ylidene]-6-fluoro-1,3-dihydro-2H- indol-2-one 447.507 58

(3E)-6-fluoro-3-[4-(3-fluoro-4- methoxyphenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 369.365 59

(3E)-3-[4-(1-benzothien-5-yl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 377.437 60

(3E)-3-{5,5-dimethyl-4-[4- (morpholin-4- ylmethyl)phenyl]furan-2(5H)- ylidene}-6-fluoro-1,3-dihydro-2H- indol-2-one 420.482 61

(3E)-3-[4-{4- [(dimethylamino)methyl]phenyl}- 5,5-dimethylfuran-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol-2- one 378.445 62

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]-2- methoxyphenyl acetate 409.411 63

(3E)-3-[5,5-dimethyl-4-(3- morpholin-4-ylphenyl)furan-2(5H)- ylidene]-6-fluoro-1,3-dihydro-2H- indol-2-one 406.455 64

(3E)-6-fluoro-3-[4-(4-hydroxy-3- methoxyphenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 367.374 65

(3E)-6-fluoro-3-[4-(1H-indazol-5- yl)-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol-2- one 361.374 66

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]benzamide 364.374 67

(3E)-3-(2′,2′-dimethyl-2,3′-bifuran- 5′(2′H)-ylidene)-6-fluoro-1,3- dihydro-2H-indol-2-one 311.311 68

(3E)-3-[4-(1-benzofuran-2-yl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 361.37 69

(3E)-3-(2,2-dimethyl-3,3′-bifuran- 5(2H)-ylidene)-6-fluoro-1,3- dihydro-2H-indol-2-one 311.311 70

(3E)-3-[4-(1-benzothien-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 377.437 71

(3E)-3-[5,5-dimethyl-4-(3- thienyl)furan-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 327.378 72

(3E)-3-[5,5-dimethyl-4-(5-phenyl- 2-thienyl)furan-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 403.475 73

(3E)-3-[4-(5-acetyl-2-thienyl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 369.414 74

(3E)-3-[4-(1-benzothien-2-yl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 377.437 75

(3E)-3-[4-(5-chloro-2-thienyl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 361.823 76

tert-butyl 2-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]-1H-pyrrole-1-carboxylate 410.443 77

(3E)-3-[5,5-dimethyl-4-(1-methyl- 1H-indol-2-yl)furan-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol-2- one 374.413 78

(3E)-3-[5,5-dimethyl-4-{1-[(4- methylphenyl)sulfonyl]-1H-indol-3- yl}furan-2(5H)-ylidene]-6-fluoro- 1,3-dihydro-2H-indol-2-one 514.575 79

(3E)-6-fluoro-3-[4-(2-fluoropyridin- 4-yl)-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol-2- one 340.328 80

(3E)-6-fluoro-3-[4-(3-fluoropyridin- 4-yl)-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol-2- one 340.328 81

(3E)-3-[4-(2-chloropyridin-4-yl)- 5,5-dimethylfuran-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol-2- one 356.783 82

(3E)-6-fluoro-3-[4-(2- fluoroquinolin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 390.387 83

(3E)-6-fluoro-3-(4-isoquinolin-4-yl- 5,5-dimethylfuran-2(5H)-ylidene)- 1,3-dihydro-2H-indol-2-one 372.397 84

(3E)-6-fluoro-3-[4-(2- methoxypyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 352.363 85

(3E)-6-fluoro-3-[4-(6-fluoropyridin- 3-yl)-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol-2- one 340.328 86

(3E)-6-fluoro-3-[4-(2-fluoropyridin- 3-yl)-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol-2- one 340.328 87

(3E)-3-[4-(6-chloropyridin-3-yl)- 5,5-dimethylfuran-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol-2- one 356.783 88

(3E)-3-(5,5-dimethyl-4-quinolin-3- ylfuran-2(5H)-ylidene)-6-fluoro- 1,3-dihydro-2H-indol-2-one 372.397 89

(3E)-6-fluoro-3-[4-(6- methoxypyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 352.363 90

(3E)-6-fluoro-3-[4-(4- methoxypyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 352.363 91

(3E)-3-(5,5-dimethyl-4-pyridin-3- ylfuran-2(5H)-ylidene)-6-fluoro- 1,3-dihydro-2H-indol-2-one 322.337 92

(3E)-3-[4-(4-benzoylphenyl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 425.457 93

(2E)-3-{3-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]phenyl}acrylonitrile 372.397 94

(3E)-6-fluoro-3-{4-[4-(3- hydroxypropyl)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 379.429 95

(3E)-6-fluoro-3-[4-(1H-indazol-6- yl)-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol-2- one 361.374 96

(3E)-3-[4-(3-amino-4- methoxyphenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 366.39 97

methyl ({4-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]benzoyl}amino)acetate 436.437 98

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]-N- methoxy-N-methylbenzamide 408.427 99

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]-N- methoxybenzamide 394.4 100

ethyl 3-{4-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]phenyl}propanoate 421.466 101

methyl 3-{3-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]phenyl}propanoate 407.439 102

methyl 3-{4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]phenyl}propanoate 407.439 103

(3E)-3-(5,5-dimethyl-4-quinoxalin- 6-ylfuran-2(5H)-ylidene)-6-fluoro- 1,3-dihydro-2H-indol-2-one 373.385 104

(3E)-3-[4-(3-chloro-4- methoxyphenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 385.82 105

(3E)-3-[4-(1-benzofuran-5-yl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 361.37 106

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]-N- methylbenzamide 378.401 107

(3E)-6-fluoro-3-{4-[4- (methoxymethyl)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 365.402 108

methyl {4-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]phenyl}carbamate 394.4 109

5-{4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]phenyl}imidazolidine-2,4-dione 419.41 110

{4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]phenyl}acetic acid 379.385 111

(3E)-3-[5,5-dimethyl-4-(1-methyl- 1H-indol-5-yl)furan-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol-2- one 374.413 112

(3E)-3-{5,5-dimethyl-4-[4- (morpholin-4- ylcarbonyl)phenyl]furan-2(5H)- ylidene}-6-fluoro-1,3-dihydro-2H- indol-2-one 434.465 113

(3E)-3-{5,5-dimethyl-4-[4- (pyrrolidin-1- ylcarbonyl)phenyl]furan-2(5H)- ylidene}-6-fluoro-1,3-dihydro-2H- indol-2-one 418.466 114

2-fluoro-4-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]benzonitrile 364.35 115

2-fluoro-5-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]benzonitrile 364.35 116

(3E)-3-(5,5-dimethyl-4-quinolin-6- ylfuran-2(5H)-ylidene)-6-fluoro- 1,3-dihydro-2H-indol-2-one 372.397 117

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]- N,N-dimethylbenzamide 392.428 118

N-{3-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]phenyl}methanesulfonamide 414.455 119

methyl (2E)-3-{3-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]phenyl}acrylate 405.423 120

N-{4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]phenyl}methanesulfonamide 414.455 121

N-{4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]phenyl}acetamide 378.401 122

(3E)-3-{4-[3-(aminomethyl)phenyl]- 5,5-dimethylfuran-2(5H)-ylidene}- 6-fluoro-1,3-dihydro-2H-indol-2- one 350.391 123

methyl 3-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]benzoate 379.385 124

2-amino-3-{4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3- yl]phenyl}propanoic acid 408.427 125

(3E)-3-{4-[4-(aminomethyl)phenyl]- 5,5-dimethylfuran-2(5H)-ylidene}- 6-fluoro-1,3-dihydro-2H-indol-2- one 350.391 126

(3E)-3-{5,5-dimethyl-4-[4- (methylsulfonyl)phenyl]furan- 2(5H)-ylidene}-6-fluoro-1,3- dihydro-2H-indol-2-one 399.44 127

(3E)-3-{5,5-dimethyl-4-[3- (methylthio)phenyl]furan-2(5H)- ylidene}-6-fluoro-1,3-dihydro-2H- indol-2-one 367.442 128

(3E)-6-fluoro-3-[4-(1H-indol-5-yl)- 5,5-dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 360.386 129

(3E)-3-{4-[3- (dimethylamino)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}-6- fluoro-1,3-dihydro-2H-indol-2-one 364.418 130

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-2H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]benzonitrile 346.359 131

(3E)-6-fluoro-3-{4-[3- (hydroxymethyl)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 351.375 132

(3E)-3-[4-(3-acetylphenyl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 363.386 133

(3E)-3-[4-(4-aminophenyl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 336.364 134

(3E)-3-[5,5-dimethyl-4-[4- (trifluoromethoxy)phenyl]furan- 2(5H)-ylidene}-6-fluoro-1,3- dihydro-2H-indol-2-one 405.345 135

(3E)-6-fluoro-3-[4-(3- hydroxyphenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 337.348 136

(3E)-3-[4-(1,3-benzodioxol-5-yl)- 5,5-dimethylfuran-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol-2-one 365.358 137

(3E)-6-fluoro-3-{4-[4- (hydroxymethyl)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 351.375 138

(3E)-3-[5,5-dimethyl-4-(4- vinylphenyl)furan-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 347.387 139

(3E)-6-fluoro-3-[4-(3-fluorophenyl)- 5,5-dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 339.34 140

N-{3-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]phenyl}acetamide 378.401 141

(3E)-3-[4-(3-chlorophenyl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 355.794 142

(3E)-3-{5,5-dimethyl-4-[4- (methylthio)phenyl]furan-2(5H)- ylidene}-6-fluoro-1,3-dihydro-2H- indol-2-one 367.442 143

(3E)-3-[4-(4-chlorophenyl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 355.794 144

(3E)-6-fluoro-3-[4-(4-fluorophenyl)- 5,5-dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 339.34 145

(3E)-3-[5-(1-benzothien-3-yl)furan- 2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 349.384 146

3-[5,5-Dimethyl-4-(6-morpholin-4- yl-pyridin-3-yl)-5H-furan-2-ylidene]- 6-fluoro-1,3-dihydro-indole-2-one 407.443 147

(3E)-3-[5,5-dimethyl-4-(1H-pyrrol- 3-yl)furan-2(5H)-ylidene]-6-fluoro- 1,3-dihydro-2H-indol-2-one 310.327 148

(3E)-3-{5,5-dimethyl-4-[1- (triisopropylsilyl)-1H-pyrrol-3- yl]furan-2(5H)-ylidene}-6-fluoro- 1,3-dihydro-2H-indol-2-one 466.669 149

N-(2-Dimethylamino-ethyl)-4-[5-(6- fluoro-2-oxo-1,2-dihydro-indol-3- ylidene)-2,2-dimethyl-2,5-dihydro- furan-3-yl]-benzamide 435.496 150

3-{4-[5-(6-Fluoro-2-oxo-1,2- dihydro-indol-3-ylidene)-2,2- dimethyl-2,5-dihydro-furan-3-yl]- phenyl}-acrylic acid methyl ester 405.423 151

3-[4-(3-Amino-phenyl)-5,5- dimethyl-5H-furan-2-ylidene]-6- fluoro-1,3-dihydro-indol-2-one 336.364 152

3-(5,5-Dimethyl-4-pyridin-4-yl-5H- furan-2-ylidene)-6-fluoro-1,3- dihydro-indol-2-one 322.337 153

6-Fluoro-3-[4-(4-hydroxy-phenyl)- 5,5-dimethyl-5H-furan-2-ylidene]- 1,3-dihydro-indol-2-one 337.348 154

(3E)-6-(4-methoxyphenyl)-3-[4-(4- methoxyphenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 439.509 155

(3E)-6-fluoro-3-{4-[(3- hydroxyphenyl)ethynyl]-5,5- dimethylfuran-2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 361.37 156

(3E)-3-{4-[4- (dimethylamino)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}-6- fluoro-1,3-dihydro-2H-indol-2-one 364.418 157

(3E)-3-{4-[4- (dimethylamino)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}-6- fluoro-1,3-dihydro-2H-indol-2-one 364.418 158

(3E)-6-fluoro-3-[4-(4- methoxyphenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 351.375

TABLE 5 [5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one benzamide derivatives Ex - am- ple # Chemical Structure Chemical Name FW 159

(3E)-6-fluoro-3-[4-{4-[(4-hydroxy- piperidin-1-yl)carbonyl]phenyl}- 5,5-dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 448.4915 160

N-[2-(diethylamino)ethyl]-4-[(5E)- 5-(6-fluoro-2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]benzamide 463.55 161

(3E)-6-fluoro-3-{4-[4-({4-[2-(2- hydroxyethoxy)ethyl]piperazin-1-yl} carbonyl)phenyl]-5,5-dimethylfuran- 2(5H)-ylidene}-1,3-dihydro-2H- indol-2-one 521.5858 162

(3E)-3-[4-(4-{[(2R,3R,4R)-3,4- dihydroxy-2-(hydroxymethyl) pyrrolidin-1-yl]carbonyl}phenyl)- 5,5-dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol-2-one 480.4895 163

(3E)-6-fluoro-3-[4-(4-{[4-(2- hydroxyethyl)piperazin-1-yl] carbonyl}phenyl)-5,5- dimethylfuran- 2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 477.5332 164

6-Fluoro-3-[4-[4-(3-hydroxy- pyrrolidine-1-carbonyl)-phenyl]-5,5- dimethyl-5H-furan-(2E)-ylidene]- 1,3-dihydro-indol-2-one 434.4647 165

3-[5,5-Dimethyl-4-[4-((3R,4R,5S)- 3,4,5-trihydroxy-piperidine-1- carbonyl)-phenyl]-5H-furan-(2E)- ylidene]-6-fluoro-1,3-dihydro-indol- 2-one 480.4895 166

3-[5,5-Dimethyl-4- [4-((2S,3R,4S,5R)-3,4,5- trihydroxy-2-methyl-piperidine- 1-carbonyl)-phenyl]-5H-furan- (2E)-ylidene]-6-fluoro-1,3- dihydro-indol-2-one 494.5163 167

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5- dihydrofuran-3-yl]-N-(2-{2-[2-(2- hydroxyethoxy)ethoxy]ethoxy} ethyl)benzamide 540.5847 168

(3E)-5-fluoro-3-[4-(4-{[4-(2- hydroxyethyl)piperazin-1-yl] carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 477.5332 169

(3E)-3-[4-(4-{[(3S,4S)-3,4- dihydroxypyrrolidin-1-yl] carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol- 2-one 450.4637 170

(3E)-3-[4-(4-{[(3S,4S)-3,4- dihydroxypyrrolidin-1-yl] carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]-5- fluoro-1,3-dihydro-2H-indol-2- one 450.4637 171

methyl (3E)-3-{5,5-dimethyl-4-[4- (pyrrolidin-1-ylcarbonyl)phenyl] furan-2(5H)-ylidene}-2- oxoindoline-5-carboxylate 458.5114 172

(3E)-3-{5,5-dimethyl-4-[4- (pyrrolidin-1-ylcarbonyl)phenyl] furan-2(5H)-ylidene}-2- oxoindoline-5-carboxylic acid 444.4846 173

methyl (3E)-3-{5,5-dimethyl-4-[4- (pyrrolidin-1-ylcarbonyl)phenyl] furan-2(5H)-ylidene}-2- oxoindoline-6-carboxylate 458.5114 174

(3E)-3-{5,5-dimethyl-4-[4- (pyrrolidin-1-ylcarbonyl)phenyl] furan-2(5H)-ylidene}-2- oxoindoline- 6-carboxylic acid 444.4846 175

methyl (3E)-3-[4-(4-{[4-(2- hydroxyethyl)piperazin-1-yl] carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]-2- oxoindoline-6-carboxylate 517.5789 176

(3E)-3-{5,5-dimethyl-4-[4- (pyrrolidin-1-ylcarbonyl)phenyl] furan-2(5H)-ylidene}-N-methyl-2- oxoindoline-6-carboxamide 457.5273 177

methyl (3E)-3-{5,5-dimethyl-4-[4- (pyrrolidin-1-ylcarbonyl)phenyl] furan-2(5H)-ylidene}-5-fluoro-2- oxoindoline-6-carboxylate 476.5015 178

methyl (3E)-3-[4-(4-{[(2,3- dihydroxypropyl)(methyl)amino] carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]-5- fluoro-2-oxoindoline-6- carboxylate 510.5153 179

4-[(5E)-5-(5,6-difluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]- N-(2,3-dihydroxypropyl)-N- methylbenzamide 470.47 180

(3E)-5,6-difluoro-3-[4-(4-{[4-(2- hydroxyethyl)piperazin-1- yl]carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 495.52 181

ethyl (2S)-2-({4-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzoyl} amino)-4-(methylthio)butanoate 524.6101 182

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]- N-(2-morpholin-4-ylethyl) benzamide 477.5332 183

(3E)-6-fluoro-3-[4-(4-{[2- (hydroxymethyl)morpholin-4-yl] carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 464.4905 184

(3E)-3-{5,5-dimethyl-4-[4- (thiomorpholin-4-ylcarbonyl) phenyl]furan-2(5H)-ylidene}-6- fluoro-1,3-dihydro-2H-indol-2-one 450.5317 185

N-(1,1-dioxidotetrahydro-3- thienyl)-4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]-N-methyl- benzamide 496.5565 186

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]- N-(2-piperidin-1-ylethyl) benzamide 475.561 187

(3E)-6-fluoro-3-[4-(4-{[2- (hydroxymethyl)piperidin-1-yl] carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 462.5183 188

(3E)-6-fluoro-3-[4-(4-{[3- (hydroxymethyl)piperidin-1-yl] carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 462.5183 189

(3E)-6-fluoro-3-[4-{4-[(3- hydroxypiperidin-1-yl)carbonyl] phenyl}-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol- 2-one 448.4915 190

(3E)-6-fluoro-3-[4-(4-{[4- (hydroxymethyl)piperidin-1-yl] carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 462.5183 191

(3E)-6-fluoro-3-[4-(4-{[3-(2- hydroxyethyl)piperidin- 1-yl]carbonyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 476.5451 192

methyl 1-{4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzoyl}-4- hydroxypyrrolidine-2-carboxylate 492.5005 193

ethyl 4-{4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzoyl} piperazine-1-carboxylate 505.5432 194

(3E)-3-[4-(4-{[4-(2-ethoxyethyl) piperazin-1-yl]carbonyl}phenyl)- 5,5-dimethylfuran-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol-2- one 505.5868 195

ethyl (4-{4-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl] benzoyl}piperazin-1-yl)acetate 519.57 196

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]- N,N-bis(2-methoxyethyl) benzamide 480.5331 197

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro- 3H-indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]-N-(2- methoxyethyl)-N- methylbenzamide 436.4805 198

N-ethyl-4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]-N- (2-hydroxyethyl)benzamide 436.4805 199

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]- N-(2-pyrrolidin-1-ylethyl) benzamide 461.5342 200

N-{2-[bis(2-hydroxyethyl)amino] ethyl}-4-[(5E)-5- (6-fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzamide 495.548 201

N-{2-[4-(2-aminoethyl)piperazin- 1-yl]ethyl}-4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzamide 519.6176 202

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]-N-[2-(4-hydroxypiperidin- 1-yl)ethyl]benzamide 491.56 203

tert-butyl 4-{4-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl] benzoyl}-3-(hydroxymethyl) piperazine-1-carboxylate 563.6226 204

methyl 4-{4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl] benzoyl}piperazine-2-carboxylate 491.5164 205

(3E)-3-[4-(4-{[(2R,3R,4R,5S)-3,4- dihydroxy-2,5-bis(hydroxymethyl) pyrrolidin-1-yl]carbonyl}phenyl)- 5,5-dimethylfuran-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol-2- one 510.5153 206

methyl 1-({4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzoyl}amino) cyclopropanecarboxylate 462.4747 207

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]- N-(tetrahydro-2H-pyran-4-yl) benzamide 448.4915 208

4-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran- 3-yl]-N-(tetrahydro-2H- pyran-4-ylmethyl)benzamide 462.5183 209

methyl (2R)-2-({4-[(5E)-5-(6- fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzoyl} amino)-3-hydroxypropanoate 466.4627 210

ethyl 3-({4-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl] benzoyl}amino)propanoate 464.4905 211

N-(2-amino-2-oxoethyl)-4-[(5E)- 5-(6-fluoro-2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]- N-methylbenzamide 435.4528 212

N-(2-amino-2-oxoethyl)-4-[(5E)- 5-(6-fluoro-2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]benzamide 421.426 213

methyl (2S)-2-({4-[(5E)-5-(6- fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzoyl} amino)-3-hydroxypropanoate 466.4627 214

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]- N-(2-hydroxyethyl)benzamide 408.4269 215

N-(2,3-dihydroxypropyl)-4-[(5E)- 5-(6-fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]-N- methylbenzamide 452.4795 216

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl]-N- methyl-N-[(2S,3R,4S,5R)- 2,3,4,5,6-pentahydroxyhexyl] benzamide 542.5569 217

methyl 1-{4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl] benzoyl}piperidine-4-carboxylate 490.5283 218

N-{[(2R,3S,4S,5R)-3,4-dihydroxy- 5-(hydroxymethyl)tetrahydrofuran- 2-yl]methyl}-4-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzamide 510.5153 219

N-[(1-ethylpyrrolidin-2-yl)methyl]- 4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl] benzamide 475.561 220

N-ethyl-4-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran-3- yl]-N-(2-pyridin-2-ylethyl) benzamide 497.5672 221

ethyl 1-{4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]benzoyl} piperidine-4-carboxylate 504.5551 222

4-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran- 3-yl]-N-[2-(2-methylpiperidin- 1-yl)ethyl]benzamide 489.5878

TABLE 6 [5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one benzylmethyl amine derivatives Ex- am- ple # Chemical Structure Chemical Name FW 223

(3E)-6-fluoro-3-{4-[4-({4-[2-(2- hydroxyethoxy)ethyl]piperazin-1- yl}methyl)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}- 1,3-dihydro-2H-indol-2-one 507.6026 224

(3E)-6-fluoro-3-[4-{4-[(4- hydroxypiperidin-1-yl)methyl] phenyl}-5,5-dimethylfuran- 2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 434.5083 225

(3E)-1-acetyl-3-{5,5-dimethyl-4- [4-(morpholin-4-ylmethyl) phenyl]furan-2(5H)-ylidene}-6- fluoro-1,3-dihydro-2H-indol-2- one 462.5183 226

(3E)-5-chloro-3-[4-(4-{[4-(2- hydroxyethyl)piperazin-1-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 480.005 227

methyl (3E)-3-{5,5-dimethyl-4- [4-(morpholin-4-ylmethyl) phenyl]furan-2(5H)-ylidene}-2- oxoindoline-5-carboxylate 460.5272 228

(3E)-5-bromo-3-{5,5-dimethyl- 4-[4-(morpholin-4-ylmethyl) phenyl]furan-2(5H)-ylidene}- 1,3-dihydro-2H-indol-2-one 481.3875 229

(3E)-3-{5,5-dimethyl-4-[4- (morpholin-4-ylmethyl)phenyl] furan-2(5H)-ylidene}-2- oxoindoline-5-carbonitrile 427.5015 230

methyl (3E)-3-{5,5-dimethyl-4- [4-(morpholin-4-ylmethyl) phenyl]furan-2(5H)-ylidene}-2- oxoindoline-6-carboxylate 460.5272 231

(3E)-3-{5,5-dimethyl-4-[4- (morpholin-4-ylmethyl)phenyl] furan-2(5H)-ylidene}-2- oxoindoline-5-carboxylic acid 446.5004 232

(3E)-3-{5,5-dimethyl-4-[4- (morpholin-4-ylmethyl)phenyl] furan-2(5H)-ylidene}-2- oxoindoline-6-carboxylicacid 446.5004 233

(3E)-3-[4-(4-{[4- (hydroxymethyl) piperidin-1-yl]methyl}phenyl)- 5,5-dimethylfuran-2(5H)- ylidene]-2-oxoindoline-5- carboxylic acid 474.554 234

methyl 1-{4-[(5E)-5-(5,6- difluoro- 2-oxo-1,2-dihydro-3H-indol- 3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzyl} piperidine-4-carboxylate 494.54 235

1-{4-[(5E)-5-(5,6-difluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzyl} piperidine-4-carboxylic acid 480.51 236

ethyl (2S)-2-({4-[(5E)-5-(6- fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]benzyl} amino)-4-(methylthio)butanoate 510.6269 237

2-({4-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzyl} amino)-4-(S- methylsulfonimidoyl)butanoic acid 513.5872 238

(3E)-3-[5,5-dimethyl-4-(4-{[(2- morpholin-4-ylethyl)amino] methyl}phenyl)furan-2(5H)- ylidene]-6-fluoro-1,3-dihydro- 2H-indol-2-one 463.55 239

(3E)-6-fluoro-3-[4-(4-{[2- (hydroxymethyl)morpholin-4-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 450.5073 240

(3E)-3-{5,5-dimethyl-4- [4-(thiomorpholin-4-ylmethyl) phenyl]furan-2(5H)-ylidene}- 6-fluoro-1,3-dihydro-2H-indol- 2-one 436.5485 241

(3E)-3-[4-(4-{[(1,1- dioxidotetrahydro-3-thienyl) (methyl)amino]methyl} phenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-6-fluoro- 1,3-dihydro-2H-indol-2-one 482.5733 242

(3E)-6-fluoro-3-[4-(4-{[3- (hydroxymethyl)piperidin-1-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol- 2-one 448.5351 243

(3E)-6-fluoro-3-[4-{4-[(3- hydroxypiperidin-1-yl)methyl] phenyl}-5,5-dimethylfuran- 2(5H)-ylidene]-1,3-dihydro- 2H-indol-2-one 434.5083 244

(3E)-6-fluoro-3-[4-(4-{[4- (hydroxymethyl)piperidin-1-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 448.5351 245

(3E)-6-fluoro-3-[4-(4-{[3-(2- hydroxyethyl)piperidin-1-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 462.5619 246

(3E)-6-fluoro-3-[4-{4-[(3- fluoropiperidin-1-yl)methyl] phenyl}-5,5-dimethylfuran- 2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 436.4994 247

methyl 1-{4-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl] benzyl}-4-hydroxypyrrolidine- 2-carboxylate 478.5173 248

ethyl 4-{4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]benzyl} piperazine-1-carboxylate 491.56 249

(3E)-3-[5,5-dimethyl-4-{4-[(4- methylpiperazin-1-yl)methyl] phenyl}furan-2(5H)-ylidene]- 6-fluoro-1,3-dihydro-2H-indol- 2-one 433.5242 250

(3E)-6-fluoro-3-[4-(4-{[4-(2- hydroxyethyl)piperazin-1-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 463.55 251

(3E)-3-[4-(4-{[4-(2-ethoxyethyl) piperazin-1-yl]methyl}phenyl)- 5,5-dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 491.6036 252

(4-{4-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran- 3-yl]benzyl}piperazin- 1-yl)acetic acid 477.5332 253

(3E)-3-[4-(4-{[ethyl(2-pyridin-2- ylethyl)amino]methyl}phenyl)- 5,5-dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 483.584 254

(3E)-3-[4-(4-{[bis(2-methoxy- ethyl)amino]methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]-6- fluoro-1,3-dihydro-2H-indol- 2-one 466.5499 255

(3E)-6-fluoro-3-[4-(4-{[(2- methoxyethyl)(methyl)amino] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 422.4973 256

(3E)-3-[4-(4-{[ethyl(2- hydroxyethyl)amino]methyl} phenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-6-fluoro- 1,3-dihydro-2H-indol-2-one 422.4973 257

(3E)-3-[4-{4-[({2-[4- (2-aminoethyl)piperazin-1- yl]ethyl}amino)methyl] phenyl}-5,5-dimethylfuran- 2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 505.6344 258

3-[2-({4-[(5E)-5-(6-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3- yl]benzyl}amino)ethyl]-1,3- thiazolidine-2,4-dione 493.5566 259

(3E)-6-fluoro-3-{4-[4- ({[2-(4-hydroxypiperidin- 1-yl)ethyl]amino}methyl) phenyl]-5,5-dimethylfuran- 2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 477.5768 260

(3E)-3-{5,5-dimethyl-4-[4-({[2- (2-oxoimidazolidin-1-yl)ethyl] amino}methyl)phenyl]furan- 2(5H)-ylidene}-6-fluoro-1,3- dihydro-2H-indol-2-one 462.5223 261

methyl ({4-[(5E)-5-(5-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzyl} amino)acetate 422.4537 262

methyl (2S,3R)-2-({4-[(5E)- 5-(5-fluoro-2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl] benzyl}amino)-3- hydroxybutanoate 466.5063 263

(3E)-3-[5,5-dimethyl-4-(4-{[(2- morpholin-4-ylethyl)amino] methyl}phenyl)furan-2(5H)- ylidene]-5-fluoro-1,3-dihydro- 2H-indol-2-one 463.55 264

(3E)-5-fluoro-3-[4-(4-{[2- (hydroxymethyl)morpholin-4-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 450.5073 265

(3E)-3-{5,5-dimethyl-4-[4- (morpholin-4-ylmethyl)phenyl] furan-2(5H)-ylidene}-5-fluoro- 1,3-dihydro-2H-indol-2-one 420.4815 266

(3E)-3-[4-(4-{[(1,1- dioxidotetrahydro-3-thienyl) (methyl)amino]methyl}phenyl)- 5,5-dimethylfuran-2(5H)- ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 482.5733 267

(3E)-3-[5,5-dimethyl-4-(4-{[(2- piperidin-1-ylethyl)amino] methyl}phenyl)furan- 2(5H)-ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 461.5778 268

(3E)-5-fluoro-3-[4-(4-{[3- (hydroxymethyl)piperidin-1-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 488.5351 269

(3E)-5-fluoro-3-[4-{4-[(3- hydroxypiperidin-1-yl)methyl] phenyl}-5,5-dimethylfuran- 2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 434.5083 270

(3E)-5-fluoro-3-[4-(4-{[4- (hydroxymethyl)piperidin-1-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 448.5351 271

(3E)-5-fluoro-3-[4-(4- {[3-(2-hydroxyethyl) piperidin-1-yl]methyl}phenyl)- 5,5-dimethylfuran- 2(5H)-ylidene]-1,3-dihydro- 2H-indol-2-one 462.5619 272

methyl (2S,4R)-1-{4-[(5E)-5-(5- fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3- yl]benzyl}-4- hydroxypyrrolidine- 2-carboxylate 478.5173 273

(3E)-3-[5,5-dimethyl-4-{4-[(4- methylpiperazin-1-yl)methyl] phenyl}furan-2(5H)-ylidene]-5- fluoro-1,3-dihydro-2H-indol- 2-one 433.5242 274

(3E)-5-fluoro-3-[4-(4-{[4-(2- hydroxyethyl)piperazin-1-yl] methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 463.55 275

(3E)-5-fluoro-3-{4-[4-({4-[2-(2- hydroxyethoxy)ethyl]piperazin- 1-yl}methyl)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}- 1,3-dihydro-2H-indol-2-one 507.6026 276

(3E)-3-[4-(4-{[4-(2-ethoxyethyl) piperazin-1-yl]methyl}phenyl)- 5,5-dimethylfuran-2(5H)- ylidene]-5-fluoro-1,3-dihydro- 2H-indol-2-one 491.6036 277

ethyl (4-{4-[(5E)-5-(5-fluoro- 2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2- dimethyl-2,5-dihydrofuran-3-yl] benzyl}piperazin-1-yl)acetate 505.5868 278

(3E)-3-[4-(4-{[bis(2- methoxyethyl)amino]methyl} phenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-5-fluoro- 1,3-dihydro-2H-indol-2-one 466.5499 279

(3E)-5-fluoro-3-[4-(4-{[(2- methoxyethyl)(methyl) amino]methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 422.4973 280

(3E)-3-[4-(4-{[ethyl(2- hydroxyethyl)amino]methyl} phenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-5-fluoro- 1,3-dihydro-2H-indol-2-one 422.4973 281

(3E)-3-[5,5-dimethyl-4-(4-{[(2- pyrrolidin-1-ylethyl)amino] methyl}phenyl)furan- 2(5H)-ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 447.551 282

(3E)-3-{4-[4-({[2- (diethylamino) ethyl]amino}methyl)phenyl]- 5,5-dimethylfuran-2(5H)- ylidene}-5-fluoro-1,3-dihydro- 2H-indol-2-one 449.5668 283

(3E)-3-[4-{4-[({2-[bis(2- hydroxyethyl)amino]ethyl} amino)methyl]phenyl}-5,5- dimethylfuran-2(5H)-ylidene]- 5-fluoro-1,3-dihydro-2H-indol- 2-one 481.5648 284

(3E)-5-fluoro-3-{4-[4-({[2-(4- hydroxypiperidin-1-yl) ethyl]amino}methyl) phenyl]-5,5-dimethylfuran- 2(5H)-ylidene}-1,3-dihydro- 2H-indol-2-one 477.5768 285

tert-butyl 4-{4-[(5E)-5-(5- fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl] benzyl}-3-(hydroxymethyl) piperazine-1-carboxylate 549.6394 286

(3E)-5-fluoro-3-[4-{4-[(3- hydroxypyrrolidin-1-yl)methyl] phenyl}-5,5-dimethylfuran- 2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 420.4815 287

(3E)-3-[4-(4-{[(2R,3R,4R,5S)- 3,4-dihydroxy-2,5-bis (hydroxymethyl) pyrrolidin-1-yl]methyl} phenyl)-5,5-dimethylfuran- 2(5H)-ylidene]-5-fluoro- 1,3-dihydro-2H-indol-2-one 496.5321 288

methyl 1-({4-[(5E)-5-(5-fluoro- 2-oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]benzyl} amino)cyclopropanecarboxylate 448.4915 289

(3E)-3-[5,5-dimethyl-4-{4- [(tetrahydro-2H-pyran- 4-ylamino) methyl]phenyl}furan-2(5H)- ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 434.5083 290

(3E)-3-[5,5-dimethyl-4-(4- {[(tetrahydro-2H-pyran- 4-ylmethyl)amino] methyl}phenyl)furan-2(5H)- ylidene]-5-fluoro-1,3-dihydro- 2H-indol-2-one 448.5351 291

methyl (2R)-2-({4-[(5E)-5- (5-fluoro-2-oxo-1,2- dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzyl} amino)-3-hydroxypropanoate 452.4795 292

2-[{4-[(5E)-5-(5-fluoro-2-oxo- 1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzyl} (methyl)amino]acetamide 421.4696 293

2-({4-[(5E)-5-(5-fluoro-2- oxo-1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl] benzyl}amino)acetamide 407.4428 294

methyl (2S)-2-({4-[(5E)-5- (5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5-dihydrofuran- 3-yl]benzyl}amino)- 3-hydroxypropanoate 452.4795 295

(3E)-5-fluoro-3-[4-(4-{[(2- hydroxyethyl)amino]methyl} phenyl)-5,5-dimethylfuran- 2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 394.4437 296

(3E)-3-[4-(4-{[(2,3- dihydroxypropyl)(methyl) amino]methyl}phenyl)- 5,5-dimethylfuran-2(5H)- ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 438.4963 297

(3E)-3-{5,5-dimethyl-4-[4- ({methyl[(2S,3R,4S,5R)- 2,3,4,5,6-pentahydroxyhexyl] amino}methyl)phenyl] furan-2(5H)-ylidene}-5-fluoro- 1,3-dihydro-2H-indol-2-one 528.5737 298

(3E)-3-[4-{4- [({[(2R,3S,4S,5R)-3,4- dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]methyl} amino)methyl]phenyl}-5,5- dimethylfuran-2(5H)-ylidene]- 5-fluoro-1,3-dihydro-2H- indol-2-one 496.5321 299

(3E)-3-{4-[4-({[(1- ethylpyrrolidin- 2-yl)methyl]amino}methyl) phenyl]-5,5-dimethylfuran- 2(5H)-ylidene}-5-fluoro-1,3- dihydro-2H-indol-2-one 461.5778 300

rel-(3E)-3-[5,5-dimethyl-4-(4- {[(3R,4r5S)-3,4,5- trihydroxypiperidin-1-yl] methyl}phenyl)furan- 2(5H)-ylidene]-5- fluoro-1,3-dihydro-2H-indol-2- one 466.5063 301

ethyl (2S,4R)-1-{4-[(5E)-5-(5- fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]benzyl}- 4-hydroxypyrrolidine-2- carboxylate 492.5441 302

ethyl 1-{4-[(5E)-5-(5-fluoro- 2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]benzyl} piperidine-4-carboxylate 490.5719 303

(3E)-3-{5,5-dimethyl-4-[4- ({[2-(2-methylpiperidin-1-yl) ethyl]amino}methyl)phenyl] furan-2(5H)-ylidene}-5-fluoro- 1,3-dihydro-2H-indol-2-one 475.6046 304

(3E)-5-fluoro-3-[4-(4-{[(2- hydroxyethyl)(2-pyridin-4- ylethyl) amino]methyl}phenyl)-5,5- dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 499.583 305

({[(2S,4R)-1-{4-[(5E)-5-(5- fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]benzyl}- 4-hydroxypyrrolidin-2-yl] carbonyl}amino)acetic acid 521.5422 306

(3E)-3-[5,5-dimethyl-4-(4- {[(2S,3R,4S,5R)-3,4,5- trihydroxy-2-methylpiperidin- 1-yl]methyl}phenyl) furan-2(5H)-ylidene]-5-fluoro- 1,3-dihydro-2H-indol-2-one 480.5331 307

(3E)-5-fluoro-3-{4-[4-(13- hydroxy-5,8,11-trioxa-2- azatridec-1-yl)phenyl]-5,5- dimethylfuran-2(5H)-ylidene}- 1,3-dihydro-2H-indol-2-one 526.6015 308

(3E)-3-{5,5-dimethyl-4-[4- (pyrrolidin-1-ylmethyl)phenyl] furan-2(5H)-ylidene}-5-fluoro- 1,3-dihydro-2H-indol-2-one 404.4825 309

1-{4-[(5E)-5-(5-fluoro-2-oxo- 1,2-dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]benzyl} piperidine-4-carboxylic acid 462.5183 310

(3E)-3-{5,5-dimethyl-4-[4- (piperidin-1-ylmethyl)phenyl] furan-2(5H)-ylidene}-5-fluoro- 1,3-dihydro-2H-indol-2-one 418.5093

TABLE 7 [5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one pyridin-3- yl derivatives Example # Chemical Structure Chemical Name FW 311

(3E)-3-{5,5-dimethyl-4-[6-(2-morpholin-4- ylethyl)pyridin-3-yl]furan-2(5H)-ylidene}-6- fluoro-1,3-dihydro-2H-indol-2-one 435.4964 312

(3E)-3-{5,5-dimethyl-4-[6′-(2-morpholin-4- ylethyl)-2,3′-bipyridin-5-yl]furan-2(5H)- ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one 512.5821 313

methyl [(2-{5-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2- yl}ethyl)amino]acetate 437.4686 314

(3E)-3-[5,5-dimethyl-4-(6-{2-[(2-morpholin-4- ylethyl)amino]ethyl}pyridin-3-yl)furan-2(5H)- ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one 478.5649 315

3-{2-[(2-{5-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2- yl}ethyl)amino]ethyl}-1,3-thiazolidine-2,4- dione 508.5715 316

(3E)-6-fluoro-3-[4-(6-{2-[2- (hydroxymethyl)morpholin-4-yl]ethyl}pyridin-3- yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 465.5222 317

(3E)-6-fluoro-3-[4-(6-{2-[2- (hydroxymethyl)piperidin-1-yl]ethyl}pyridin-3- yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 463.55 318

(3E)-6-fluoro-3-[4-(6-{2-[3- (hydroxymethyl)piperidin-1-yl]ethyl}pyridin-3- yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 463.55 319

(3E)-6-fluoro-3-[4-{6-[2-(4-hydroxypiperidin-1- yl)ethyl]pyridin-3-yl}-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol-2-one 449.5232 320

(3E)-6-fluoro-3-[4-{6-[2-(3-hydroxypiperidin-1- yl)ethyl]pyridin-3-yl}-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol-2-one 449.5232 321

(3E)-6-fluoro-3-[4-(6-{2-[4- (hydroxymethyl)piperidin-1-yl]ethyl}pyridin-3- yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 463.55 322

(3E)-6-fluoro-3-[4-(6-{2-[3-(2- hydroxyethyl)piperidin-1-yl]ethyl}pyridin-3-yl)- 5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro- 2H-indol-2-one 477.5768 323

(3E)-6-fluoro-3-[4-{6-[2-(3-fluoropiperidin-1- yl)ethyl]pyridin-3-yl}-5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H-indol-2-one 451.5143 324

ethyl 4-(2-{5-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}ethyl)piperazine- 1-carboxylate 506.5749 325

(3E)-3-[5,5-dimethyl-4-{6-[2-(4- methylpiperazin-1-yl)ethyl]pyridin-3-yl}furan- 2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol- 2-one 448.5391 326

(3E)-6-fluoro-3-[4-(6-{2-[4-(2- hydroxyethyl)piperazin-1-yl]ethyl}pyridin-3-yl)- 5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro- 2H-indol-2-one 478.5649 327

(3E)-6-fluoro-3-{4-[6-(2-{4-[2-(2- hydroxyethoxy)ethyl]piperazin-1- yl}ethyl)pyridin-3-yl]-5,5-dimethylfuran-2(5H)- ylidene}-1,3-dihydro-2H-indol-2-one 522.6175 328

(3E)-3-[4-(6-{2-[4-(2-ethoxyethyl)piperazin-1- yl]ethyl}pyridin-3-yl)-5,5-dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one 506.6185 329

(3E)-3-[4-(6-{2-[ethyl(2-pyridin-2- ylethyl)amino]ethyl}pyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 498.5989 330

(3E)-6-fluoro-3-[4-(6-{2-[(2- methoxyethyl)(methyl)amino]ethyl}pyridin-3- yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 437.5122 331

(3E)-3-[4-(6-{2-[ethyl(2- hydroxyethyl)amino]ethyl}pyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 437.5122 332

(3E)-6-fluoro-3-{4-[6-(4-hydroxypiperidin-1- yl)pyridin-3-yl]-5,5-dimethylfuran-2(5H)- ylidene}-1,3-dihydro-2H-indol-2-one 421.4696 333

(3E)-6-fluoro-3-[4-(6-{4-[2-(2- hydroxyethoxy)ethyl]piperazin-1-yl}pyridin-3- yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 494.5639 334

methyl ({5-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro 3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}amino)acetate 409.415 335

methyl (2S,3R)-2-({5-[(5E)-5-(6-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]pyridin-2-yl}amino)-3- hydroxybutanoate 453.4676 336

ethyl (2S)-2-({5-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}amino)-4- (methylthio)butanoate 497.5882 337

(2S)-2-({5-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}amino)-3-(1,3- thiazol-4-yl)propanoic acid 492.5289 338

(3E)-3-[5,5-dimethyl-4-{6-[(2-morpholin-4- ylethyl)amino]pyridin-3-yl}furan-2(5H)- ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one 450.5113 339

(3E)-6-fluoro-3-[4-{6-[2- (hydroxymethyl)morpholin-4-yl]pyridin-3-yl}- 5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro- 2H-indol-2-one 437.4686 340

(3E)-3-[5,5-dimethyl-4-(6-thiomorpholin-4- ylpyridin-3-yl)furan-2(5H)-ylidene]-6-fluoro- 1,3-dihydro-2H-indol-2-one 423.5098 341

(3E)-3-[4-{6-[(1,1-dioxidotetrahydro-3- thienyl)(methyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 469.5346 342

(3E)-3-[5,5-dimethyl-4-{6-[(2-piperidin-1- ylethyl)amino]pyridin-3-yl}furan-2(5H)- ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one 448.5391 343

(3E)-6-fluoro-3-[4-{6-[2- (hydroxymethyl)piperidin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 435.4964 344

(3E)-6-fluoro-3-[4-{6-[3- (hydroxymethyl)piperidin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 435.4964 345

1-{5-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}piperidine-4- sulfonic acid 485.5336 346

(3E)-6-fluoro-3-{4-[6-(3-hydroxypiperidin-1- yl)pyridin-3-yl]-5,5-dimethylfuran-2(5H)- ylidene}-1,3-dihydro-2H-indol-2-one 421.4696 347

(3E)-6-fluoro-3-[4-{6-[4- (hydroxymethyl)piperidin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 435.4964 348

(3E)-6-fluoro-3-[4-{6-[3-(2- hydroxyethyl)piperidin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 449.5232 349

(3E)-6-fluoro-3-{4-[6-(3-fluoropiperidin-1- yl)pyridin-3-yl]-5,5-dimethylfuran-2(5H)- ylidene}-1,3-dihydro-2H-indol-2-one 423.4607 350

methyl 1-{5-[(5E)-5-(6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}-4- hydroxypyrrolidine-2-carboxylate 465.4786 351

(3E)-6-fluoro-3-[4-{6-[(2-hydroxyethyl)(2- pyridin-4-ylethyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 486.5443 352

ethyl 4-{5-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}piperazine-1- carboxylate 478.5213 353

(3E)-3-{5,5-dimethyl-4-[6-(4-methylpiperazin- 1-yl)pyridin-3-yl]furan-2(5H)-ylidene}-6-fluoro- 1,3-dihydro-2H-indol-2-one 420.4855 354

(3E)-6-fluoro-3-[4-{6-[4-(2- hydroxyethyl)piperazin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 450.5113 355

(3E)-3-[4-{6-[4-(2-ethoxyethyl)piperazin-1- yl]pyridin-3-yl}-5,5-dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one 478.5649 356

(4-{5-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}piperazin-1- yl)acetic acid 464.4945 357

(3E)-3-[4-{6-[ethyl(2-pyridin-2- ylethyl)amino]pyridin-3-yl}-5,5-dimethylfuran- 2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol- 2-one 470.5453 358

(3E)-3-[4-{6-[bis(2- methoxyethyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 453.5112 359

(3E)-6-fluoro-3-[4-{6-[(2- methoxyethyl)(methyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 409.4586 360

(3E)-3-[4-{6-[ethyl(2- hydroxyethyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 409.4586 361

(3E)-3-[5,5-dimethyl-4-{6-[(tetrahydrofuran-2- ylmethyl)(2-thienylmethyl)amino]pyridin-3- yl}furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro- 2H-indol-2-one 517.6222 362

(3E)-3-[5,5-dimethyl-4-{6-[(2-pyrrolidin-1- ylethyl)amino]pyridin-3-yl}furan-2(5H)- ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one 434.5123 363

(3E)-3-[4-(6-{[2- (diethylamino)ethyl]amino}pyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 436.5281 364

(3E)-3-{4-[6-({2-[bis(2- hydroxyethyl)amino]ethyl}amino)pyridin-3-yl]- 5,5-dimethylfuran-2(5H)-ylidene}-6-fluoro-1,3- dihydro-2H-indol-2-one 468.5261 365

(3E)-3-[4-{6-[3-(2-aminoethyl)-2- oxoimidazolidin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 449.4836 366

(3E)-3-{4-[6-({2-[4-(2-aminoethyl)piperazin-1- yl]ethyl}amino)pyridin-3-yl]-5,5-dimethylfuran- 2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol- 2-one 492.5957 367

(3E)-6-fluoro-3-[4-(6-{[2-(4-hydroxypiperidin- 1-yl)ethyl]amino}pyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 464.5381 368

(3E)-3-[5,5-dimethyl-4-(6-{[2-(2- methylpiperidin-1-yl)ethyl]amino}pyridin-3- yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro- 2H-indol-2-one 462.5659 369

(3E)-6-f luoro-3-[4-(6-{[2-(1H-imidazol-1- yl)ethyl]amino}pyridin-3-yl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one 431.4688 370

6-Fluoro-3-[4-{6-[(2-hydroxy-ethyl)-(2-pyridin- 4-yl-ethyl)-amino]-pyridin-3-yl}-5,5-dimethyl- 5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2- one 486.5443 371

methyl ({5-[(5E)-5-(5-fluoro-2-oxo-1,2-dihydro 3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}amino)acetate 409.415 372

methyl (2S,3R)-2-({5-[(5E)-5-(5-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]pyridin-2-yl}amino)-3- hydroxybutanoate 453.4676 373

(3E)-3-[5,5-dimethyl-4-{6-[(2-morpholin-4- ylethyl)amino]pyridin-3-yl}furan-2(5H)- ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one 450.5113 374

(3E)-5-fluoro-3-[4-{6-[2- (hydroxymethyl)morpholin-4-yl]pyridin-3-yl}- 5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro- 2H-indol-2-one 437.4686 375

(3E)-3-[5,5-dimethyl-4-{6-[(2-piperidin-1- ylethyl)amino]pyridin-3-yl}furan-2(5H)- ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one 448.5391 376

(3E)-5-fluoro-3-[4-{6-[2- (hydroxymethyl)piperidin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 435.4964 377

(3E)-5-fluoro-3-[4-{6-[3- (hydroxymethyl)piperidin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 435.4964 378

(3E)-5-fluoro-3-{4-[6-(4-hydroxypiperidin-1- yl)pyridin-3-yl]-5,5-dimethylfuran-2(5H)- ylidene}-1,3-dihydro-2H-indol-2-one 421.4696 379

1-{5-[(5E)-5-(5-fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}piperidine-4- sulfonic acid 485.5336 380

(3E)-5-fluoro-3-{4-[6-(3-hydroxypiperidin-1- yl)pyridin-3-yl]-5,5-dimethylfuran-2(5H)- ylidene}-1,3-dihydro-2H-indol-2-one 421.4696 381

(3E)-5-fluoro-3-[4-{6-[4- (hydroxymethyl)piperidin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 435.4964 382

(3E)-5-fluoro-3-[4-{6-[3-(2- hydroxyethyl)piperidin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 449.5232 383

methyl (2S,4R)-1-{5-[(5E)-5-(5-fluoro-2-oxo- 1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl- 2,5-dihydrofuran-3-yl]pyridin-2-yl}-4- hydroxypyrrolidine-2-carboxylate 465.4786 384

(3E)-5-fluoro-3-[4-{6-[4-(2- hydroxyethyl)piperazin-1-yl]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 450.5113 385

(3E)-5-fluoro-3-[4-(6-{4-[2-(2- hydroxyethoxy)ethyl]piperazin-1-yl}pyridin-3- yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 494.5639 386

(3E)-3-[4-{6-[4-(2-ethoxyethyl)piperazin-1- yl]pyridin-3-yl}-5,5-dimethylfuran-2(5H)- ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one 478.5649 387

ethyl (4-{5-[(5E)-5-(5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}piperazin-1- yl)acetate 492.5481 388

(3E)-3-[4-{6-[bis(2- methoxyethyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 453.5112 389

(3E)-5-fluoro-3-[4-{6-[(2- methoxyethyl)(methyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 409.4586 390

(3E)-3-[4-{6-[ethyl(2- hydroxyethyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 409.4586 391

(3E)-3-[5,5-dimethyl-4-{6-[(2-pyrrolidin-1- ylethyl)amino]pyridin-3-yl}furan-2(5H)- ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one 434.5123 392

(3E)-3-[4-(6-{[2- (diethylamino)ethyl]amino}pyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 436.5281 393

(3E)-3-{4-[6-({2-[bis(2- hydroxyethyl)amino]ethyl}amino)pyridin-3-yl]- 5,5-dimethylfuran-2(5H)-ylidene}-5-fluoro-1,3- dihydro-2H-indol-2-one 468.5261 394

(3E)-5-fluoro-3-[4-(6-{[2-(4-hydroxypiperidin- 1-yl)ethyl]amino}pyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 464.5381 395

(3E)-3-{4-[6-({2-[4-(2-aminoethyl)piperazin-1- yl]ethyl}amino)pyridin-3-yl]-5,5-dimethylfuran- 2(5H)-ylidene}-5-fluoro-1,3-dihydro-2H-indol- 2-one 492.5957 396

tert-butyl 4-{5-[(5E)-5-(5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}-3- (hydroxymethyl)piperazine-1-carboxylate 536.6007 397

methyl 4-{5-[(5E)-5-(5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}piperazine-2- carboxylate 464.4945 398

(3E)-5-fluoro-3-{4-[6-(3-hydroxypyrrolidin-1- yl)pyridin-3-yl]-5,5-dimethylfuran-2(5H)- ylidene}-1,3-dihydro-2H-indol-2-one 407.4428 399

(3E)-3-[4-{6-[(2R,3R,4R,5S)-3,4-dihydroxy- 2,5-bis(hydroxymethyl)pyrrolidin-1-yl]pyridin-3- yl}-5,5-dimethylfuran-2(5H)-ylidene]-5-fluoro- 1,3-dihydro-2H-indol-2-one 483.4934 400

methyl 1-({5-[(5E)-5-(5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2- yl}amino)cyclopropanecarboxylate 435.4528 401

(3E)-3-[5,5-dimethyl-4-{6-[(tetrahydro-2H- pyran-4-ylmethyl)amino]pyridin-3-yl}furan- 2(5H)-ylidene]-5-fluoro-1,3-dihydro-2H-indol- 2-one 435.4964 402

methyl (2R)-2-({5-[(5E)-5-(5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}amino)-3- hydroxypropanoate 439.4408 403

ethyl 3-({5-[(5E)-5-(5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2- yl}amino)propanoate 437.4686 404

2-[{5-[(5E)-5-(5-fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2- yl}(methyl)amino]acetamide 408.4309 405

2-({5-[(5E)-5-(5-fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2- yl}amino)acetamide 394.4041 406

methyl (2S)-2-({5-[(5E)-5-(5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}amino)-3- hydroxypropanoate 439.4408 407

(3E)-5-fluoro-3-[4-{6-[(2- hydroxyethyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 381.405 408

(3E)-3-[4-{6-[(2,3- dihydroxypropyl)(methyl)amino]pyridin-3-yl}- 5,5-dimethylfuran-2(5H)-ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 425.4576 409

(3E)-3-{4-[6-({[(2R,3S,4S,5R)-3,4-dihydroxy- 5-(hydroxymethyl)tetrahydrofuran-2- yl]methyl}amino)pyridin-3-yl]-5,5- dimethylfuran-2(5H)-ylidene}-5-fluoro-1,3- dihydro-2H-indol-2-one 483.4934 410

(3E)-3-[4-(6-{[(1-ethylpyrrolidin-2- yl)methyl]amino}pyridin-3-yl)-5,5- dimethylfuran-2(5H)-ylidene]-5-fluoro-1,3- dihydro-2H-indol-2-one 448.5391 411

ethyl (2S,4R)-1-{5-[(5E)-5-(5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}-4- hydroxypyrrolidine-2-carboxylate 479.5054 412

ethyl 1-{5-[(5E)-5-(5-fluoro-2-oxo-1,2-dihydro- 3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}piperidine-4- carboxylate 477.5332 413

(3E)-3-[5,5-dimethyl-4-(6-{[2-(2- methylpiperidin-1-yl)ethyl]amino}pyridin-3- yl)furan-2(5H)-ylidene]-5-fluoro-1,3-dihydro- 2H-indol-2-one 462.5659 414

({[(2S,4R)-1-{5-[(5E)-5-(5-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}-4- hydroxypyrrolidin-2-yl]carbonyl}amino)acetic acid 508.5035 415

(3E)-5-fluoro-3-[4-{6-[(4-hydroxy-1,1- dioxidotetrahydro-3-thienyl)(3- hydroxypropyl)amino]pyridin-3-yl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 529.5862 416

(3E)-3-[5,5-dimethyl-4-(6-{[(2S)-pyrrolidin-2- ylmethyl]amino}pyridin-3-yl)furan-2(5H)- ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one 420.4855 417

(3E)-3-[5,5-dimethyl-4-{6-[(2S,3R,4S,5R)- 3,4,5-trihydroxy-2-methylpiperidin-1-yl]pyridin- 3-yl}furan-2(5H)-ylidene]-5-fluoro-1,3-dihydro- 2H-indol-2-one 467.4944 418

(3E)-5-fluoro-3-[4-{6-[(2-{2-[2-(2- hydroxyethoxy)ethoxy]ethoxy}ethyl)amino] pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]- 1,3-dihydro-2H-indol-2-one 513.5628 419

1-{5-[(5E)-5-(5-fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin-2-yl}piperidine-4- carboxylic acid 449.4796 420

(3E)-3-[5,5-dimethyl-4-(6-piperidin-1-ylpyridin- 3-yl)furan-2(5H)-ylidene]-5-fluoro-1,3-dihydro- 2H-indol-2-one 405.4706 421

(3E)-3-[4-{6-[(2,3- dihydroxypropyl)(methyl)amino]pyridin-3-yl}- 5,5-dimethylfuran-2(5H)-ylidene]-5,6-difluoro- 1,3-dihydro-2H-indol-2-one 443.4477

TABLE 8 [5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one pyridin-4- yl derivatives Example # Chemical Structure Chemical Name FW 422

(3E)-6-fluoro-3-[4-(2-{4-[2-(2- hydroxyethoxy)ethyl] piperazin-1-yl}pyridin-4- yl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 494.5639 423

(3E)-6-fluoro-3-{4-[2-(4- hydroxypiperidin-1- yl)pyridin-4-yl]-5,5- dimethylfuran-2(5H)- ylidene}-1,3-dihydro- 2H-indol-2-one 421.4696 424

ethyl (2S)-2-({4-[(5E)-5- (6-fluoro-2-oxo-1,2- dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl] pyridin-2-yl}amino)-4- (methylthio)butanoate 497.5882 425

(3E)-3-[5,5-dimethyl-4- (2-{[2-(1,3-thiazol-4- yl)ethyl]amino}pyridin- 4-yl)furan-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 448.5199 426

(3E)-3-[5,5-dimethyl- 4-{2-[(2-morpholin-4- ylethyl)amino]pyridin- 4-yl}furan-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 450.5113 427

(3E)-3-[5,5-dimethyl- 4-{2-[(2-piperidin-1- ylethyl)amino]pyridin- 4-yl}furan-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 448.5391 428

(3E)-3-[5,5-dimethyl- 4-{2-[(2-pyrrolidin-1- ylethyl)amino]pyridin- 4-yl}furan-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 434.5123 429

(3E)-3-[4-(2-{[2- (diethylamino)ethyl] amino}pyridin-4-yl)-5,5- dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 436.5281 430

(3E)-3-{4-[2-({2-[bis(2- hydroxyethyl)amino]ethyl} amino)pyridin-4-yl]- 5,5-dimethylfuran-2(5H)- ylidene}-6-fluoro-1,3- dihydro-2H-indol-2-one 468.5261 431

(3E)-3-[5,5-dimethyl- 4-(2-{[2-(2- oxoimidazolidin-1-yl) ethyl]amino}pyridin-4- yl)furan-2(5H)-ylidene]- 6-fluoro-1,3-dihydro- 2H-indol-2-one 449.4836 432

(3E)-6-fluoro-3-[4-(2-{[2- (4-hydroxypiperidin- 1-yl)ethyl]amino} pyridin-4-yl)-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H- indol-2-one 464.5381 433

(3E)-3-[5,5-dimethyl- 4-(2-{[2-(2- methylpiperidin-1-yl) ethyl]amino}pyridin-4- yl)furan-2(5H)-ylidene]- 6-fluoro-1,3-dihydro- 2H-indol-2-one 462.5659 434

(3E)-6-fluoro-3-[4-(2- {[2-(1H-imidazol-1- yl)ethyl]amino}pyridin-4- yl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 431.4688 435

(3E)-6-fluoro- 3-[4-{2-[2- (hydroxymethyl)morpholin- 4-yl]pyridin-4-yl}- 5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro- 2H-indol-2-one 437.4686 436

(3E)-3-[5,5-dimethyl- 4-(2-morpholin-4- ylpyridin-4-yl)furan- 2(5H)-ylidene]-6-fluoro- 1,3-dihydro-2H-indol-2-one 407.4428 437

(3E)-3-[5,5-dimethyl-4- (2-thiomorpholin-4- ylpyridin-4-yl)furan- 2(5H)-ylidene]-6-fluoro- 1,3-dihydro-2H-indol-2-one 423.5098 438

(3E)-6-fluoro-3-[4-{2-[2- (hydroxymethyl)piperidin- 1-yl]pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H- indol-2-one 435.4964 439

(3E)-6-fluoro- 3-[4-{2-[3- (hydroxymethyl)piperidin- 1-yl]pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H- indol-2-one 435.4964 440

1-{4-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro-3H- indol-3-ylidene)- 2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin- 2-yl}piperidine-4- sulfonic acid 485.5336 441

(3E)-6-fluoro-3-{4-[2-(3- hydroxypiperidin-1- yl)pyridin-4-yl]-5,5- dimethylfuran-2(5H)- ylidene}-1,3-dihydro- 2H-indol-2-one 421.4696 442

(3E)-6-fluoro- 3-[4-{2-[4- (hydroxymethyl)piperidin- 1-yl]pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H- indol-2-one 435.4964 443

(3E)-6-fluoro- 3-[4-{2-[3-(2- hydroxyethyl)piperidin-1- yl]pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H- indol-2-one 449.5232 444

(3E)-6-fluoro-3-{4- [2-(3-fluoropiperidin-1- yl)pyridin-4-yl]-5,5- dimethylfuran-2(5H)- ylidene}-1,3-dihydro- 2H-indol-2-one 423.4607 445

(3E)-6-fluoro-3-[4- {2-[(2-hydroxyethyl)(2- pyridin-4-ylethyl) amino]pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H- indol-2-one 486.5443 446

ethyl 4-{4-[(5E)-5-(6- fluoro-2-oxo-1,2-dihydro- 3H-indol-3-ylidene)- 2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin- 2-yl}piperazine-1- carboxylate 478.5213 447

(3E)-6-fluoro- 3-[4-{2-[4-(2- hydroxyethyl)piperazin- 1-yl]pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H- indol-2-one 450.5113 448

(3E)-3-[4-{2-[4-(2- ethoxyethyl)piperazin-1- yl]pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 478.5649 449

(4-{4-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro-3H- indol-3-ylidene)- 2,2-dimethyl-2,5- dihydrofuran-3-yl]pyridin- 2-yl}piperazin-1- yl)acetic acid 464.4945 450

(3E)-3-[4-{2- [ethyl(2-pyridin-2- ylethyl)amino]pyridin-4- yl}-5,5-dimethylfuran- 2(5H)-ylidene]-6-fluoro- 1,3-dihydro-2H-indol- 2-one 470.5453 451

(3E)-3-[4-{2-[bis(2- methoxyethyl)amino] pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 453.5112 452

(3E)-6-fluoro- 3-[4-{2-[(2- methoxyethyl)(methyl) amino]pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro-2H- indol-2-one 409.4586 453

(3E)-3-[4- {2-[ethyl(2- hydroxyethyl)amino] pyridin-4-yl}-5,5- dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 409.4586 454

(3E)-3-[5,5-dimethyl-4- {2-[(tetrahydrofuran-2- ylmethyl)(2-thienylmethyl) amino]pyridin-4- yl}furan-2(5H)-ylidene]- 6-fluoro-1,3-dihydro- 2H-indol-2-one 517.6222

TABLE 9 [5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one thienylmethyl derivatives Example# Chemical Structure Chemical Name FW 455

(3E)-6-fluoro-3-[4-{5- [(4-hydroxypiperidin-1- yl)methyl]-3-thienyl}-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro- 2H-indol-2-one 440.5365 456

(3E)-6-fluoro-3- {4-[5-({4-[2-(2- hydroxyethoxy)ethyl] piperazin-1-yl}methyl)-3- thienyl]-5,5-dimethylfuran- 2(5H)-ylidene}-1,3- dihydro-2H-indol-2-one 513.6308 457

methyl [({4-[(5E)-5- (6-fluoro-2-oxo-1,2- dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]-2- thienyl}methyl)amino]acetate 428.4819 458

(3E)-6-fluoro- 3-[4-(5-{[2- (hydroxymethyl)morpholin- 4-yl]methyl}-3- thienyl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 456.5355 459

(3E)-3-{5,5-dimethyl- 4-[5-(morpholin-4- ylmethyl)-3-thienyl]furan- 2(5H)-ylidene}-6- fluoro-1,3-dihydro- 2H-indol-2-one 426.5097 460

(3E)-3-[4-(5-{[(1,1- dioxidotetrahydro-3- thienyl)(methyl)amino] methyl}-3-thienyl)-5,5- dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 488.6015 461

(3E)-6-fluoro- 3-[4-(5-{[3- (hydroxymethyl)piperidin- 1-yl]methyl}-3- thienyl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 454.5633 462

(3E)-6-fluoro-3-[4-{5- [(3-hydroxypiperidin-1- yl)methyl]-3-thienyl)-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro- 2H-indol-2-one 440.5365 463

(3E)-6-fluoro- 3-[4-(5-{[4- (hydroxymethyl)piperidin- 1-yl]methyl}-3- thienyl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 454.5633 464

(3E)-6-fluoro- 3-[4-(5-{[3-(2- hydroxyethyl)piperidin-1- yl]methyl}-3-thienyl)- 5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro- 2H-indol-2-one 468.5901 465

(3E)-6-fluoro-3-[4-{5- [(3-fluoropiperidin-1- yl)methyl]-3-thienyl}-5,5- dimethylfuran-2(5H)- ylidene]-1,3-dihydro- 2H-indol-2-one 442.5276 466

methyl 1-({4-[(5E)-5- (6-fluoro-2-oxo-1,2- dihydro-3H-indol-3- ylidene)-2,2-dimethyl-2,5- dihydrofuran-3-yl]-2- thienyl}methyl)-4- hydroxypyrrolidine- 2-carboxylate 484.5455 467

ethyl 4-({4-[(5E)-5- (6-fluoro-2-oxo-1,2- dihydro-3H-indol-3-ylidene)- 2,2-dimethyl-2,5- dihydrofuran-3-yl]-2- thienyl}methyl)piperazine- 1-carboxylate 497.5882 468

(3E)-6-fluoro-3- [4-(5-{[4-(2- hydroxyethyl)piperazin-1- yl]methyl}-3-thienyl)- 5,5-dimethylfuran-2(5H)- ylidene]-1,3-dihydro- 2H-indol-2-one 469.5782 469

(3E)-3-[4-(5- {[ethyl(2-pyridin-2- ylethyl)amino]methyl}- 3-thienyl)-5,5- dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 489.6122 470

(3E)-3-[4-(5-{[bis(2- methoxyethyl)amino] methyl}-3-thienyl)-5,5- dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 472.5781 471

(3E)-6-fluoro- 3-[4-(5-{[(2- methoxyethyl)(methyl) amino]methyl}-3- thienyl)-5,5-dimethylfuran- 2(5H)-ylidene]-1,3- dihydro-2H-indol-2-one 428.5255 472

(3E)-3-[4- (5-{[ethyl(2- hydroxyethyl)amino] methyl}-3-thienyl)-5,5- dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 428.5255 473

(3E)-3-[4-{5-[({2-[4- (2-aminoethyl)piperazin-1- yl]ethyl}amino)methyl]- 3-thienyl}-5,5- dimethylfuran-2(5H)- ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 511.6626 474

(3E)-6-fluoro-3-{4-[5- ({[2-(4-hydroxypiperidin- 1-yl)ethyl]amino}methyl)- 3-thienyl]-5,5- dimethylfuran-2(5H)- ylidene}-1,3-dihydro-2H- indol-2-one 483.605 475

(3E)-3-{5,5- dimethyl-4-[5-({[2-(2- oxoimidazolidin-1- yl)ethyl]amino}methyl)-3- thienyl]furan-2(5H)- ylidene}-6-fluoro-1,3- dihydro-2H-indol-2-one 468.5505

TABLE 10 [5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one amine derivatives Example # Chemical Structure Chemical Name FW 476

(3E)-6-fluoro-3-{4-[4-(2- hydroxyethyl) piperazin-1-yl]-5,5- dimethylfuran-2(5H)- ylidene}-1,3-dihydro-2H- indol-2-one 373.4256 477

(3E)-3-{4-[(2,4- dimethoxybenzyl)amino]-5,5- dimethylfuran-2(5H)- ylidene}-6-fluoro-1,3- dihydro-2H-indol-2-one 410.4427 478

N-[(5E)-5-(6-fluoro- 2-oxo-1,2-dihydro-3H- indol-3-ylidene)- 2,2-dimethyl-2,5- dihydrofuran- 3-yl]-6-[4-(2- hydroxyethyl)piperazin- 1-yl]nicotinamide 493.5362 479

(3E)-6-bromo-3-(5,5- dimethyl-4-morpholin-4- ylfuran-2(5H)-ylidene)- 1,3-dihydro-2H-indol-2- one 391.2631 480

(3E)-3-(5,5-dimethyl-4- morpholin-4-ylfuran- 2(5H)-ylidene)-6-iodo- 1,3-dihydro-2H-indol-2- one 438.26

TABLE 11 [5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one carbonyl derivatives Example # Structure Chemical Name FW 481

(3E)-3-[5,5-dimethyl-4-(morpholin-4- ylcarbonyl)furan-2(5H)-ylidene]-6-fluoro-1,3- dihydro-2H-indol-2-one 358.3671 482

(3E)-6-fluoro-3-[4-{[4-(2- hydroxyethyl)piperazin-1-yl]carbonyl}-5,5- dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H- indol-2-one 401.4356

TABLE 12 [(3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3- dihydro-1H-indol-6-yl] derivatives Example # Chemical Structure Chemical Name FW 483

methyl 2-{[(3E)-3-(5,5-dimethyl-4-morpholin- 4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro- 1H-indol-6-yl]thio}benzoate 478.5664 484

2-{[(3E)-3-(5,5-dimethyl-4-morpholin-4- ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H- indol-6-yl]thio}benzoic acid 464.5396 485

2-{[(3E)-3-(5,5-dimethyl-4-morpholin-4- ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H- indol-6-yl]thio}-N-methylbenzamide 477.5823 486

N-(3-{[(3E)-3-(5,5-dimethyl-4-morpholin-4- ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H- indol-6-yl]amino}phenyl)acetamide 460.5312 The present invention is further directed to pharmaceutical compositions comprising a pharmaceutically effective amount of the above-described compounds and a pharmaceutically acceptable carrier or excipient. Such a composition is believed to modulate signal transduction by a tyrosine kinase, either by inhibition of catalytic activity, affinity to ATP or ability to interact with a substrate.

More particularly, the compositions of the present invention may be included in methods for treating diseases comprising proliferation, fibrotic or metabolic disorders, for example cancer, fibrosis, psoriasis, atherosclerosis, arthritis, and other disorders related to abnormal vasculogenesis and/or angiogenesis, such as diabetic retinopathy.

The following defined terms are used throughout this specification:

“Me” refers to methyl.

“Et” refers to ethyl.

“tBu” refers to t-butyl.

“iPr” refers to i-propyl.

“Ph” refers to phenyl.

“Pharmaceutically acceptable salt” refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

“Alkyl” refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, most preferably 1 to 4 carbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like. The alkyl group may be optionally substituted with one or more substituents are selected from the group consisting of hydroxyl, cyano, alkoxy, ═O, ═S, NO₂, halogen, dimethyl amino, and SH.

“Alkenyl” refers to a straight-chain, branched or cyclic unsaturated hydrocarbon group containing at least one carbon-carbon double bond. Preferably, the alkenyl group has 2 to 12 carbons. More preferably it is a lower alkenyl of from 2 to 7 carbons, most preferably 2 to 4 carbons. The alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, ═O, ═S, NO₂, halogen, dimethyl amino, and SH.

“Alkynyl” refers to a straight-chain, branched or cyclic unsaturated hydrocarbon containing at least one carbon-carbon triple bond. Preferably, the alkynyl group has 2 to 12 carbons. More preferably it is a lower alkynyl of from 2 to 7 carbons, most preferably 2 to 4 carbons. The alkynyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, ═O, ═S, NO₂, halogen, dimethyl amino, and SH.

“Alkoxyl” refers to an “O-alkyl” group.

“Aryl” refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups. The aryl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxyl, SH, OH, NO₂, amine, thioether, cyano, alkoxy, alkyl, and amino.

“Alkaryl” refers to an alkyl that is covalently joined to an aryl group. Preferably, the alkyl is a lower alkyl.

“Carbocyclic aryl” refers to an aryl group wherein the ring atoms are carbon.

“Carbocyclic ring” refers to a cyclic aliphatic ring or an aryl ring wherein the ring atoms are carbon.

“Heterocyclic aryl” refers to an aryl group having from 1 to 3 heteroatoms as ring atoms, the remainder of the ring atoms being carbon. Heteroatoms include oxygen, sulfur, and nitrogen. Thus, heterocyclic aryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like.

“Heterocyclic ring” refers to an aliphatic ring or heterocyclic aryl wherein one or more of the ring atoms are heteroatoms.

“Hydrocarbyl” refers to a hydrocarbon radical having only carbon and hydrogen atoms. Preferably, the hydrocarbyl radical has from 1 to 20 carbon atoms, more preferably from 1 to 12 carbon atoms and most preferably from 1 to 7 carbon atoms.

“Substituted hydrocarbyl” refers to a hydrocarbyl radical wherein one or more, but not all, of the hydrogen and/or the carbon atoms are replaced by a halogen, nitrogen, oxygen, sulfur or phosphorus atom or a radical including a halogen, nitrogen, oxygen, sulfur or phosphorus atom, e.g. fluoro, chloro, cyano, nitro, hydroxyl, phosphate, thiol, etc.

“Amide” refers to —C(O)—NH—R′, wherein R′ is alkyl, aryl, alkylaryl or hydrogen.

“Thioamide” refers to —C(S)—NH—R′, wherein R′ is alkyl, aryl, alkylaryl or hydrogen.

“Amine” refers to a —N(R″)R′″ group, wherein R″ and R′″ are independently selected from the group consisting of alkyl, aryl, and alkylaryl.

“Thioether” refers to —S—R″, wherein R″ is alkyl, aryl, or alkylaryl.

“Sulfonyl” refers to —S(O)₂—R″″, where R″″ is aryl, C(CN)═C-aryl, CH₂CN, alkyaryl, sulfonamide, NH-alkyl, NH-alkylaryl, or NH-aryl.

The present invention relates to compounds capable of regulating and/or modulating tyrosine kinase signal transduction and more particularly receptor and non-receptor tyrosine kinase signal transduction.

Receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response (e.g., cell division, metabolic effects and responses to the extracellular microenvironment).

It has been shown that tyrosine phosphorylation sites in growth factor receptors function as high-affinity binding sites for SH2 (src homology) domains of signaling molecules. Several intracellular substrate proteins that associate with receptor tyrosine kinases have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such domain but serve as adapters and associate with catalytically active molecules. The specificity of the interactions between receptors and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. These observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

Tyrosine kinase signal transduction results in, among other responses, cell proliferation, differentiation and metabolism. Abnormal cell proliferation may result in a wide array of disorders and diseases, including the development of neoplasia such as carcinoma, sarcoma, leukemia, glioblastoma, hemangioma, psoriasis, arteriosclerosis, arthritis and diabetic retinopathy (or other disorders related to uncontrolled angiogenesis and/or vasculogenesis, e.g. macular degeneration).

This invention is therefore directed to compounds which regulate, modulate and/or inhibit tyrosine kinase signal transduction by affecting the enzymatic activity of the RTKs and/or the non-receptor tyrosine kinases and interfering with the signal transduced such proteins. More particularly, the present invention is directed to compounds which regulate, modulate and/or inhibit the RTK and/or non-receptor tyrosine kinase mediated signal transduction pathways as a therapeutic approach to cure many kinds of solid tumors, including but not limited to carcinoma, sarcoma, leukemia, erythroblastoma, glioblastoma, meningioma, astrocytoma, melanoma and myoblastoma. Indications may include, but are not limited to brain cancers, bladder cancers, ovarian cancers, gastric cancers, pancreas cancers, colon cancers, blood cancers, lung cancers and bone cancers.

The invention is further illustrated by the following non-limiting examples.

Preparation of 6-Fluoro-3-(4-methoxy-5H-furan-2-ylidene)-1,3-dihydro-indol-2-one

To a stirred solution of 6-fluorooxindole (2.6 g, 17.5 mmol) in anhydrous THF (30 mL) under nitrogen was added 1.0M LiHMDS/THF solution (35 mL, 35 mmol). The mixture was stirred at room temperature for 10 minutes. Methyl tetronate (1.0 g, 8.8 mmol) was added as one portion. After stirring at room temperature for 1 hour, the reaction was cooled to 0° C., and quenched with 2M HCl until pH=3. The mixture was stirred at room temperature for 2 more hours, and poured into 250 mL of water. The resulting precipitates were filtered, rinsed with water and dried in vacuum to give 6-fluoro-3-(4-methoxy-5H-furan-2-ylidene)-1,3-dihydro-indol-2-one as off-white solid. Yield: 840 mg, 38%.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 3.99 (s, 3H) 5.22 (s, 2H) 6.59 (dd, J=9.52, 2.20 Hz, 1H) 6.63 (s, 1H) 6.66-6.72 (m, 1H) 7.43 (dd, J=8.06, 5.61 Hz, 1H) 10.32 (s, 1H)

Preparation of 3-(4-Methoxy-5H-furan-2-ylidene)-1,3-dihydro-indol-2-one

¹HNMR (500 MHz, DMSO-d₆) δ ppm 3.99 (s, 3H) 5.22 (s, 2H) 6.67 (s, 1H) 6.78 (d, J=7.32 Hz, 1H) 6.88 (t, J=7.32 Hz, 1H) 6.99 (t, J=7.57 Hz, 1H) 7.47 (d, J=7.81 Hz, 1H) 10.17 (s, 1H)

Example 1

6-Fluoro-3-{4-[(2-methoxy-ethyl)-methyl-amino]-5H-furan-2-ylidene}-1,3-dihydro-indol-2-one

HR MS (ES+): 305.0476 (MH⁺)

-   -   (ES−): 303.1947 (M−H)

Example 2

6-Fluoro-3-[4-(4-methyl-piperazin-1-yl)-5H-furan-2-ylidene]-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.22 (s, 3H) 2.40 (t, J=4.88 Hz, 4H) 3.32 (br.s., 4H) 5.33 (s, 2H) 6.21 (s, 1H) 6.52 (dd, J=9.76, 2.44 Hz, 1H) 6.57-6.64 (m, 1H) 7.33 (dd, J=8.30, 5.86 Hz, 1H) 10.05 (s, 1H)

HR MS (ES+): 316.3362 (MH⁺)

Example 3

6-Fluoro-3-(4-{4-[2-(2-hydroxy-ethoxy)-ethyl]-piperazin-1-yl}-5H-furan-2-ylidene)-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.54 (br. s., 6H) 3.32 (br.s., 4H) 3.41 (t, J=5.37 Hz, 2H) 3.49 (q, J=4.88 Hz, 2H) 3.54 (t, J=5.61 Hz, 2H) 4.59 (t, J=5.13 Hz, 1H) 5.32 (s, 2H) 6.20 (s, 1H) 6.52 (d, J=9.28 Hz, 1H) 6.60 (t, J=9.52 Hz, 1H) 7.33 (dd, J=8.06, 6.10 Hz, 1H) 10.05 (s, 1H)

Example 4

6-Fluoro-3-[4-(3-hydroxy-piperidin-1-yl)-5H-furan-2-ylidene]-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.50 (br. s., 2H) 1.82 (br. s., 2H) 3.03 (dd, J=12.69, 7.32 Hz, 1H) 3.10-3.55 (m, 3H) 3.67 (br. s., 1H) 4.99 (br. s., 1H) 5.31 (s, 2H) 6.18 (s, 1H) 6.52 (dd, J=9.76, 2.44 Hz, 1H) 6.56-6.64 (m, 1H) 7.32 (dd, J=8.30, 5.86 Hz, 1H) 10.03 (s, 1H)

Example 5

6-Fluoro-3-[4-(4-hydroxy-piperidin-1-yl)-5H-furan-2-ylidene]-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.41-1.53 (m, 2H) 1.77-1.87 (m, 2H) 3.18 (t, J=7.32 Hz, 2H) 3.49 (br. s., 2H) 3.71-3.80 (m, 1H) 4.84 (d, J=3.91 Hz, 1H) 5.32 (s, 2H) 6.18 (s, 1H) 6.52 (dd, J=9.76, 2.44 Hz, 1H) 6.56-6.63 (m, 1H) 7.32 (dd, J=8.30, 5.86 Hz, 1H) 10.03 (s, 1H)

HR MS (ES+): 317.1436 (MH⁺)

Example 6

6-Fluoro-3-{4-[2-(2-hydroxy-ethoxy)-ethylamino]-5H-furan-2-ylidene}-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 3.34 (br. s, 2H) 3.46-3.50 (m, 2H) 3.53 (q, J=5.21 Hz, 2H) 3.61 (br. s., 2H) 4.60 (t, J=5.61 Hz, 1H) 5.13 (s, 2H) 6.15 (s, 1H) 6.53 (dd, J=9.52, 2.20 Hz, 1H) 6.57-6.67 (m, 1H) 7.34 (dd, J=7.81, 5.86 Hz, 1H) 7.92 (s, 1H) 10.05 (s, 1H)

Example 7

3-[4-(3-Diethylamino-propylamino)-5H-furan-2-ylidene]-6-fluoro-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.96 (t, J=7.08 Hz, 6H) 1.63-1.73 (m, 2H) 2.41-2.49 (m, 6H) 3.19 (br. s., 2H) 5.13 (s, 2H) 6.11 (s, 1H) 6.53 (dd, J=9.52, 2.20 Hz, 1H) 6.57-6.65 (m, 1H) 7.34 (dd, J=8.30, 5.86 Hz, 1H) 7.86 (s, 1H) 10.04 (s, 1H).

Example 8

6-Fluoro-3-[4-(2-morpholin-4-yl-ethylamino)-5H-furan-2-ylidene]-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.43 (br. s., 4H) 2.53 (t, J=5.86 Hz, 2H) 3.29 (br. s, 2H) 3.60 (t, J=4.39 Hz, 4H) 5.13 (s, 2H) 6.14 (s, 1H) 6.53 (dd, J=9.52, 2.20 Hz, 1H) 6.57-6.64 (m, 1H) 7.34 (dd, J=8.30, 5.86 Hz, 1H) 7.80 (s, 1H) 10.04 (s, 1H)

Example 9

6-Fluoro-3-(4-morpholin-4-yl-5H-furan-2-ylidene)-1,3-dihydro-indol-2-one

A mixture of 6-fluoro-3-(4-methoxy-5H-furan-2-ylidene)-1,3-dihydro-indol-2-one (100 mg, 0.40 mmol) and morpholine (0.5 mL, 5.7 mmol) in 20 mL of EtOH was heated at reflux for 16 hours. The mixture was cooled to room temperature. The precipitates were filtered, rinsed with EtOH and dried in vacuum to give 6-fluoro-3-(4-morpholin-4-yl-5H-furan-2-ylidene)-1,3-dihydro-indol-2-one as a pale yellow powder. Yield: 55 mg, 45%.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 3.34 (br. s., 4H) 3.70 (t, J=4.88 Hz, 4H) 5.35 (s, 2H) 6.25 (s, 1H) 6.54 (dd, J=9.28, 2.44 Hz, 1H) 6.59-6.65 (m, 1H) 7.35 (dd, J=8.54, 5.61 Hz, 1H) 10.07 (s, 1H)

Example 10

6-Fluoro-3-[4-(3-morpholin-4-yl-propylamino)-5H-furan-2-ylidene]-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.68-1.77 (m, 2H) 2.35 (t, J=6.59 Hz, 6H) 3.22 (br. s., 2H) 3.59 (t, J=4.39 Hz, 4H) 5.13 (s, 2H) 6.13 (s, 1H) 6.53 (dd, J=9.52, 1.71 Hz, 1H) 6.58-6.64 (m, 1H) 7.34 (dd, J=7.81, 5.86 Hz, 1H) 7.86 (s, 1H) 10.04 (s, 1H).

Example 11

3-{4-[4-(3-Diethylamino-propoxy)-3-fluoro-phenylamino]-5H-furan-2-ylidene}-6-fluoro-1,3-dihydro-indol-2-one

HR MS (ES+): 456.1934 (MH⁺)

-   -   (ES−): 454.2536 (M−H)

Example 12

3-{4-[4-(2-Diethylamino-ethoxy)-phenylamino]-5H-furan-2-ylidene}-6-fluoro-1,3-dihydro-indol-2-one

HR MS (ES+): 424.2889 (MH⁺)

-   -   (ES−): 422.2836 (M−H)

Preparation of 4-Bromo-5H-furan-2-one

To a stirred suspension of tetronic acid (5.0 g, 50 mmol) in 100 mL of anhydrous CH₂Cl₂, was added 5 mL of anhydrous DMF, and cooled with ice bath. Oxalyl bromide (5.6 mL, 60 mmol) was added slowly over 50 minutes. The mixture was stirred at 0° C. for 30 minutes and then room temp for 2 hours. Water (100 mL) was added and the mixture separated into two layers. The aqueous layer was extracted with Et₂O (2×100 mL). All the organic layers were combined, washed with water (100 mL), saturated NaHCO₃ (2×100 mL) and brine (100 mL), dried over Na₂SO₄, and evaporated to dryness to give 4-bromo-5H-furan-2-one as a light brown solids.

Yield: 5.6 g, 69%.

¹H NMR (500 MHz, CDCl₃) δ ppm 4.87-4.89 (m, 2H) 6.36-6.38 (m, 1H)

Preparation of 3-(4-Bromo-5H-furan-2-ylidene)-6-fluoro-1,3-dihydro-indol-2-one

To a 0° C. stirred solution of 6-fluorooxindole (370 mg, 2.45 mmol) in anhydrous THF (10 mL) was added 1M LiHMDS/THF solution (4.9 mL, 4.9 mmol). The mixture was stirred at 0° C. for 10 minutes. 4-Bromo-5H-furan-2-one (200 mg, 1.23) was added as a solution in 2 mL of THF. The resulting mixture was stirred at 0° C. for 30 minutes, then at room temperature for 1 hour and quenched with 10 mL of 2M HCl. Methanol (5 mL) was added and the mixture was stirred at 50° C. for 0.5 hour. The mixture was poured into 150 mL of water and then stirred for 30 minutes. The precipitates were filtered, washed with water, and dried in vacuum to give 3-(4-bromo-5H-furan-2-ylidene)-6-fluoro-1,3-dihydro-indol-2-one as a yellow solid. Yield: 228 mg, 63%.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 5.44 (s, 2H) 6.62 (dd, J=9.28, 2.44 Hz, 1H) 6.70-6.76 (m, 1H) 7.47 (dd, J=8.30, 5.37 Hz, 1H) 7.67 (t, J=1.71 Hz, 1H) 10.48 (s, 1H)

Example 40

4-[5-(6-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidene)-2,5-dihydro-furan-3-yl]-benzoic acid methyl ester

To a 1:1 mixture of toluene/water (10 mL), were added the bromide (40 mg, 0.14 mmol), 4-methoxycarbonylphenylboronic acid (49 mg, 0.27 mmol), PdCl₂(PPh₃)₂ (17 mg, 0.024 mmol), 2M KF aqueous solution (0.35 mL, 0.7 mmol), benzyltriethylammonium chloride (3 mg, 0.013 mmol). The mixture was heated at 80° C. under N₂ for 16 hours, cooled to room temperature and extracted with EtOAc (2×50 mL). The organic layers were combined, washed with saturated NaHCO₃ (50 mL) and brine (50 mL), dried over Na₂SO₄. Purification through silica gel column with 10-25% MeOH/CHCl₃ led to the product as a brown solid. Yield: 29 mg, 62%.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 3.88 (s, 3H) 5.83 (s, 2H) 6.63 (dd, J=9.28, 2.44 Hz, 1H) 6.70-6.79 (m, 1H) 7.55 (dd, J=8.30, 5.86 Hz, 1H) 7.86 (d, J=8.30 Hz, 2H) 7.98 (s, 1H) 8.04 (d, J=8.30 Hz, 2H) 10.48 (s, 1H)

The Examples 13 through 46 were prepared using the experiment procedure described in Example 40, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation

Example 34

(3E)-6-fluoro-3-[4-(1H-pyrrol-3-yl)furan-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

A solution of (3E)-6-fluoro-3-{4-[1-(triisopropylsilyl)-1H-pyrrol-3-yl]furan-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one (Example 33; 90 mg) in a mixture of trifluoroacetic acid (7 mL) and CH₂Cl₂ (7 mL) was stirred at room temperature for 3 days. The mixture was evaporated to dryness, and re-dissolved in 1:1 THF/MeOH (6 mL). The solution was slowly added into diluted NaHCO₃ solution (100 mL) with stirring. The precipitates were filtered, washed with water, and dried in vacuum to give (3E)-6-fluoro-3-[4-(1H-pyrrol-3-yl)furan-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as brown solid. Yield: 40 mg.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 5.60 (s, 2H) 6.49 (s, 1H) 6.59 (dd, J=9.28, 1.95 Hz, 1H) 6.66-6.74 (m, 1H) 6.92 (s, 1H) 7.38 (d, J=5.86 Hz, 2H) 7.49 (dd, J=7.81, 5.86 Hz, 1H) 10.32 (s, 1H) 11.43 (s, 1H)

Example 35

(3E)-6-fluoro-3-{4-[1-(triisopropylsilyl)-1H-pyrrol-3-yl]furan-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.06 (d, J=7.81 Hz, 18H) 1.51-1.61 (m, 3H) 5.62 (s, 2H) 6.59 (dd, J=9.28, 2.44 Hz, 1H) 6.63 (d, J=1.95 Hz, 1H) 6.67-6.74 (m, 1H) 6.97 (s, 1H) 7.44-7.53 (m, 3H) 10.33 (s, 1H) LR MS (EI): 438 (M⁺)

Example 36

(3E)-6-fluoro-3-[4-(1H-pyrrol-2-yl)furan-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

A solution of tert-butyl 2-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,5-dihydrofuran-3-yl]-1H-pyrrole-1-carboxylate (Example 37; 30 mg) in a mixture of trifluoroacetic acid (2 mL) and CH₂Cl₂ (10 mL) was stirred at room temperature for 16 hours. The mixture was evaporated to dryness, and re-dissolved in 1:1 THF/MeOH (4 mL). The solution was slowly added into diluted NaHCO₃ solution (100 mL) with stirring. The precipitates were filtered, washed with water, and dried in vacuum to give (3E)-6-fluoro-3-[4-(1H-pyrrol-2-yl)furan-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as brown solid. Yield: 15 mg.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 5.62 (s, 2H) 6.21-6.25 (m, 1H) 6.57-6.62 (m, 2H) 6.67-6.73 (m, 1H) 7.13 (s, 1H) 7.49 (dd, J=8.06, 5.61 Hz, 1H) 7.61 (s, 1H) 10.32 (s, 1H) 11.95 (s, 1H)

LR MS (EI): 282 (M⁺)

Example 37

tert-butyl 2-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,5-dihydrofuran-3-yl]-1H-pyrrole-1-carboxylate

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.59 (s, 9H) 5.66 (s, 2H) 6.40 (t, J=3.42 Hz, 1H) 6.61 (dd, J=9.76, 2.44 Hz, 1H) 6.69-6.75 (m, 1H) 6.82 (dd, J=3.42, 1.46 Hz, 1H) 7.50 (dd, J=8.30, 5.37 Hz, 1H) 7.59 (dd, J=3.42, 1.46 Hz, 1H) 7.70 (s, 1H) 10.35 (s, 1H)

LR MS (EI): 382 (M⁺)

Example 38

(3E)-6-fluoro-3-[4-(3-thienyl)furan-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 5.71 (s, 2H) 6.61 (dd, J=9.52, 2.20 Hz, 1H) 6.70-6.76 (m, 1H) 7.53 (dd, J=8.30, 5.86 Hz, 1H) 7.60 (d, J=5.37 Hz, 1H) 7.68 (s, 1H) 7.72 (dd, J=5.13, 2.69 Hz, 1H) 8.06 (d, J=2.44 Hz, 1H) 10.42 (s, 1H)

LR MS (EI): 299 (M⁺)

Example 39

3-{4-[5-(6-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidene)-2,5-dihydro-furan-3-yl]-phenyl}-propionic acid

HR MS (ES−): 364.0864 (M−H)

Example 43

6-Fluoro-3-[4-(3-methoxy-phenyl)-5H-furan-2-ylidene]-1,3-dihydro-indol-2-one

HR MS (ES+): 324.2709 (MH⁺)

Example 44

6-Fluoro-3-{4-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-5H-furan-2-ylidene}-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.47 (br.s., 4H) 2.70 (t, J=5.61 Hz, 2H) 3.57 (t, J=4.88 Hz, 4H) 4.17 (t, J=5.61 Hz, 2H) 5.76 (s, 2H) 6.61 (dd, J=9.28, 2.44 Hz, 1H) 6.68-6.76 (m, 1H) 7.07 (d, J=8.79 Hz, 2H) 7.52 (dd, J=8.30, 5.86 Hz, 1H) 7.66 (d, J=8.79 Hz, 2H) 7.72 (s, 1H) 10.40 (s, 1H)

Example 45

3-[4-(4-Dimethylamino-phenyl)-5H-furan-2-ylidene]-6-fluoro-1,3-dihydro-indol-2-one

HR MS (ES+): 337.1384 (MH⁺)

Example 46

6-Fluoro-3-[4-(4-methoxy-phenyl)-5H-furan-2-ylidene]-1,3-dihydro-indol-2-one

¹H NMR (500 MHz, DMSO-d₆) δ ppm 3.83 (s, 3H) 5.77 (s, 2H) 6.61 (dd, J=9.28, 2.44 Hz, 1H) 6.69-6.77 (m, 1H) 7.06 (d, J=8.79 Hz, 2H) 7.52 (dd, J=8.30, 5.86 Hz, 1H) 7.67 (d, J=8.79 Hz, 2H) 7.72 (s, 1H) 10.40 (s, 1H)

Preparation of 4-pyrrolidin-1-ylfuran-2(5H)-one

A mixture of methyl tetronate (2.0 g, 17.5 mmol) and pyrrolidine (4.0 mL, 48 mmol) in EtOH (20 mL) was heated at reflux for 2 hours. The mixture was cooled to room temperature, and evaporated to dryness. The resulting solid was recrystallized with benzene/hexanes to give 4-pyrrolidin-1-ylfuran-2(5H)-one as white crystals. Yield: 2.60 g, 96%.

¹H NMR (500 MHz, CDCl₃) δ ppm 2.01-2.05 (m, 4H) 3.28 (t, J=6.83 Hz, 4H) 4.53 (s, 1H) 4.67 (s, 2H)

Preparation of 5,5-dimethyl-4-pyrrolidin-1-ylfuran-2(5H)-one

To a −78° C. stirred suspension of 4-pyrrolidin-1-ylfuran-2(5H)-one (1.0 g, 6.5 mmol) in 20 ml, of anhydrous THF, was slowly added 1M LiHMDS/THF solution (14.4 mL, 14.4 mmol). The mixture was stirred at −78° C. under nitrogen for 30 minutes, and methyl iodide (3 mL, 24 mmol) was added. The mixture was stirred at −78° C. for 1 hour, then allowed to warm up to room temp. The reaction was quenched with AcOH (3 mL) and water (10 mL), concentrated to about 15 mL, and extracted with CHCl₃ (3×50 mL). The organic layers were combined, washed with 0.5M HCl(2×50 mL), brine (50 mL), dried over Na₂SO₄, and evaporated to give 5,5-dimethyl-4-pyrrolidin-1-ylfuran-2(5H)-one as a brown solid. Yield: 1.08 g, 92%.

¹H NMR (500 MHz, CDCl₃) δ ppm 1.54 (s, 6H) 1.89-1.99 (m, 4H) 3.32 (br. s., 4H) 4.33 (s, 1H)

Preparation of 4-Hydroxy-5,5-dimethyl-5H-furan-2-one

A suspension of 5,5-dimethyl-4-pyrrolidin-1-ylfuran-2(5H)-one (535 mg) in a mixture of MeOH (2 mL) and 5M HCl (8 mL) was heated at 88° C. for 2 hours. The mixture was cooled to room temp., extracted with CHCl₃ (10×15 mL), combined, dried over Na₂SO₄, and evaporated to dryness to give 4-hydroxy-5,5-dimethyl-5H-furan-2-one as light brown solid. Yield: 359 mg, 95%.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.37 (s, 6H) 4.78 (s, 1H) 12.64 (s, 1H)

Preparation of 2,2-dimethyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate

To a −78° C. stirred solution of 4-hydroxy-5,5-dimethyl-5H-furan-2-one (250 mg, 1.95 mmol) in 18 mL of anhydrous CH₂Cl₂, was added triethylamine (0.40 mL, 2.9 mmol) and Tf₂O (0.49 mL, 2.9 mmol). The reaction was stirred at −78° C. for 30 minutes, and quenched with saturated NH₄Cl solution (10 mL). The mixture was warmed up to room temperature and separated. The aqueous layer was extracted with CH₂Cl₂ (2×20 mL). All organic layers were combined, dried over Na₂SO₄ and evaporated to brown oil, which was purified by plugging through a short pad of silica gel column with EtOAc/hexanes (1/3). Evaporation of solvents gave 2,2-dimethyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate as a light brown oil (450 mg, 89%).

Preparation of 4-(4-methoxyphenyl)-5,5-dimethylfuran-2(5H)-one

To a 1:1 mixture of toluene/water (20 mL), were added 2,2-dimethyl-5-oxo-2,5-dihydrofuran-3-yltrifluoromethanesulfonate (100 mg, 0.38 mmol), 4-methoxyphenylboronic acid (87 mg, 0.57 mmol), PdCl₂(PPh₃)₂ (27 mg, 0.038 mmol), 2M KF aqueous solution (0.95 mL, 1.9 mmol), benzyltriethylammonium chloride (8.7 mg, 0.038 mmol). The mixture was heated at 50° C. under N₂ for 30 minutes, cooled to room temperature and extracted with EtOAc (2×50 mL). The organic layers were combined, washed with saturated NaHCO₃ (50 mL) and brine (50 mL), dried over Na₂SO₄. Purification through silica gel column with 10-30% EtOAc/hexanes led to the product as yellow solid. Yield: 33 mg, 40%.

¹H NMR (500 MHz, CDCl₃) δ ppm 1.70 (s, 6H) 3.87 (s, 3H) 6.14 (s, 1H) 6.97 (d, J=8.79 Hz, 2H) 7.53 (d, J=8.79 Hz, 2H)

Example 158

(3E)-6-fluoro-[4-(4-methoxyphenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

To a 0° C. stirred solution of 6-fluorooxindole (45 mg, 0.3 mmol) in anhydrous THF (5 mL) was added 1M LiHMDS/THF solution (0.6 mL, 0.6 mmol). The mixture was stirred at 0° C. for 10 minutes. 4-(4-methoxyphenyl)-5,5-dimethylfuran-2(5H)-one (33 mg, 0.15 mmol) was added. The resulting mixture was stirred at room temperature for 1 hour and quenched with 2 mL of 2M HCl. The mixture was stirred at room temperature for 16 hours and poured into 100 mL of water. The precipitates were filtered, washed with water, and dried in vacuo to give 3(3E)-6-fluoro-3-[4-(4-methoxyphenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as yellow solids. Yield: 228 mg, 63%.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.76 (s, 6H) 3.83 (s, 3H) 6.60 (dd, J=9.28, 2.44 Hz, 1H) 6.69-6.78 (m, 1H) 7.05 (d, J=9.28 Hz, 2H) 7.53 (dd, J=8.30, 5.86 Hz, 1H) 7.66 (s, 1H) 7.76 (d, J=8.79 Hz, 2H) 10.38 (s, 1H)

Preparation of 4-Bromo-5,5-dimethyl-5H-furan-2-one

To a solution of 4-hydroxy-5,5-dimethyl-5H-furan-2-one (2.1 g, 16.4 mmol) in DCE (40 mL) and DMF (1.5 mL) at 0° C. was added dropwise oxalyl bromide (3.0 mL, 32 mmol, 2 equiv). The mixture was stirred at room temperature for 4-5 h, and then put in an ice bath. Ice water (100 mL) was added slowly. The mixture was extracted with CH₂Cl₂ (100 mL). The organic phase was washed with 10% NaHCO₃ and again with water, dried over sodium sulfate and evaporated to give the title compound 2.7 g (86% yield).

¹H NMR (300 MHz, CDCl₃) δ 6.17 (s, 1H), 1.54 (s, 6H), ESI-MS m/z 251.9 (M+H)⁺

Preparation of 3-[4-Bromo-5,5-dimethyl-5H-furan-(2E)-ylidene]-6-fluoro-1.3-dihydro-indol-2-one

To a solution of 6-fluorooxindole (3 g, 20 mmol) in THF (50 mL) at 0° C., was added 40 mL of 1M LHMDS in THF. The reaction mixture was stirred at 0° C. for 15 minutes. A solution of 4-bromo-5,5-dimethyl-5H-furan-2-one (5) (1.91 g, 10 mmol) in 5 mL of THF was added to the above reaction mixture. The reaction was stirred at 0° C. for further 30 minutes and then at room temperature for 2.5 hrs. To the reaction, 80 mL of 2M HCl was added. The resulting mixture was stirred at 50-55° C. for one hour, cooled down to room temperature, poured to 1000 mL of water and was stirred at room temperature for one hour. The precipitates formed were collected and washed with water, dried in vacuum to give the title compound as a yellow solid product (2.4 g, yield: 74%).

¹H NMR (300 MHz, DMSO-d₆) δ 10.46 (s, 1H), 7.54 (s, 1H), 7.49 (dd, J=8.7, 5.4 Hz, 1H), 6.73 (ddd, J=10.8, 8.1, 2.4 Hz, 1H), 6.61 (dd, J=9.3, 2.7 Hz, 1H). 1.57 (s, 6H). ESI-MS m/z 324.3 M⁺

Preparation of Examples 46-158 FIG. 3

Each of the examples was synthesized in 40 mL vial. To each reaction vial, 3-[4-Bromo-5,5-dimethyl-5H-furan-(2E)-ylidene]-6-fluoro-1.3-dihydro-indol-2-one (55 mg, 0.17 mmol), boronic acid (0.4 mmol), THF (4 mL), 1M of potassium carbonate water solution (1.5 mL) and tetrakis(triphenylphosphine) palladium(0) (18 mg) were added. The reaction was heated at 60° C. overnight under nitrogen atmosphere. After cooling down to room temperature, 10 mL of ethyl acetate and 8 mL of water were added. The organic layer was evaporated to give the crude product that was subjected to QC and purification. The library compounds were purified by high throughput RP-HPLC. Each compound was re-analyzed by LCMS after purification.

Preparation of methyl 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoate

To 30 mL of 1,4-dioxane, was added the following reagents: (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (500 mg, 1.54 mmol), 4-methoxycarbonylphenylboronic acid (333 mg, 1.85 mmol), PdCl₂(PPh₃)₂ (54 mg, 0.077 mmol), 1M Na₂CO₃ aqueous solution (6.2 mL, 6.2 mmol). The mixture was heated at 80° C. under N₂ for 1 hour, cooled to room temperature and poured into 200 mL of water. The brown precipitates were filtered, washed with water and dried to give the crude product. Purification through silica gel column with 1-5% MeOH/CHCl₃ led to methyl 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoate as orange/red solid. Yield: 500 mg, 86%.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.79 (s, 6H) 3.89 (s, 3H) 6.63 (d, J=8.79 Hz, 1H) 6.77 (t, J=8.30 Hz, 1H) 7.57 (dd, J=7.57, 5.61 Hz, 1H) 7.89 (s, 1H) 7.96 (d, J=8.30 Hz, 2H) 8.05 (d, J=8.30 Hz, 2H) 10.47 (s, 1H)

Preparation of 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoic acid

Methyl 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoate (500 mg, 1.32 mmol) was added to a mixture of 1M NaOH (4 mL, 4 mmol), THF (8 mL) and MeOH (20 mL). The mixture was heated at 58° C. for 5 hours, cooled to room temp., and poured into 200 mL of water. 2M HCl was added to bring pH down to 3. The precipitates were filtered, washed with water and dried in vacuo to give 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoic acid as an orange/red solid. Yield: 480 mg, quantitative.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.77 (s, 6H) 6.61 (dd, J=9.38, 2.35 Hz, 1H) 6.71-6.78 (m, 1H) 7.55 (dd, J=8.50, 5.57 Hz, 1H) 7.86 (s, 1H) 7.90 (d, J=8.50 Hz, 2H) 8.02 (d, J=8.50 Hz, 2H) 10.44 (s, 1H) 13.16 (br s, 1H)

LR MS (ES−): 364 (M−1)

Example 159

(3E)-6-Fluoro-3-[4-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

A mixture of 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoic acid (50 mg, 0.137 mmol), 4-hydroxypiperidine (15 mg, 0.15 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) (57 mg, 0.15 mmol) and diisopropylethylamine (39 mg, 0.30 mmol) in 3 mL of anhydrous DMF was stirred at room temperature. The mixture was poured into 75 mL of water. The precipitates were filtered, washed with water, and dried in vacuo to give (3E)-6-fluoro-3-[4-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as orange solid. Yield: 52 mg, 85%.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.30-1.43 (m, 2H) 1.68-1.83 (m, 2H) 1.79 (s, 6H) 3.12-3.28 (m, 2H) 3.51 (br s, 1H) 3.72-3.78 (m, 1H) 4.02 (br s, 1H) 4.80 (d, J=3.91 Hz, 1H) 6.63 (dd, J=9.28, 2.44 Hz, 1H) 6.73-6.79 (m, 1H) 7.49 (d, J=8.30 Hz, 2H) 7.56 (dd, J=8.30, 5.86 Hz, 1H) 7.83 (s, 1H) 7.86 (d, J=8.30 Hz, 2H) 10.44 (s, 1H)

LR MS (ES+): 449 (M+1)

The following examples 160 through 178 were prepared using the experiment procedure described in Example 159, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 160

N-[2-(diethylamino)ethyl]-4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzamide

¹H NMR (500 MHz, d₆-DMSO) δ ppm 0.98 (t, J=7.08 Hz, 6H) 1.79 (s, 6H) 2.53 (q, J=7.32 Hz, 4H) 2.58 (t, J=6.83 Hz, 2H) 3.28-3.38 (m, 2H) 6.63 (dd, J=9.28, 2.44 Hz, 1H) 6.74-6.79 (m, 1H) 7.57 (dd, J=8.30, 5.86 Hz, 1H) 7.85 (s, 1H) 7.89 (d, J=8.79 Hz, 2H) 7.94 (d, J=8.79 Hz, 2H) 8.54 (t, J=5.86 Hz, 1H) 10.46 (s, 1H)

Example 161

(3E)-6-fluoro-3-{4-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.79 (s, 6H) 2.40-2.50 (br, 6H) 3.34-3.37 (m, 2H) 3.40 (t, J=5.13 Hz, 2H) 3.48 (q, J=5.21 Hz, 2H) 3.53 (t, J=5.86 Hz, 2H) 3.63 (br s, 2H) 4.61 (t, J=5.61 Hz, 1H) 6.64 (dd, J=9.76, 2.44 Hz, 1H) 6.74-6.80 (m, 1H) 7.51 (d, J=8.30 Hz, 2H) 7.57 (dd, J=8.30, 5.86 Hz, 1H) 7.83 (s, 1H) 7.87 (d, J=8.30 Hz, 2H) 10.45 (s, 1H)

LR MS (ES+): 522 (M+1)

Example 162

(3E)-3-[4-(4-{[(2R,3R,4R)-3,4-Dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.80 (s, 6H) 3.26-3.30 (m, 1H) 3.54 (dd, J=10.74, 5.86 Hz, 1H) 3.64-3.71 (m, 1H) 3.78-3.83 (m, 1H) 3.86-3.89 (m, 2H) 4.04-4.07 (m, 1H) 4.98 (t, J=5.37 Hz, 1H) 5.23 (d, J=4.39 Hz, 1H) 5.30 (d, J=4.39 Hz, 1H) 6.63 (dd, J=9.76, 2.44 Hz, 1H) 6.74-6.79 (m, 1H) 7.54-7.61 (m, 3H) 7.84 (s, 1H) 7.87 (d, J=8.30 Hz, 2H) 10.45 (s, 1H)

LR MS (ES+): 481 (M+1)

Example 163

(3E)-6-fluoro-3-[4-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.77 (s, 6H) 2.39-2.45 (m, 6H) 3.34 (br s, 2H) 3.49 (q, J=5.96 Hz, 2H) 3.60 (br s, 2H) 4.41 (t, J=5.28 Hz, 1H) 6.61 (dd, J=9.53, 2.49 Hz, 1H) 6.71-6.78 (m, 1H) 7.48 (d, J=8.21 Hz, 2H) 7.54 (dd, J=8.35, 5.72 Hz, 1H) 7.81 (s, 1H) 7.84 (d, J=8.50 Hz, 2H) 10.42 (s, 1H)

LR MS (ES+): 478 (M+1)

Example 164

5-Fluoro-3-[4-[4-(3-hydroxy-pyrrolidine-1-carbonyl)-phenyl]-5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one

LR MS (ES−): 433 (M−1)

Example 165

3-[5,5-Dimethyl-4-[4-((3R,4R,5S)-3,4,5-trihydroxy-piperidine-1-carbonyl)-phenyl]5H-furan-(2E)-ylidene]-6-fluoro-1,3-dihydro-indol-2-one

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.78 (s, 6H) 2.71 (br, 1H) 2.90 (br, 1H) 3.09-3.16 (m, 2H) 3.21 (br, 1H) 3.49 (br, 1H) 4.28 (br, 1H) 5.00 (d, J=3.81 Hz, 2H) 5.15 (br, 1H) 6.61 (dd, J=9.38, 2.35 Hz, 1H) 6.71-6.78 (m, 1H) 7.49 (d, J=8.50 Hz, 2H) 7.54 (dd, J=8.21, 5.86 Hz, 1H) 7.82 (s, 1H) 7.86 (d, J=8.50 Hz, 2H) 10.42 (s, 1H)

LR MS (ES−): 479 (M−1)

Example 166

3-[5,5-Dimethyl-4-[4-((2S,3R,4S,5R)-3,4,5-trihydroxy-2-methyl-piperidine-1-carbonyl)-phenyl]-5H-furan-(2E)-ylidene]-6-fluoro-1,3-dihydro-indol-2-one

LR MS (ES−): 493 (M−1)

Example 167

4-[(5E)-5-(6-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-N-(2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl)benzamide

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.77 (s, 6H) 3.35-3.55 (m, 16H) 4.53 (t, J=5.42 Hz, 1H) 6.61 (dd, J=9.38, 2.35 Hz, 1H) 6.71-6.78 (m, 1H) 7.55 (dd, J=8.35, 5.72 Hz, 1H) 7.83 (s, 1H) 7.87 (d, J=8.79 Hz, 2H) 7.94 (d, J=8.50 Hz, 2H) 8.65 (t, J=5.42 Hz, 1H) 10.43 (s, 1H)

LR MS (ES+): 563 (M+Na⁺)

Example 168

(3E)-5-Fluoro-3-[4-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.81 (s, 6H) 2.36-2.48 (m, 6H) 3.34 (br s, 2H) 3.49-3.53 (m, 2H) 3.63 (br s, 2H) 4.43 (t, J=5.13 Hz, 1H) 6.78 (dd, J=8.54, 4.64 Hz, 1H) 6.85-6.92 (m, 1H) 7.35 (dd, J=8.79, 2.44 Hz, 1H) 7.51 (d, J=8.30 Hz, 2H) 7.85 (s, 1H) 7.88 (d, J=8.30 Hz, 2H) 10.30 (s, 1H)

Example 169

(3E)-3-[4-(4-{[(3S,4S)-3,4-Dihydroxypyrrolidin-1-yl]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.78 (s, 6H) 3.19 (d, J=10.85 Hz, 1H) 3.34 (d, J=12.90 Hz, 1H) 3.63-3.73 (m, 2H) 3.90 (br s, 1H) 3.97 (br s, 1H) 5.10 (d, J=3.22 Hz, 1H) 5.21 (d, J=3.52 Hz, 1H) 6.61 (dd, J=9.38, 2.35 Hz, 1H) 6.71-6.78 (m, 1H) 7.54 (dd, J=8.35, 5.72 Hz, 1H) 7.61 (d, J=8.50 Hz, 2H) 7.82 (s, 1H) 7.84 (d, J=8.50 Hz, 2H) 10.42 (s, 1H)

LR MS (ES−): 449 (M−1)

Example 170

(3E)-3-[4-(4-{[(3S,4S)-3,4-Dihydroxypyrrolidin-1-yl]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.80 (s, 6H) 3.19 (d, J=10.85 Hz, 1H) 3.34 (d, J=12.90 Hz, 1H) 3.63-3.73 (m, 2H) 3.90 (br s, 1H) 3.97 (br s, 1H) 5.10 (d, J=3.22 Hz, 1H) 5.21 (d, J=3.22 Hz, 1H) 6.76 (dd, J=8.50, 4.69 Hz, 1H) 6.84-6.91 (m, 1H) 7.33 (dd, J=8.79, 2.35 Hz, 1H) 7.61 (d, J=8.21 Hz, 2H) 7.84 (s, 1H) 7.86 (d, J=8.50 Hz, 2H) 10.28 (s, 1H)

LR MS (ES−): 449 (M−1)

Example 171

Methyl (3E)-3-{5,5-dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carboxylate

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.83 (s, 6H) 1.79-1.89 (m, 4H) 3.42 (t, J=6.30 Hz, 2H) 3.49 (t, J=6.45 Hz, 2H) 3.84 (s, 3H) 6.92 (d, J=7.92 Hz, 1H) 7.65 (d, J=8.21 Hz, 2H) 7.77 (dd, J=8.06, 1.61 Hz, 1H) 7.88 (d, J=8.50 Hz, 2H) 7.90 (s, 1H) 8.16 (d, J=1.17 Hz, 1H) 10.73 (s, 1H)

Example 172

(3E)-3-{5,5-Dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carboxylic acid

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.83 (s, 6H) 1.82-1.92 (m, 4H) 3.42 (t, J=6.35 Hz, 2H) 3.49 (t, J=6.83 Hz, 2H) 6.89 (d, J=8.30 Hz, 1H) 7.64 (d, J=8.30 Hz, 2H) 7.75 (dd, J=8.06, 1.71 Hz, 1H) 7.88 (d, J=8.30 Hz, 2H) 7.91 (s, 1H) 8.15 (d, J=1.95 Hz, 1H) 10.70 (s, 1H) 12.58 (s, 1H)

LR MS (ES−): 443 (M−1)

Example 173

Methyl (3E)-3-{5,5-dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-6-carboxylate

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.83 (s, 6H) 1.79-1.91 (m, 4H) 3.41 (t, J=6.01 Hz, 2H) 3.49 (t, J=6.74 Hz, 2H) 3.84 (s, 3H) 7.37 (s, 1H) 7.60-7.70 (m, 4H) 7.88-7.91 (m, 3H) 10.52 (s, 1H)

Example 174

(3E)-3-{5,5-Dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-6-carboxylic acid

¹H NMR (300 MHz, d₆-DMSO) ppm 1.80 (s, 6H) 1.79-1.86 (m, 4H) 3.40 (t, J=6.01 Hz, 2H) 3.47 (t, J=6.74 Hz, 2H) 7.34 (s, 1H) 7.56-7.67 (m, 4H) 7.83-7.92 (m, 3H) 10.46 (s, 1H) 12.69 (s, 1H)

LR MS (ES−): 443 (M−1)

Example 175

Methyl (3E)-3-[4-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-2-oxoindoline-6-carboxylate

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.81 (s, 6H) 2.41 (t, J=5.86 Hz, 6H) 3.34 (br s, 2H) 3.49 (q, J=5.28 Hz, 2H) 3.61 (br s, 2H) 3.82 (s, 3H) 4.42 (t, J=5.57 Hz, 1H) 7.35 (d, J=1.17 Hz, 1H) 7.50 (d, J=8.21 Hz, 2H) 7.60 (dd, J=7.62, 1.47 Hz, 1H) 7.67 (d, J=7.92 Hz, 1H) 7.88 (d, J=8.21 Hz, 2H) 7.89 (s, 1H) 10.50 (s, 1H)

LR MS (ES+): 539 (M+Na⁺)

LR MS (ES−): 516 (M−1)

Example 176

(3E)-3-{5,5-Dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-N-methyl-2-oxoindoline-6-carboxamide

LR MS (ES−): 456 (M−1)

Example 177

Methyl (3E)-3-{5,5-dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-5-fluoro-2-oxoindoline-6-carboxylate

LR MS (ES+): 499 (M+Na⁺)

LR MS (ES−): 475 (M−1)

Example 178

Methyl (3E)-3-[4-(4-{[(2,3-dihydroxypropyl)(methyl)amino]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-5-fluoro-2-oxoindoline-6-carboxylate

LR MS (ES−): 509 (M−1)

Preparation of (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-5,6-difluoro-1,3-dihydro-2H-indol-2-one

To a solution of 5,6-difluorooxindole (450 mg, 2.66 mmol) in THF (20 mL) at 0° C., was added 1M LiHMDS in THF (5.3 mL, 5.3 mmol). The reaction mixture was stirred at 0° C. for 10 minutes. 4-bromo-5,5-dimethyl-5H-furan-2-one (340 mg, 1.78 mmol) was then added. The reaction mixture was stirred at 0° C. for 30 min., and then at room temperature for an additional 30 min and quenched with 2.5M aqueous H₂SO₄ (3 mL). The resulting mixture was stirred at room temperature for 16 hours and poured into water (100 mL). The precipitates were filtered, washed with water and dried in vacuo to yield (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-5,6-difluoro-1,3-dihydro-2H-indol-2-one as yellow solid. Yield: 547 mg, 90%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.58 (s, 6H) 6.81 (dd, J=10.55, 6.74 Hz, 1H) 7.45 (dd, J=10.55, 8.21 Hz, 1H) 7.54 (s, 1H) 10.44 (s, 1H)

Preparation of methyl 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoate

To 10 mL of 1,4-dioxane, was added the following reagents: (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-5,6-difluoro-1,3-dihydro-2H-indol-2-one (250 mg, 0.73 mmol), 4-methoxycarbonylphenylboronic acid (158 mg, 0.88 mmol), PdCl₂(PPh₃)₂ (25 mg, 0.036 mmol), 2M Na₂CO₃ aqueous solution (1.5 mL, 3.0 mmol). The mixture was heated at 86° C. under N₂ for 2 hours, cooled to room temperature and poured into 100 mL of water. The brown precipitates were filtered, washed with water and dried to give the crude product. Purification through silica gel column with 1-2% MeOH/CHCl₃ led to methyl 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoate as orange/red solid. Yield: 112 mg, 39%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.79 (s, 6H) 3.87 (s, 3H) 6.81 (dd, J=10.85, 7.04 Hz, 1H) 7.50 (dd, J=10.55, 8.21 Hz, 1H) 7.85 (s, 1H) 7.95 (d, J=8.50 Hz, 2H) 8.04 (d, J=8.50 Hz, 2H) 10.43 (s, 1H)

LR MS (ES−): 396 (M−1)

Preparation of 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoic acid

To a solution of methyl 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoate (100 mg, 0.25 mmol) in a 1:1 mixture of THF/MeOH (5 mL/5 mL), was added 1M NaOH (2 mL). The mixture was heated in 60° C. bath for 1.5 hours, poured into 100 mL of water and acidified with 2M HCl (2 mL). The precipitates were filtered, washed with water, and dried in vacuum to give 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoic acid as yellow solid. Yield: 90 mg, 93%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.79 (s, 6H) 6.81 (dd, J=10.85, 6.74 Hz, 1H) 7.49 (dd, J=10.41, 8.35 Hz, 1H) 7.84 (s, 1H) 7.92 (d, J=8.50 Hz, 2H) 8.02 (d, J=8.50 Hz, 2H) 10.42 (s, 1H) 13.17 (s, 1H)

LR MS (ES−): 382 (M−1)

Example 179

4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-N-(2,3-dihydroxypropyl)-N-methylbenzamide

A mixture of 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydro furan-3-yl]benzoic acid (50 mg, 0.13 mmol), 3-methylamino-1,2-propanediol (40 mg, 0.38 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU, 61 mg, 0.16 mmol) and diisopropylethylamine (37 mg, 0.29 mmol) in 6 mL of anhydrous DMF was stirred at room temperature for 10 minutes. The mixture was poured into 100 mL of water. The precipitates were filtered, washed with water, and dried in vacuum to give 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-N-(2,3-dihydroxypropyl)-N-methylbenzamide as yellow solid. Yield: 47 mg, 81%.

LR MS (ES−): 469 (M−1)

Example 180

(3E)-5,6-Difluoro-3-[4-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

Similar procedure as Example 179.

LR MS (ES−): 494 (M−1)

Preparation of Examples 181-222 FIG. 4

Each of the examples was prepared through the library synthesis as follows:

To an 8-mL screw cap vial was added 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoic acid (58.5 mg, 0.16 mmol), amine (0.24 mmol, 1.5 eq.), DMF (1 mL), and DIPEA (0.06 mL, 0.35 mmol, 2.2 eq.), and O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) (91 mg, 0.24 mmol, 1.5 eq). The reaction mixture was shaken at room temperature for 24 hours. The resulting clear reaction mixture was submitted for preparative RP-HPLC purification without workup. The library compounds were purified by high throughput RP-HPLC. Each compound was re-analyzed by LCMS after purification.

Example 97 is the compound example for the library synthesis (FIG. 4).

Methyl ({4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoyl}amino)acetate

¹H NMR (300 MHz, DMSO-d₆) δ ppm 10.45 (s, 1H), 9.11 (t, J=5.7 Hz, 1H), 7.97 (d, J=8.4 Hz, 2H), 7.91 (d, J=8.4 Hz, 2H), 7.85 (s, 1H), 7.55 (dd, J=8.4, 5.7 Hz, 1H), 6.75 (ddd, J=2.4, 8.4, 10.5 Hz, 1H), 6.62 (dd, J=2.4, 9.3 Hz, 1H), 4.03 (d, J=5.7 Hz, 2H), 3.66 (s, 3H), 1.79 (s, 6H). ESI-MS m/z 437.4 (M+H)'.

Preparation of 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzaldehyde

Method A: To 10 mL of 1,4-dioxane was added the following reagents: (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (100 mg, 0.31 mmol), 4-formylphenylboronic acid (56 mg, 0.37 mmol), PdCl₂(PPh₃)₂ (22 mg, 0.031 mmol), 1M Na₂CO₃ aqueous solution (1.2 mL, 1.2 mmol). The mixture was heated at 80° C. under N₂ for 1 hour, cooled to room temperature and poured into 100 mL of water. The mixture was extracted with EtOAc (3×50 mL). The organic layers were combined, washed with brine (50 mL), dried over Na₂SO₄, and concentrated to give the crude product, which was purified through silica gel column with 1-5% MeOH/CHCl₃ to give 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzaldehyde as orange/red solid. Yield: 100 mg, 93%.

Method B: To a mixture of (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (2.0 g, 6.17 mmol), 4-formyl phenylboronic acid (1.85 g, 12.3 mmol), aqueous potassium carbonate (1M, 31 mL, 31 mmol) in THF (120 mL) under a nitrogen atmosphere, was added palladium(0)tetrakis(triphenylphosphine) (356 mg, 0.3 mmol, 5 mol %). The mixture was heated at 65° C. overnight (20 h). The reaction was cooled to room temperature and ethyl acetate (500 mL) was added. The organic phase was washed with water (100 mL×2), dried over sodium sulfate, and evaporated. The residue was purified by silica gel column chromatography (5% CH₃OH/CH₂Cl₂ elution). Trituration of the product obtained from the column chromatography with ethyl acetate/hexane (1/1), followed by isolation of the precipitate by filtration, provided 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzaldehyde as a red orange solid (1.1 g, yield 51%).

¹H NMR (300 MHz, DMSO-d₆) δ ppm 10.47 (s, 1H), 10.05 (s, 1H), 8.0 (m, 4H), 7.91 (s, 1H), 7.55 (dd, J=8.4, 6.0 Hz, 1H), 6.75 (ddd, J=10.5, 8.4, 2.4 Hz, 1H), 6.60 (dd, J=9.3, 2.4 Hz, 1H), 1.80 (s, 6H). ESI-MS m/z 350.1 (M+1)⁺.

Example 223

(3E)-6-Fluoro-3-{4-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}methyl)phenyl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one

A mixture of 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzaldehyde (55 mg, 0.16 mmol), 2-(2-(piperazin-1-yl)ethoxy)ethanol (56 mg, 0.32 mmol) and 4 Å molecular sieves (100 mg) in anhydrous DMF (3 mL) was stirred at room temp for 16 hours. To this stirred mixture was added AcOH (10 mg), 1M sodium cyanoborohydride in THF solution (0.32 mL, 0.32 mmol) and 3 mL of anhydrous methanol. The reaction mixture was stirred at room temp for 5 hours and poured into 100 mL of water. Saturated NaHCO₃ solution was then added until pH=9. The precipitates were filtered, washed with water, and dried in vacuo to give the crude product, which was purified through silica gel column with 5-10% MeOH/CHCl₃ to give (3E)-6-fluoro-3-{4-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}methyl)phenyl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one as yellow solid. Yield: 45 mg, 56%.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.78 (s, 6H) 2.36-2.51 (m, 10H) 3.40 (t, J=5.13 Hz, 2H) 3.46-3.52 (m, 6H) 4.61 (s, 1H) 6.62 (dd, J=9.28, 2.44 Hz, 1H) 6.73-6.77 (m, 1H) 7.43 (d, J=8.30 Hz, 2H) 7.55 (dd, J=8.30, 5.86 Hz, 1H) 7.76 (t, J=4.15 Hz, 3H) 10.42 (s, 1H)

LR MS (ES+): 508 (M+1)

The following examples 224-226 were prepared using the experiment procedure described in Example 223, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 224

(3E)-6-Fluoro-3-[4-{4-[(4-hydroxypiperidin-1-yl)methyl]phenyl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.41 (br s, 2H) 1.71 (br s, 2H) 1.78 (s, 6H) 2.07 (br s, 2H) 2.68 (br s, 2H) 3.49 (br s, 3H) 4.55 (br s, 1H) 6.62 (dd, J=9.28, 1.95 Hz, 1H) 6.73-6.77 (m, 1H) 7.43 (d, J=6.83 Hz, 2H) 7.55 (dd, J=8.30, 5.86 Hz, 1H) 7.76 (br s, 3H) 10.42 (s, 1H)

LR MS (ES+): 435 (M+1)

Example 225

(3E)-1-Acetyl-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one

¹H NMR (500 MHz, d₆-DMSO) ppm 1.83 (s, 6H) 2.39 (br s, 4H) 2.65 (s, 3H) 3.54 (br s, 2H) 3.59 (s, 4H) 7.07-7.11 (m, 1H) 7.48 (d, J=7.81 Hz, 2H) 7.78 (dd, J=8.30, 5.86 Hz, 1H) 7.84 (s, 1H) 7.85 (d, J=7.81 Hz, 2H) 7.92 (dd, J=10.74, 2.44 Hz, 1H)

LR MS (ES+): 463 (M+1)

Example 226

(3E)-5-Chloro-3-[4-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]methyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.79 (s, 6H) 2.34-2.44 (m, 10H) 3.46 (q, J=5.28 Hz, 2H) 3.49 (s, 2H) 4.33 (t, J=4.84 Hz, 1H) 6.78 (d, J=8.21 Hz, 1H) 7.07 (dd, J=8.35, 2.20 Hz, 1H) 7.42 (d, J=8.50 Hz, 2H) 7.50 (d, J=2.05 Hz, 1H) 7.76 (d, J=8.50 Hz, 2H) 7.77 (s, 1H) 10.38 (s, 1H)

LR MS (ES+): 480 (M+1)

Preparation of methyl (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-2-oxoindoline-5-carboxylate

To a 0° C. stirred solution of methyl oxindole-5-carboxylate (421 mg, 2.2 mmol) and 4-bromo-5,5-dimethylfuran-2(5H)-one (382 mg, 2.0 mmol) in THF (10 mL), was added 1M LiHMDS/THF solution (4.4 mL, 4.4 mmol) under nitrogen. The mixture was stirred at 0° C. for 80 min, quenched with 2.5M H₂SO₄ (3 mL), and poured into 100 mL of water. The precipitates were filtered, washed with water, and dried in vacuo to give methyl (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-2-oxoindoline-5-carboxylate as yellow solid. Yield: 408 mg, 56%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.61 (s, 6H) 3.83 (s, 3H) 6.91 (d, J=8.21 Hz, 1H) 7.64 (s, 1H) 7.78 (dd, J=8.21, 1.76 Hz, 1H) 8.09 (d, J=1.47 Hz, 1H) 10.76 (s, 1H)

Example 227

Methyl (3E)-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carboxylate

A mixture of methyl (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-2-oxoindoline-5-carboxylate (90 mg, 0.25 mmol), 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine hydrochloride (92 mg, 0.27 mol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with CH₂Cl₂, mg, 0.027 mmol) and 2M Na₂CO₃ (0.5 mL, 1.0 mmol) in 8 mL of DMF was heated in 85° C. bath under nitrogen for 90 minutes. The mixture was cooled to room temperature and poured into 100 mL of water. The precipitates were filtered, washed with water and dried to give the crude product, which was purified through silica gel column with 1-5% MeOH/CHCl₃ to give methyl (3E)-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carboxylate as yellow solid. Yield: 20 mg, 18%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.82 (s, 6H) 2.38 (t, J=4.69 Hz, 4H) 3.53 (s, 2H) 3.59 (t, J=4.69, 4H) 3.84 (s, 3H) 6.91 (d, J=8.21 Hz, 1H) 7.47 (d, J=8.21 Hz, 2H) 7.75 (dd, J=8.21, 1.76 Hz, 1H) 7.80 (d, J=8.50 Hz, 2H) 7.84 (s, 1H) 8.15 (d, J=1.17 Hz, 1H) 10.71 (s, 1H)

The following examples 228 through 235 were prepared using the experiment procedure described in Example 227, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 228

(3E)-5-bromo-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.81 (s, 6H) 2.38 (br s, 4H) 3.52 (br s, 2H) 3.59 (br s, 4H) 6.77 (d, J=8.21 Hz, 1H) 7.22 (dd, J=8.21, 2.05 Hz, 1H) 7.46 (d, J=8.21 Hz, 2H) 7.64 (d, J=1.76 Hz, 1H) 7.79 (d, J=8.21 Hz, 2H) 7.80 (s, 1H) 10.42 (s, 1H)

Example 229

(3E)-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carbonitrile

LR MS (ES+): 428 (M+1)

Example 230

Methyl (3E)-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-6-carboxylate

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.82 (s, 6H) 2.38 (br s, 4H) 3.53 (br s, 2H) 3.59 (br s, 4H) 3.84 (s, 3H) 7.36 (s, 1H) 7.47 (d, J=8.50 Hz, 2H) 7.61 (d, J=7.33 Hz, 1H) 7.68 (d, J=7.92 Hz, 1H) 7.81 (d, J=8.21 Hz, 2H) 7.85 (s, 1H) 10.50 (s, 1H)

LR MS (ES−): 459 (M−1)

Example 231

(3E)-3-{5,5-Dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carboxylic acid

To a stirred solution of methyl (3E)-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carboxylate (18 mg, 0.039 mmol) in MeOH (1 mL) was added 1M NaOH solution (1 mL, 1 mmol). The mixture was heated in 50° C. bath under nitrogen for 4 hours, cooled to room temp, and neutralized with 1M HCl to about pH 7. The mixture was extracted with 10% MeOH/CHCl₃ solution (3×30 mL). The organic layers were combined, dried over Na₂SO₄, and evaporated to dryness to give (3E)-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carboxylic acid as yellow solid. Yield: 15 mg, 88%.

LR MS (ES−): 445 (M−1)

The following examples 232 through 233 were prepared using the experiment procedure described in Example 231, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 232

(3E)-3-{5,5-Dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-6-carboxylic acid

LR MS (ES−): 445 (M−1)

Example 233

(3E)-3-[4-(4-{[4-(Hydroxymethyl)piperidin-1-yl]methyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-2-oxoindoline-5-carboxylic acid

LR MS (ES+): 475 (M+1)

LR MS (ES−): 473 (M−1)

Preparation of 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzaldehyde

To 10 mL of 1,4-dioxane was added (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-5,6-difluoro-1,3-dihydro-2H-indol-2-one (85 mg, 0.25 mmol), 4-formylphenylboronic acid (45 mg, 0.30 mmol), PdCl₂(PPh₃)₂ (10 mg, 0.014 mmol), 2M Na₂CO₃ aqueous solution (0.5 mL, 1.0 mmol). The mixture was heated at 80° C. under N₂ for 30 minutes. After cooling to room temperature, the mixture was diluted with EtOAc (80 mL). The EtOAc solution was washed with brine (2×50 mL), dried over Na₂SO₄, and concentrated to give 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzaldehyde as the crude product, which was used in the next step without further purification.

Example 234

Methyl 1-{4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzyl}piperidine-4-carboxylate

A mixture of 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzaldehyde (60 mg, 0.16 mmol), methyl isonipecotate (50 mg, 0.35 mmol), and 100 mg of 4 Å molecular sieves in 5 mL of anhydrous DMF was stirred under nitrogen for 16 hours. Acetic acid (20 mg) and 1M sodium cyanoborohydride/THF solution (0.35 mL, 0.35 mmol) were then added. The mixture was diluted with 5 mL of anhydrous methanol, stirred at room temperature for 1 hour, and poured into 100 mL of water with stirring. The resulting precipitates were filtered, washed with water, and dried in vacuo to give the crude product, which was purified through silica gel column with 1-5% MeOH/CHCl₃ to give methyl 1-{4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzyl}piperidine-4-carboxylate as yellow solid. Yield: 50 mg, 62%.

LR MS (ES−): 493 (M−1)

Example 235

1-{4-[(5E)-5-(5,6-Difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzyl}piperidine-4-carboxylic acid

To a suspension of methyl 1-{4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzyl}piperidine-4-carboxylate (50 mg, 0.10 mmol) in MeOH (5 mL), was added 1M NaOH (1 mL). The mixture was heated in 50° C. bath for 1 hour, poured into 50 mL of water and neutralized with 0.5M HCl to pH 7. The precipitates were filtered, washed with water, and dried in vacuo to give 1-{4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzyl}piperidine-4-carboxylic acid as a yellow solid. Yield: 9 mg, 19%.

LR MS (ES−): 479 (M−1) Preparation of Examples 236-260 (FIG. 5)

Each of the examples was prepared through the library synthesis as follows: To each 8-mL reaction vial was added 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzaldehyde (25 mg, 0.07 mmol), amine (0.105 mmol, 1.5 eq), 5% HOAc/DMF (v/v) (1 mL), and NaBH(OAc)₃ (45 mg, 0.21 mmol, 3 eq.). The reaction was shaken at room temperature for 20 hours. It was then quenched with water (0.1 mL). The solvents were evaporated in a SpeedVac and the residue was dissolved in DMSO (1 mL). The DMSO solution was submitted for preparative RP-HPLC purification. Each compound was re-analyzed by LCMS after purification.

Preparation of 3-[4-bromo-5,5-dimethyl-5H-furan-(2E)-ylidene]-5-fluoro-1,3-dihydro-indol-2-one

To a solution of 5-fluorooxindole (7.5 g, 49 mmol) in THF (80 mL) at 0° C., was added 1 M LHMDS in THF (100 mL, 100 mmol). The reaction mixture was stirred at 0° C. for 20 minutes. A solution of 4-bromo-5,5-dimethyl-5H-furan-2-one (6.4 g, 33 mmol) in THF (20 mL) was added to the reaction mixture. The reaction was stirred at 0° C. for 30 minutes and then allowed to warm to room temperature over 5 hours. To the reaction mixture was added aqueous 2 M HCl (100 mL). The resulting mixture was stirred at 60-65° C. for 1 hour, cooled to room temperature, poured into water (3000 mL) and stirred at room temperature for 2 hours. The precipitates separated and were collected, washed with water, and dried in vacuo to provide 3-[4-bromo-5,5-dimethyl-5H-furan-(2E)-ylidene]-5-fluoro-1,3-dihydro-indol-2-one as a yellow solid (8.7 g, yield 80%), which was used for the next reaction without further purification.

¹H NMR (300 MHz, DMSO-d₆) δ ppm 0.26 (s, 1H), 7.50 (s, 1H), 7.22 (dd, J=9.0, 2.7 Hz, 1H), 6.84 (ddd, J=11.1, 8.7, 2.7 Hz, 1H), 6.69 (dd, J=8.7, 4.5 Hz, 1H). 1.53 (s, 6H).

ESI-MS m/z 324.0 M⁺.

Preparation of 4-{5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3E)-ylidene]-2,2-dimethyl-2,5-dihydro-furan-3-yl}-benzaldehyde

To a mixture of 3-[4-bromo-5,5-dimethyl-5H-furan-(2E)-ylidene]-5-fluoro-1,3-dihydro-indol-2-one (6.5 g, 20 mmol), 4-formyl phenyl boronic acid (3.6 g, 24 mmol) in THF (250 mL), was added a solution of potassium carbonate (27.6 g, 200 mmol) in water (25 mL). The resulting mixture was deoxygenated with nitrogen, and palladium(0)tetrakis(triphenylphosphine) (1.15 g, 1.0 mmol, 5 mol %) then added. The reaction mixture was heated at 65° C. for 20 hours and then it was allowed to cool to room temperature. Ethyl acetate (800 mL) was added. The organic phase was washed with water (200 mL×2), dried over sodium sulfate and evaporated to give crude product. The purification first by column (SiO₂) chromatography (5% CH₃OH/CH₂Cl₂) and then by titration with ethyl acetate led to 4-{5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3E)-ylidene]-2,2-dimethyl-2,5-dihydro-furan-3-yl}-benzaldehyde as a deep red solid (3.6 g, yield 51.5%).

¹H NMR (300 MHz, DMSO-d₆) δ ppm 10.33 (s, 1H), 10.05 (s, 1H), 8.01 (m, 4H), 7.92 (s, 1H), 7.34 (dd, J=9.0, 2.7 Hz, 1H), 6.90 (ddd, J=9.9, 8.4, 2.7 Hz, 1H), 6.77 (dd, J=8.4, 4.5 Hz, 1H), 1.82 (s, 6H).

ESI-MS m/z 350.1 (M+1)⁺.

Preparation of Examples 261-310 FIG. 6

Each of the examples was prepared through the library synthesis as follows: To each 8-mL reaction vial was added 4-{5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3E)-ylidene]-2,2-dimethyl-2,5-dihydro-furan-3-yl}-benzaldehyde (55 mg, 0.16 mmol), amine (0.24 mmol, 1.5 eq.), 5% HOAc/DMF (v/v) (1 mL), and NaBH(OAc)₃ (62 mg, 0.29 mmol, 1.8 eq.) were added. The reaction was shaken at room temperature overnight. The reaction was quenched with water (0.1 mL), the solvents were evaporated in a SpeedVac, and the residue was dissolved in DMSO (1 mL). The DMSO solution was submitted for preparative RP-HPLC purification. Each compound was re-analyzed by LCMS after purification.

Preparation of 3-[4-(6-chloro-pyridin-3-yl)-5,5-dimethyl-5H-furan-(2E)-ylidene]-6-fluoro-1.3-dihydro-indol-2-one

To 240 mL of 1,4-dioxane, were added (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (3.0 g, 9.3 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with CH₂Cl₂, 360 mg, 0.49 mmol), 1M KF aqueous solution (37.5 mL, 37.5 mmol). The resulting mixture was heated at 70° C. under Ar and then 2-chloro-5-pyridineboronic acid (1.57 g, 10.0 mmol) was added in several portions. The reaction was heated at 70° C. under Ar for 22 hours. LC-MS indicated that no starting material molecular peak left; the major peak at 2.59 min with MH'=357.0 was assigned to the product, 3-[4-(6-chloro-pyridin-3-yl)-5,5-dimethyl-5H-furan-(2E)-ylidene]-6-fluoro-1.3-dihydro-indol-2-one (yield>60%).

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.76 (s, 6H) 6.63 (dd, J=9.28, 2.44 Hz, 1H) 6.73-6.80 (m, 1H) 7.57 (dd, J=8.54, 5.61 Hz, 1H) 7.63 (d, J=8.79 Hz, 1H) 7.88 (s, 1H) 8.28 (dd, J=8.54, 2.68 Hz, 1H) 8.83 (d, J=2.44 Hz, 1H) 10.47 (s, 1H).

Preparation of (3E)-3-[4-(6′-chloro-2,3′-bipyridin-5-yl)-5,5-dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one

A minor product in a similar procedure as 3-[4-(6-chloro-pyridin-3-yl)-5,5-dimethyl-5H-furan-(2E)-ylidene]-6-fluoro-1.3-dihydro-indol-2-one.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.82 (s, 6H) 6.63 (dd, J=9.28, 2.44 Hz, 1H) 6.74-6.80 (m, 1H) 7.58 (dd, J=8.30, 5.37 Hz, 1H) 7.70 (d, J=8.30 Hz, 1H) 7.94 (s, 1H) 8.21 (d, J=8.79 Hz, 1H) 8.37 (dd, J=8.30, 2.44 Hz, 1H) 8.59 (dd, J=8.30, 2.44 Hz, 1H) 9.12 (d, J=1.95 Hz, 1H) 9.19 (d, J=2.44 Hz, 1H) 10.47 (s, 1H)

Preparation of (3E)-3-[5,5-Dimethyl-4-(6-vinylpyridin-3-yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one

Method A: A mixture of 3-[4-(6-chloro-pyridin-3-yl)-5,5-dimethyl-5H-furan-(2E)-ylidene]-6-fluoro-1.3-dihydro-indol-2-one (60 mg, 0.17 mmol), potassium vinyltrifluoroborate (40 mg, 0.30 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with CH₂Cl₂, 10 mg, 0.012 mmol) and triethylamine (60 mg, 0.59 mmol) in isopropanol/water (10 mL/5 mL) solution was heated at 76° C. under nitrogen for 2.5 hours. The reaction was cooled to room temperature and poured into 100 mL of water. The resulting precipitates were filtered, washed with water and dried in vacuo to give (3E)-3-[5,5-dimethyl-4-(6-vinylpyridin-3-yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one as a brown solid. Yield: 50 mg, 85%.

Method B: To a solution of (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (3.0 g, 9.3 mmol, 1 eq.) in 1,4-dioxane (240 mL) were added Pd(dppf)Cl₂ (0.36 g, 0.49 mmol, 0.05 eq.) and 1 M KF aqueous solution (37.5 mL, 37.5 mmol, 4 eq.). The reaction mixture was first heated at 70° C. under Ar and was then added 2-chloro-5-pyridineboronic acid (1.57 g, 10.0 mmol, 1.08 eq.) in several portions in 15 minutes. The reaction mixture was continuously heated at 70° C. under Ar for another 22 hours. LC-MS analysis confirmed that (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one had completely disappeared and 3-[4-(6-chloro-pyridin-3-yl)-5,5-dimethyl-5H-furan-(2E)-ylidene]-6-fluoro-1,3-dihydro-indol-2-one was produced (ESI-MS m/z 357.0 (M+H)⁺).

To the above reaction mixture under Ar were added Potassium vinyltrifluoroborate (4.98 g, 37.2 mmol, 4 eq.) and extra Pd(dppf)Cl₂ (0.36 g, 0.49 mmol, 0.05 eq.). The mixture was heated at 70° C. for 6 hours, cooled to room temperature, and poured into water (300 mL) with stirring. The precipitates were collected by filtration, washed with water (50 mL×2) and dried in vacuo to provide (3E)-3-[5,5-dimethyl-4-(6-vinylpyridin-3-yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one as a brown solid (1.94 g, 60% yield for two steps; >90% purity by ELS).

ESI-MS m/z 349.2 (M+H)⁺.

Preparation of (3E)-3-[5,5-Dimethyl-4-(6′-vinyl-2,3′-bipyridin-5-yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one

Similar procedure as (3E)-3-[5,5-dimethyl-4-(6-vinylpyridin-3-yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one by Method A.

Example 311

(3E)-3-{5,5-Dimethyl-4-[6-(2-morpholin-4-ylethyl)pyridin-3-yl]furan-2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one

A mixture of (3E)-3-[5,5-dimethyl-4-(6-vinylpyridin-3-yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one (50 mg, 0.14 mmol) and morpholine (0.2 mL, 2.3 mmol) in 5 mL of DMF was heated in 96° C. bath under nitrogen for 3 hours. The mixture was cooled to room temperature and poured into 100 mL of water. The precipitates were filtered, washed with water and dried in vacuo to give (3E)-3-{5,5-dimethyl-4-[6-(2-morpholin-4-ylethyl)pyridin-3-yl]furan-2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one as a brown solid. Yield: 40 mg, 64%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.75 (s, 6H) 2.50 (br s, 4H) 2.72 (br s, 2H) 2.96 (t, J=7.92 Hz, 2H) 3.56 (br s, 4H) 6.61 (d, J=9.67 Hz, 1H) 6.74 (t, J=9.53 Hz, 1H) 7.42 (d, J=8.21 Hz, 1H) 7.54 (dd, J=7.77, 6.01 Hz, 1H) 7.80 (s, 1H) 8.11 (br s, 1H) 8.86 (d, J=1.17 Hz, 1H) 10.42 (s, 1H)

LR MS (ES+): 436 (M+1)

Example 312

(3E)-3-{5,5-dimethyl-4-[6′-(2-morpholin-4-ylethyl)-2,3′-bipyridin-5-yl]furan-2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one

Similar procedure as Example 311.

LR MS (ES+): 513 (M+1)

Preparation of Examples 314-331 FIG. 7

Each of the examples was prepared through the library synthesis as follows: To each reaction vial were added (3E)-3-[5,5-dimethyl-4-(6-vinylpyridin-3-yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one (70 mg, 0.20 mmol, 1 eq.), amine (0.40 mmol, 2 eq.) and DMSO (1 mL). The resulting reaction mixtures were heated at 75° C. for either 20 hours or 45 hours (for the reaction mixtures with the less reactive amine). Representative examples of the reactions were monitored by LCMS. After cooling to room temperature, the DMSO solutions were then submitted for preparative RP-HPLC purification. Each compound was re-analyzed by LCMS after purification.

Example 314 is the compound example for the library synthesis (FIG. 7).

(3E)-3-[5,5-Dimethyl-4-(6-{2-[(2-morpholin-4-ylethyl)amino]ethyl}pyridin-3-yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one

To a 8-mL vial were added 3E)-3-[5,5-dimethyl-4-(6-vinylpyridin-3-yl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one (32 mg, 0.095 mmol, 1 eq.), 4-(2-aminoethyl)morpholine (62 mg, 0.48 mmol, 5 eq.) and DMSO (2.5 mL). The reaction was heated at 75° C. for 20 hour. After cooling to room temperature, the DMSO solution was then submitted for preparative RP-HPLC purification to provide (E)-3-(5,5-dimethyl-4-(6-(2-(2-morpholinoethylamino)-ethyl)pyridin-3-yl)furan-2(5H)-ylidene)-6-fluoroindolin-2-one (8.0 mg, 18% yield) as a brown solid.

ESI-MS m/z 479.1 (M+H)⁺.

Preparation of (3E)-6-fluoro-3-[4-(6-fluoropyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

To 10 mL of 1,4-dioxane were added (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (200 mg, 0.62 mmol), 6-fluoropyridin-3-ylboronic acid (104 mg, 0.74 mmol), PdCl₂(PPh₃)₂ (22 mg, 0.031 mmol), 1M Na₂CO₃ aqueous solution (2.5 mL, 2.5 mmol). The mixture was heated at 88° C. under N₂ for 2 hours, cooled to room temperature and poured into 100 mL of water. The precipitates were filtered, washed with water and dried to give the crude product. Purification of the crude product through silica gel column with 1-5% MeOH/CHCl₃ afforded (3E)-6-fluoro-3-[4-(6-fluoropyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as a yellow solid. Yield: 100 mg, 47%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.75 (s, 6H) 6.61 (dd, J=9.38, 2.64 Hz, 1H) 6.70-6.77 (m, 1H) 7.30 (dd, J=8.65, 3.08 Hz, 1H) 7.54 (dd, J=8.35, 5.72 Hz, 1H) 7.81 (s, 1H) 8.39-8.45 (m, 1H) 8.65 (d, J=2.64 Hz, 1H) 10.43 (s, 1H)

LR MS (ES−): 339 (M−1)

Example 332

(3E)-6-Fluoro-3-{4-[6-(4-hydroxypiperidin-1-yl)pyridin-3-yl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one

A mixture of (3E)-6-fluoro-3-[4-(6-fluoropyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one (50 mg, 0.15 mmol) and 4-hydroxypiperidine (50 mg, 0.49 mL) in anhydrous DMSO (3 mL) was heated at 100° C. under nitrogen for 6 hours. The mixture was cooled to room temp and poured into 100 mL of water. The precipitates were filtered, washed with water and dried in vacuo to give (3E)-6-fluoro-3-{4-[6-(4-hydroxypiperidin-1-yl)pyridin-3-yl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one as a yellow solid. Yield: 55 mg, 89%.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.33-1.40 (m, 2H) 1.76 (s, 6H) 1.75-1.82 (m, 2H) 3.25-3.30 (m, 2H) 3.73-3.79 (m, 1H) 4.08-4.13 (m, 2H) 4.74 (d, J=4.39 Hz, 1H) 6.60 (dd, J=9.76, 2.44 Hz, 1H) 6.70-6.75 (m, 1H) 6.95 (d, J=8.79 Hz, 1H) 7.53 (dd, J=8.30, 5.86 Hz, 1H) 7.58 (s, 1H) 7.93 (dd, J=9.03, 2.68 Hz, 1H) 8.51 (d, J=2.44 Hz, 1H) 10.35 (s, 1H)

LR MS (ES+): 422 (M+1)

Example 333

(3E)-6-Fluoro-3-[4-(6-{4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}pyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

Similar procedure as Example 332.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.76 (s, 6H) 2.50-2.54 (m, 6H) 3.42 (t, J=5.13 Hz, 2H) 3.50 (q, J=5.21 Hz, 2H) 3.56 (t, J=5.86 Hz, 2H) 3.63 (t, J=5.37 Hz, 4H) 4.61 (t, J=5.37 Hz, 1H) 6.60 (dd, J=9.52, 2.20 Hz, 1H) 6.71-6.75 (m, 1H) 6.94 (d, J=9.28 Hz, 1H) 7.53 (dd, J=8.30, 5.86 Hz, 1H) 7.60 (s, 1H) 7.95 (dd, J=9.28, 2.44 Hz, 1H) 8.53 (d, J=2.44 Hz, 1H) 10.36 (s, 1H)

LR MS (ES+): 495 (M+1)

Preparation of Examples 334-369 FIG. 8

Each of the examples was prepared through the library synthesis as follows: To each 8-mL screw cap reaction vial were added (3E)-6-fluoro-3-[4-(6-fluoropyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one (40 mg, 0.11 mmol), amine (0.25 mmol, 2.3 eq.), DMSO (1 mL), and DIPEA (0.1 mL, 5 eq.). The vial was flushed with nitrogen, capped, and heated at 115-120° C. for 18 hours. After cooling to room temperature, the reaction mixtures were filtered through a plug of cotton and the resulting DMSO solutions were submitted for preparative RP-HPLC purification. Each compound was re-analyzed by LCMS after purification.

Example 338 is the compound example for the library synthesis (FIG. 8):

(3E)-3-[5,5-Dimethyl-4-{6-[(2-morpholin-4-ylethyl)amino]pyridin-3-yl}furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one

32.6 mg, yield 65.7%.

¹H NMR (300 MHz, DMSO-d₆) δ ppm 10.32 (s, 1H), 8.40 (d, J=2.4 Hz, 1H), 7.80 dd, J=9.0, 2.4 Hz, 1H), 7.52 (s, 1H), 7.50 (dd, J=8.4, 6.3 Hz, 1H), 7.25 (m, 1H), 6.71 (ddd, J=10.5, 8.4, 2.7 Hz, 1H), 6.62 (d, J=8.4 Hz, 1H), 6.60 (dd, J=9.0, 2.4 Hz, 1H), 3.57 (t, J=5.4 Hz, 4H), 3.45 (m, 2H), 2.45-2.55 (m, 4H), 2.38-2.44 (m, 2H), 1.75 (s, 6H).

ESI-MS m/z 450.6 (M)⁺.

Preparation of 5-fluoro-3-[4-(6-fluoro-pyridin-3-yl)-5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one

To a mixture or 3-[4-bromo-5,5-dimethyl-5H-furan-(2E)-ylidene]-5-fluoro-1,3-dihydro-indol-2-one (3.24 g, 10.0 mmol), 6-fluoropyridin-3-ylboronic acid (1.8 g, 12 mmol) in THF (150 mL), was added a solution of potassium carbonate (13.8 g, 100 mmol) in water (20 mL). The resulting mixture was deoxygenated by bubbling nitrogen through the reaction mixture for 3 minutes and palladium(0)tetrakis(triphenylphosphine) (578 mg, 5 mol %) was then added. The reaction mixture was heated at 65° C. for 18 hours. The reaction was cooled to room temperature and ethyl acetate (500 mL) added. The organic phase was washed with water (100 mL×2), dried over sodium sulfate, and evaporated to give the crude product, which was purified first by silica gel column chromatography (5% CH₃OH/CH₂Cl₂ elution) and then by titration with ethyl acetate. The resulting product was isolated by filtration and dried under vacuum to provide 5-fluoro-3-[4-(6-fluoro-pyridin-3-yl)-5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one as a yellow solid (1.6 g, yield 48%).

¹H NMR (300 MHz, DMSO-d₆) δ ppm 10.31 (s, 1H), 8.67 (d, J=2.7 Hz, 1H), 8.44 (ddd, J=8.4, 7.5, 2.7 Hz, 1H), 7.84 (s, 1H), 7.33 (m, 2H), 6.89 (ddd, J=9.6, 8.4, 2.7 Hz, 1H), 6.76 (dd, J=8.4, 4.5 Hz, 1H), 1.79 (s, 6H).

ESI-MS m/z 341.3 (M+1)⁺

Preparation of Examples 370-420 FIG. 8

Each of the examples was prepared through the library synthesis as follows: To each 8-mL screw cap reaction vial were added 5-fluoro-3-[4-(6-fluoro-pyridin-3-yl)-5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one (55 mg, 0.16 mmol), amine (0.24 mmol, 1.5 eq.), DIPEA (0.1 mL, 0.57 mmol, 3.6 eq.) and DMSO (1.0 mL). The reaction vial was capped and heated at 110° C. for 20 h. After cooling to room temperature, the resulting solution was submitted for preparative RP-HPLC purification. Each compound was re-analyzed by LCMS after purification.

Preparation of (3E)-5,6-difluoro-3-[4-(6-fluoropyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

To 10 mL of 1,4-dioxane were added (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-5,6-difluoro-1,3-dihydro-2H-indol-2-one (150 mg, 0.44 mmol), 6-fluoropyridin-3-ylboronic acid (74 mg, 0.53 mmol), PdCl₂(PPh₃)₂ (22 mg, 0.031 mmol), 2M Na₂CO₃ aqueous solution (0.6 mL, 1.2 mmol). The mixture was heated at 78° C. under N₂ for 3 hours, cooled to room temperature and poured into 100 mL of water. The precipitates were filtered, washed with water and dried to give the crude product. Purification of the crude product through silica gel column with 1-3% MeOH/CHCl₃ gave (3E)-5,6-difluoro-3-[4-(6-fluoropyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as a yellow solid (yield: 60 mg, 38%).

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.77 (s, 6H) 6.80 (dd, J=10.70, 6.89 Hz, 1H) 7.31 (dd, J=8.79, 2.93 Hz, 1H) 7.49 (dd, J=10.55, 8.21 Hz, 1H) 7.80 (s, 1H) 8.40-8.47 (m, 1H) 8.67 (d, J=2.64 Hz, 1H) 10.41 (s, 1H)

Example 421

(3E)-3-[4-{6-[(2,3-Dihydroxypropyl)(methyl)amino]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-5,6-difluoro-1,3-dihydro-2H-indol-2-one

A mixture of (3E)-5,6-difluoro-3-[4-(6-fluoropyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one (50 mg, 0.14 mmol) and 3-methylamino-1,2-propanediol (50 mg, 0.48 mmol) in 5 mL of DMF was heated in 100° C. bath under nitrogen for 16 hours. The mixture was cooled to room temp and poured into 100 mL of water. The precipitates were filtered, washed with water and dried in vacuo to give (3E)-3-[4-{6-[(2,3-dihydroxypropyl)(methyl)amino]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-5,6-difluoro-1,3-dihydro-2H-indol-2-one as a brown solid. Yield: 51 mg, 82%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.76 (s, 6H) 3.14 (s, 3H) 3.31-3.37 (m, 2H) 3.44 (dd, J=13.78, 7.04 Hz, 1H) 3.67-3.79 (m, 2H) 4.65 (t, J=5.57 Hz, 1H) 4.82 (d, J=4.98 Hz, 1H) 6.73-6.80 (m, 2H) 7.44 (dd, J=10.70, 8.06 Hz, 1H) 7.53 (s, 1H) 7.91 (dd, J=9.09, 2.64 Hz, 1H) 8.50 (d, J=2.34 Hz, 1H) 10.29 (s, 1H)

LR MS (ES−): 442 (M−1)

Preparation of (3E)-6-fluoro-3-[4-(2-fluoropyridin-4-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

Method A: To 10 mL of 1,4-dioxane were added (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (200 mg, 0.62 mmol), 2-fluoropyridin-4-ylboronic acid (104 mg, 0.74 mmol), PdCl₂(PPh₃)₂ (22 mg, 0.031 mmol), 1M Na₂CO₃ aqueous solution (2.5 mL, 2.5 mmol). The mixture was heated at 96° C. under N₂ for 4 hours, cooled to room temperature and poured into 150 mL of water. The precipitates were filtered, washed with water and dried to give the crude product. Purification of the crude product through silica gel column with 1-5% MeOH/CHCl₃ led to (3E)-6-fluoro-3-[4-(2-fluoropyridin-4-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as a brown solid. Yield: 100 mg, 48%.

Method B: To a mixture of (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (2.0 g, 6.1 mmol), 2-fluoropyridine-4-boronic acid (1.1 g, 8.0 mmol), potassium fluoride (1.8 g, 5 eq.) in dioxane (50 mL) and water (5 mL) under a nitrogen atmosphere, was added [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (250 mg, 5%). The mixture was heated at 80° C. for 20 hour. The reaction was allowed to cool to room temperature and ethyl acetate (350 mL) was added. The organic phase was washed with water (100 mL×2) and evaporated to provide the crude product. The crude product was purified by column chromatography (silica gel, 5% CH₃OH/CH₂Cl₂ elution) and then recrystallized from ethyl acetate/hexanes (80/20) to provide (3E)-6-fluoro-3-[4-(2-fluoropyridin-4-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as a yellow-orange solid (1.2 g, yield 57%).

¹H NMR (300 MHz, DMSO-d₆) δ 10.50 (s, 1H), 8.34 (d, J=5.4 Hz, 1H), 7.99 (s, 1H), 7.55 (dd, J=8.4, 6.0 Hz, 1H), 7.71 (d, J=5.7 Hz, 1H), 7.50-7.58 (m, 2H), 6.73 (dt, J=10.2, 2.4 Hz, 1H), 6.62 (dd, J=15.6, 5.4 Hz, 1H), 1.77 (s, 6H). ESI-MS m/z 341.1 (M+1)⁺.

Example 422

(3E)-6-fluoro-3-[4-(2-{4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}pyridin-4-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

A mixture of (3E)-6-fluoro-3-[4-(2-fluoropyridin-4-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one (50 mg, 0.15 mmol) and 2-(2-(piperazin-1-yl)ethoxy)ethanol (50 mg, 0.29 mmol) in 2 mL of DMSO was heated in 105° C. bath for 6 hours. The mixture was cooled to room temp and poured into 100 mL of water. The precipitates were filtered, washed with water and dried in vacuo to give (3E)-6-fluoro-3-[4-(2-{4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}pyridin-4-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as a brown solid. Yield: 64 mg, 89%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.72 (s, 6H) 2.48-2.53 (m, 6H) 3.38-3.56 (m, 10H) 4.61 (br s, 1H) 6.60 (dd, J=9.38, 2.35 Hz, 1H) 6.70-6.77 (m, 1H) 6.89 (d, J=5.28 Hz, 1H) 6.92 (s, 1H) 7.54 (dd, J=8.35, 5.72 Hz, 1H) 7.80 (s, 1H) 8.19 (d, J=5.28 Hz, 1H) 10.45 (s, 1H)

LR MS (EI+): 495 (MH⁺)

Example 423

(3E)-6-Fluoro-3-{4-[2-(4-hydroxypiperidin-1-yl)pyridin-4-yl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one

Similar procedure as Example 422.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.30-1.42 (m, 2H) 1.72 (s, 6H) 1.73-1.82 (m, 2H) 3.08-3.17 (m, 2H) 3.65-3.74 (m, 1H) 4.02-4.10 (m, 2H) 4.67 (d, J=4.10 Hz, 1H) 6.61 (dd, J=9.38, 2.64 Hz, 1H) 6.70-6.77 (m, 1H) 6.83 (dd, J=5.28, 1.17 Hz, 1H) 6.91 (s, 1H) 7.54 (dd, J=8.35, 5.72 Hz, 1H) 7.79 (s, 1H) 8.18 (d, J=5.28 Hz, 1H) 10.44 (s, 1H)

LR MS (EI+): 422 (MH⁺)

Preparation of Examples 424-454 FIG. 9

Each of the examples was prepared through the library synthesis as follows: To each 8-mL screw cap reaction vial were added (3E)-6-fluoro-3-[4-(2-fluoropyridin-4-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one (40 mg, 0.11 mmol), amine (0.25 mmol, 2.3 eq.), DMSO (1 mL), and DIPEA (0.1 mL, 5 eq.). The reaction was heated at 115-120° C. for 1-4 days and monitored by LCMS. After cooling to room temperature, the reaction mixtures were filtered through a plug of cotton and the resulting DMSO solutions were submitted for preparative RP-HPLC purification. Each compound was re-analyzed by LCMS after purification.

Example 426 is the compound example for the library synthesis (FIG. 9).

(3E)-3-[5,5-dimethyl-4-{2-[(2-morpholin-4-ylethyl)amino]pyridin-4-yl}furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one

25.2 mg, yield 51%.

¹H NMR (300 MHz, DMSO-d₆) δ 10.45 (s, 1H), 8.04 (d, J=5.7 Hz, 1H), 7.78 (s, 1H), 7.53 (dd, J=8.4, 5.7 Hz, 1H), 6.86 (s, 1H), 6.70-6.80 (m, 2H), 6.60-6.65 (m, 2H), 3.06 (m, 4H), 2.38-3.44 (m, 2H), 2.45-2.5 (m, 2H), 2.38-2.44 (m, 4H), 1.74 (s, 6H).

ESI-MS m/z 450.9 (M+H)⁺.

Preparation of 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]thiophene-2-carbaldehyde

To 30 mL of 1,4-dioxane were added (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (600 mg, 1.85 mmol), 5-formylthiophene-3-boronic acid (348 mg, 2.23 mmol), PdCl₂(PPh₃)₂ (60 mg, 0.085 mmol), 1M Na₂CO₃ aqueous solution (7.4 mL, 7.4 mmol). The mixture was heated at 80° C. under N₂ for 3.5 hours, cooled to room temperature and poured into 200 mL of water. The mixture was extracted with EtOAc (3×80 mL). The organic layers were combined, washed with brine (50 mL), dried over Na₂SO₄, and concentrated to give the crude product, which was purified through silica gel column with 1-5% MeOH/CHCl₃ to give 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]thiophene-2-carbaldehyde as brown solid. Yield: 458 mg, 70%.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.78 (s, 6H) 6.62 (dd, J=9.52, 2.20 Hz, 1H) 6.74-6.78 (m, 1H) 7.56 (dd, J=5.37, 2.93 Hz, 1H) 7.77 (s, 1H) 8.65 (d, J=1.46 Hz, 1H) 8.70 (t, J=1.46 Hz, 1H) 10.02 (s, 1H) 10.44 (s, 1H)

Example 455

(3E)-6-Fluoro-3-[4-{5-[(4-hydroxypiperidin-1-yl)methyl]-3-thienyl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

A mixture of 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]thiophene-2-carbaldehyde (120 mg, 0.34 mmol), 4-hydroxypiperidine (69 mg, 0.68 mmol) and 100 mg of 4 Å molecular sieves in 5 mL of anhydrous DMF was stirred under nitrogen for 16 hours. Acetic acid (20 mg) and 1M sodium cyanoborohydride (0.68 mL, 0.68 mmol) were then added. The mixture was diluted with 5 mL of anhydrous methanol and stirred at room temperature for 3 hours. The mixture was poured into 100 mL of water with stirring, and basified to about pH 8 with saturated NaHCO₃ solution. The resulting precipitates were filtered, washed with water, and dried in vacuo to give the crude product, which was purified through silica gel column with 10-20% MeOH/CHCl₃ to give (3E)-6-fluoro-3-[4-{5-[(4-hydroxypiperidin-1-yl)methyl]-3-thienyl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one as yellow powder. Yield: 38 mg, 26%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.32-1.43 (m, 2H) 1.66-1.72 (m, 2H) 1.73 (s, 6H) 2.09 (t, J=9.67 Hz, 2H) 2.67-2.74 (m, 2H) 3.40-3.49 (m, 1H) 3.66 (s, 2H) 4.52 (d, J=4.40 Hz, 1H) 6.59 (dd, J=9.38, 2.35 Hz, 1H) 6.68-6.75 (m, 1H) 7.42 (s, 1H) 7.49-7.53 (m, 2H) 8.04 (d, J=1.47 Hz, 1H) 10.37 (s, 1H)

LR MS (ES−): 439 (M−1)

Example 456

(3E)-6-Fluoro-3-{4-[5-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}methyl)-3-thienyl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one

Similar procedure as Example 455.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.73 (s, 6H) 2.38-2.47 (m, J=6.16 Hz, 10H) 3.37 (t, J=4.98 Hz, 2H) 3.46 (q, J=6.16 Hz, 4H) 3.68 (s, 2H) 6.59 (dd, J=9.38, 2.05 Hz, 1H) 6.68-6.75 (m, 1H) 7.44 (s, 1H) 7.49-7.54 (m, 2H) 8.05 (d, J=1.17 Hz, 1H) 10.38 (s, 1H)

LR MS (ES+): 514 (M+1)

Preparation of Examples 457-475 FIG. 5

Each of the examples was prepared through the library synthesis as follows:

To each 8-mL reaction vial were added 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]thiophene-2-carbaldehyde (25 mg, 0.07 mmol), amine (0.105 mmol, 1.5 eq), 5% HOAc/DMF (v/v) (1 mL), and NaBH(OAc)₃ (45 mg, 0.21 mmol, 3 eq.). The resulting reaction mixture was shaken at room temperature for 20 hours. It was then quenched by the addition of water (0.1 mL). The solvents were evaporated in a SpeedVac and the residue was dissolved in DMSO (1 mL). The DMSO solutions were submitted for preparative RP-HPLC purification. Each compound was re-analyzed by LCMS after purification.

Example 476

(3E)-6-Fluoro-3-{4-[4-(2-hydroxyethyl)piperazin-1-yl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one

A mixture of (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (95 mg, 0.29 mmol) and 1-(2-hydroxyethyl)piperazine (0.40 mL, 3.3 mmol) in 6 mL of DMF was heated in 100° C. bath for 2 hours. The mixture was cooled, diluted with ethyl acetate (60 mL), washed with brine (3×50 mL), and concentrated to give the crude product, which was purified by silica gel chromatography with 5-20% methanol in chloroform to give (3E)-6-fluoro-3-{4-[4-(2-hydroxyethyl)piperazin-1-yl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one as a grey solid. Yield: 73 mg, 67%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.64 (s, 6H) 2.42 (t, J=6.16 Hz, 2H) 2.51 (br s, 4H) 3.41 (br s, 4H) 3.51 (q, J=5.96 Hz, 2H) 4.44 (t, J=5.28 Hz, 1H) 6.10 (s, 1H) 6.50 (dd, J=9.53, 2.49 Hz, 1H) 6.56-6.63 (m, 1H) 7.33 (dd, J=8.35, 5.72 Hz, 1H) 10.02 (s, 1H)

LR MS (ES−): 372 (M−1)

Example 477

(3E)-3-{4-[(2,4-Dimethoxybenzyl)amino]-5,5-dimethylfuran-2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one

Similar procedure as Example 476.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.56 (s, 6H) 3.75 (s, 3H) 3.83 (s, 3H) 4.25 (d, J=5.37 Hz, 2H) 5.96 (s, 1H) 6.49-6.54 (m, 2H) 6.58-6.62 (m, 2H) 7.11 (d, J=8.30 Hz, 1H) 7.34 (dd, J=8.30, 5.86 Hz, 1H) 8.00 (t, J=5.61 Hz, 1H) 9.98 (s, 1H)

LR MS (ES+): 411 (M+1)

LR MS (ES−): 409 (M−1)

Preparation of 6-fluoro-N-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]nicotinamide

To a stirred solution of (3E)-3-{4-[(2,4-dimethoxybenzyl)amino]-5,5-dimethylfuran-2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one (370 mg, 0.90 mmol) in 5 mL of methylene chloride was added 5 mL of TFA. The mixture was stirred at room temperature for 1 hour and evaporated to dryness. The residue was re-dissolved in ethyl acetate (80 mL), washed with saturated NaHCO₃ solution (2×30 mL) and brine (30 mL), dried over Na₂SO₄, and evaporated to dryness to afford the enamine intermediate as a light yellow solid. The enamine was dissolved in 10 mL of dry THF, and then cooled to 0° C. Pyridine (0.5 mL, 6.2 mmol) and 6-fluoronicotinoyl chloride (180 mg, 1.13 mmol) were then added. The mixture was allowed to warm up to room temperature and stirred for 1 hour. The mixture was diluted with ethyl acetate (80 mL), washed with 0.1M HCl (2×30 mL), saturated NaHCO₃ (30 mL) and brine (30 mL), concentrated, and purified by silica gel chromatography to give 6-fluoro-N-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]nicotinamide as a yellow solid. Yield: 150 mg, 43%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.51 (s, 6H) 6.02 (s, 1H) 6.49 (dd, J=9.53, 2.49 Hz, 1H) 6.53-6.61 (m, 1H) 7.29-7.36 (m, 2H) 7.38 (br s, 1H) 8.42-8.49 (m, 1H) 8.78 (d, J=1.76 Hz, 1H) 9.90 (s, 1H)

LR MS (ES−): 382 (M−1)

Example 478

N-[(5E)-5-(6-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-6-[4-(2-hydroxyethyl)piperazin-1-yl]nicotinamide

To a stirred solution of 6-fluoro-N-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]nicotinamide (75 mg, 0.20 mmol) in DMF (3 mL) was added 1-(2-hydroxyethyl)piperazine (70 mg, 0.54 mmol). The reaction mixture was heated in 66° C. bath for 30 minutes, cooled to room temperature, and diluted with ethyl acetate (80 mL). The ethyl acetate solution was washed with brine (4×20 mL), dried over Na₂SO₄, and concentrated to give the crude product. Purification of the crude product by silica gel chromatography with a gradient of methanol in chloroform (5-20%) gave N-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-6-[4-(2-hydroxyethyl)piperazin-1-yl]nicotinamide as a yellow solid. Yield: 42 mg, 43%.

LR MS (ES+): 494 (M+1)

LR MS (ES−): 492 (M−1)

Example 479

(3E)-6-Bromo-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-1,3-dihydro-2H-indol-2-one

A mixture of (3E)-6-bromo-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-1,3-dihydro-2H-indol-2-one (2.3 g, 6.0 mmol) and morpholine (1.0 mL, 11.4 mmol) in 10 mL of DMF was heated in 96 C bath for 3 hours. The mixture was cooled to room temperature and poured into 200 mL of water. The precipitates were filtered, washed with water, and dried in vacuo to give (3E)-6-bromo-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-1,3-dihydro-2H-indol-2-one as a brown solid. Yield: 2.1 g, 89%.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.68 (s, 6H) 3.45 (br s, 4H) 3.70 (br s, 4H) 6.18 (s, 1H) 6.85 (s, 1H) 6.98 (d, J=7.81 Hz, 1H) 7.32 (d, J=7.32 Hz, 1H) 10.05 (s, 1H)

Example 480

(3E)-3-(5,5-Dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-6-iodo-1,3-dihydro-2H-indol-2-one

To a heavy-wall pressure tube were added (3E)-6-bromo-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-1,3-dihydro-2H-indol-2-one (1.6 g, 4.09 mmol), copper(I)iodide (39 mg, 0.20 mmol), sodium iodide (1.23 g, 8.18 mmol), rac-trans-N,N′-dimethylcyclohexane-1,2-diamine (58 mg, 0.41 mmol), and 20 mL of anhydrous 1,4-dioxane. The mixture was purged with nitrogen, sealed and heated in 110° C. bath for 3 days. The mixture was poured into 200 mL of water. The precipitates were filtered, washed with water and dried in vacuo to give the crude product, (3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-6-iodo-1,3-dihydro-2H-indol-2-one, as a brown solid. Yield: 2.1 g. This crude material was used in the next step without further purification.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.67 (s, 6H) 3.45 (t, J=4.88 Hz, 4H) 3.69 (t, J=4.88 Hz, 4H) 6.18 (s, 1H) 7.01 (d, J=1.46 Hz, 1H) 7.14 (dd, J=7.81, 1.46 Hz, 1H) 7.21 (d, J=7.81 Hz, 1H) 10.01 (s, 1H)

LR MS (ES+): 439 (M+1)

Example 481

(3E)-3-[5,5-Dimethyl-4-(morpholin-4-ylcarbonyl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one

A pressure tube was charged with (3E)-3-(4-bromo-5,5-dimethylfuran-2(5H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one (60 mg, 0.19 mmol), morpholine (48 mg, 0.56 mmol), Mo(CO)₆ (49 mg, 0.19 mmol), palladium(II) acetate (4.0 mg, 0.018 mmol), DBU (85 mg, 0.56 mmol) and anhydrous THF (3 mL). The tube was immediately capped under nitrogen and heated in 108° C. bath for 1 hour. After cooling, the reaction mixture was filtered through a short celite pad. The filtrate was concentrated and purified by silica gel flash chromatography (5-10% MeOH in CHCl₃) to give (3E)-3-[5,5-dimethyl-4-(morpholin-4-ylcarbonyl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one as a yellow solid. Yield: 39 mg, 55%.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.61 (s, 6H) 3.53-3.65 (m, 8H) 6.62 (dd, J=9.28, 2.44 Hz, 1H) 6.74-6.78 (m, 1H) 7.36 (s, 1H) 7.52 (dd, J=8.30, 5.86 Hz, 1H) 10.46 (s, 1H)

LR MS (ES−): 357 (M−1)

Example 482

(3E)-6-Fluoro-3-[4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one

Similar procedure as Example 481.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.67 (s, 6H) 2.44 (t, J=6.10 Hz, 2H) 2.53 (t, J=4.88 Hz, 4H) 3.43 (t, J=4.88 Hz, 4H) 3.53 (q, J=5.37 Hz, 2H) 4.46 (t, J=5.37 Hz, 1H) 6.12 (s, 1H) 6.52 (dd, J=9.28, 2.44 Hz, 1H) 6.60-6.64 (m, 1H) 7.35 (dd, J=8.30, 5.37 Hz, 1H) 10.04 (s, 1H)

LR MS (ES+): 402 (M+1)

Example 483

Methyl 2-{[(3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}benzoate

A 25 mL reaction vessel was charged with (3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-6-iodo-1,3-dihydro-2H-indol-2-one (100 mg, 0.23 mmol), methyl thiosalicylate (77 mg, 0.46 mmol), PdCl₂(dppf). CH₂Cl₂ (19 mg, 0.023 mmol), cesium carbonate (225 mg, 0.69 mmol) and 8 mL of anhydrous DMF. The mixture was purged with nitrogen and heated in 90° C. bath for 2.5 hours. The mixture was cooled to room temperature, diluted with 50 mL of water and extracted with EtOAc (3×50 mL). The organic layers were combined, washed with saturated NaHCO₃ (50 mL), brine (2×50 mL), dried over Na₂SO₄, and concentrated to give a brown oil. Purification of the oily mixture by silica gel chromatography eluted with 1-10% MeOH/CHCl₃ provided methyl 2-{[(3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}benzoate as a brown solid. Yield: 60 mg, 55%.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.70 (s, 6H) 3.48 (br s, 4H) 3.71 (br s, 4H) 3.87 (s, 3H) 6.23 (s, 1H) 6.77 (d, J=8.30 Hz, 1H) 6.83 (d, J=1.46 Hz, 1H) 7.03 (dd, J=7.81, 1.46 Hz, 1H) 7.16-7.19 (m, 1H) 7.35-7.38 (m, 1H) 7.52 (d, J=7.81 Hz, 1H) 7.89 (d, J=7.81 Hz, 1H) 10.08 (s, 1H)

LR MS (ES+): 479 (M+1)

Example 484

2-{[(3E)-3-(5,5-Dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}benzoic acid

A mixture of methyl 2-{[(3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}benzoate (50 mg) and 1M NaOH (3 mL) in 20 mL of MeOH was heated in 66° C. bath for 2 hours. The mixture was cooled to room temp, poured into 100 mL of water, and acidified to about pH 3. The precipitates were filtered, washed with water and dried in vacuo to give 2-{[(3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}benzoic acid as a brown solid. Yield: 50 mg, 97%.

LR MS (ES−): 463 (M−1)

Example 485

2-{[(3E)-3-(5,5-Dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}-N-methylbenzamide

To a stirred solution of 2-{[(3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}benzoic acid in 5 mL of anhydrous DMF, were added 2M methylamine in THF solution (0.066 mL, 0.13 mmol), HBTU (49 mg, 0.13 mmol) and DIPEA (31 mg, 0.24 mmol). The reaction mixture was stirred at room temperature for 15 minutes and poured into 100 mL of water. The precipitates were filtered, washed with water and dried to give the crude product as a brown solid. Purification of the crude product by silica gel chromatography eluted with a gradient of 5-15% MeOH in CHCl₃ afforded 2-{[(3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]thio}-N-methylbenzamide as brown solid. Yield: 6 mg, 12%.

¹H NMR (300 MHz, d₆-DMSO) δ ppm 1.70 (s, 6H) 2.78 (d, J=4.69 Hz, 3H) 3.47 (br s, 4H) 3.71 (br s, 4H) 6.22 (s, 1H) 6.79-6.84 (m, 2H) 6.99 (dd, J=7.92, 1.47 Hz, 1H) 7.11-7.16 (m, 1H) 7.20-7.27 (m, 1H) 7.41 (dd, J=7.33, 1.47 Hz, 1H) 7.48 (d, J=7.92 Hz, 1H) 8.32 (br s, 1H) 10.05 (s, 1H)

LR MS (ES−): 476 (M−1)

Example 486

N-(3-{[(3E)-3-(5,5-Dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]amino}phenyl)acetamide

A 25 mL reaction flask was charged with (3E)-6-bromo-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-1,3-dihydro-2H-indol-2-one (100 mg, 0.26 mmol), N-(4-aminophenyl)acetamide (46 mg, 0.31 mmol), dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (4.9 mg, 0.012 mmol), Pd₂(dba)₃ (4.8 mg, 0.0052 mmol), 1M LiHMDS in THF (0.83 mL, 0.83 mmol) and dry THF (10 mL). The mixture was purged with nitrogen and heated in 62° C. bath under nitrogen for 2 hours. After cooling to room temperature, the reaction mixture was quenched with 0.5 mL of 2M HCl, and diluted with ethyl acetate (100 mL). The solution was washed with saturated NaHCO₃ (2×50 mL), brine (50 mL), and concentrated to give the crude product. Purification of the crude product by silica gel chromatography with a gradient of methanol in chloroform (5-10%) led to N-(3-{[(3E)-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-2-oxo-2,3-dihydro-1H-indol-6-yl]amino}phenyl)acetamide as a yellow solid. Yield: 20 mg, 17%.

¹H NMR (500 MHz, d₆-DMSO) δ ppm 1.66 (s, 6H) 2.00 (s, 3H) 3.39 (t, J=4.39 Hz, 4H) 3.69 (t, J=4.39 Hz, 4H) 6.15 (s, 1H) 6.53 (s, 1H) 6.63 (t, J=7.57 Hz, 2H) 6.94 (d, J=8.30 Hz, 1H) 7.05 (t, J=8.06 Hz, 1H) 7.29 (d, J=7.81 Hz, 1H) 7.34 (s, 1H) 7.91 (s, 1H) 9.73 (s, 1H) 9.81 (s, 1H)

LR MS (ES−): 459 (M−1)

The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention only. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. For example novel compounds of formula VIII, below may be utilized in the method of treating diseases described above.

wherein D is a 5-membered unsaturated heterocyclic group, R⁸, R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen, halogen, nitro, hydroxy, hydrocarbyl, substituted hydrocarbyl, amide, thioamide, amine, thioether and sulfonyl.

Such modifications are intended to fall within the scope of the appended claims.

All references cited herein are hereby incorporated by reference in their entirety.

The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. However, it is apparent for one of ordinary skill in the art that further compounds with the desired pharmacological properties can be prepared in an analogous manner, and that the disclosed compounds can also be obtained from different starting compounds via different chemical reactions. Similarly, different pharmaceutical compositions may be prepared and used with substantially the same result. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the appended claims. 

1. A compound represented by one of the general formulae:

wherein X is O or S; Y is selected from the group consisting of O, S, NR³ and CR³R⁴; and wherein the ring system represented by A in formula V, below, is a 5 or 6 membered aryl group,

wherein said aryl group is selected from the group consisting of:

and wherein the ring system represented by B in formula VI, above, is a five membered unsaturated heterocyclic ring wherein said unsaturated heterocyclic ring is selected from the group consisting of:

wherein Z is selected from the group consisting of [C(R²)₂]_(c), O, NR³ and S;

and wherein the ring system represented by C in formula VII, above, is a 5 or 6 membered aryl group e.g. a carbocyclic aryl or heterocyclic aryl, wherein said aryl group is selected from the group consisting of:

wherein R¹ is selected from the group consisting of halogen, aryl, C₁ to C₈ alkyl, C₂ to C₈ alkenyl; CF₃, OCF₃, OCF₂H, S(O)_(f)R², (CR³R⁴)_(d)C(O)OR², O(CR³R⁴)_(e)C(O)OR², NR²(CR³R⁴)_(d)C(O)R², NR²(CR³R⁴)_(d)C(O)OR², OP(O)(OR²)₂, OC(O)OR², OCH₂O, NR²(CH₂)_(e)N(R²)₂, O(CH₂)_(e)N(R²)₂, (CR³R⁴)_(d)CN, O(CR³R⁴)_(e)CN, (CR³R⁴)_(g)Ar, NR²(CR³R⁴)_(e)Ar, O(CR³R⁴)_(e)Ar, S(O)_(f)(CR³R⁴)_(e)Ar, (CR³R⁴)_(e)SO₂R², (CR³R⁴)_(e)C(O)N(R²)₂, NR²(CR³R⁴)_(e)C(O)N(R²)₂, O(CR³R⁴)_(d)C(O)N(R²)₂, C(O)(CR²CR³)_(e)Ar, S(O)_(f)(CR³R⁴)_(e)C(O)N(R²)₂, (CR³R⁴)_(d)OR², NR²(CR³R⁴)_(e)OR², O(CR³R⁴)_(e)OR², S(O)_(f)(CR³R⁴)_(d)OR², C(O)(CR³R⁴)_(d)R³, NR²C(O)(CR³R⁴)_(e)R³, OC(O)(CR³R⁴)_(d)N(R²)₂, C(O)(CR³R⁴)_(e)N(R²)₂, NR²C(O)(CR³R⁴)_(d)N(R²)₂, OC(O)(CR³R⁴)_(d)N(R²)₂, (CR³R⁴)_(d)R³, NR²(CR³R⁴)_(d)R³, O(CR³R⁴)_(d)R³, S(O)_(f)(CR³R⁴)_(d)R³, (CR³R⁴)_(e)N(R²)₂, NR²(CR³R⁴)_(e)N(R²)₂, O(CR³R⁴)_(e)N(R²)₂, S(O)_(f) (CR³R⁴)_(d)N(R²)₂; R² is selected from the group consisting of hydrogen, C₁ to C₈ alkyl, C₂ to C₈ alkenyl, C₂ to C₈ alkynyl, C₁ to C₄ alkylol, lower alkylphenyl, phenyl, (CR³R⁴)_(d)Ar, (CR³R⁴)_(d)C(O)OR⁶, (CR³R⁴)_(d)SO₂R⁶, (CR³R⁴)_(d)OR⁶, (CR³R⁴)_(d)OSO₂R⁶, (CR³R⁴)_(d)P(O)(OR⁶)₂, (CR³R⁴)_(d)R⁶, (CR³R⁴)_(e)N(R⁶)₂ and (CR³R⁴)_(e)NR⁶C(O)N(R⁶)₂; wherein N(R⁶)₂ may form a 3-7 membered heterocyclic ring, for example, pyrrolidine, 3-fluoropyrrolidine, piperidine, 4-fluoropiperidine, N-methylpiperazine, morpholine, 2,6-dimethylmorpholine, thiomorpholine, and wherein said heterocyclic ring may be substituted with one or more of R³; and [C(R²)₂]_(c) may form a 3-7 membered carbocyclic or heterocyclic ring; R is selected from the group consisting of halogen, C₁ to C₈ alkyl, C₂ to C₈ conjugated alkenyl, (CR²═CR²)_(d)CON(R²)₂, CF₃, OCF₃, OCF₂H, (CR³R⁴)_(d)CN, NR²(CR³R⁴)_(e)CN, O(CR³R⁴)_(e)CN, S(O)_(f)R², (CR³R⁴)_(d)C(O)OR², NR²(CR³R⁴)_(d)C(O)OR², O(CR³R⁴)_(d)C(O)OR², S(O)_(f)(CR³R⁴)_(d)C(O)OR², (CR³R⁴)_(d)Ar, NR²(CR³R⁴)_(d)Ar, O(CR³R⁴)_(d)Ar, S(O)_(f)(CR³R⁴)_(d)Ar, (CR³R⁴)_(d)SO₂R², NR²(CR³R⁴)_(d)S(O)_(f)R², O(CR³R⁴)_(d)S(O)_(f)R², S(O)_(f)(CR³R⁴)_(e)S(O)_(f)R², (CR³R⁴)_(d)C(O)N(R²)₂, NR²(CR³R⁴)_(d)C(O)N(R²)₂, O(CR³R⁴)_(d)C(O)N(R²)₂, S(O)_(f)(CR³R⁴)_(e)C(O)N(R²)₂, (CR³R⁴)_(d)OR², NR² (CR³R⁴)_(e)OR², O(CR³R⁴)_(e)OR², S(O)_(f)(CR³R⁴)_(d)OR², (CR³R⁴)_(d)OSO₂R², NR²(CR³R⁴)_(e)OSO₂R², O(CR³R⁴)_(e)OSO₂R², S(O)_(f)(CR³R⁴)_(e)OSO₂R²(CR³R⁴)_(d)P(O)(OR²)₂, NR² (CR³R⁴)_(d)P(O)(OR²)₂, O(CR³R⁴)_(d)P(O)(OR²)₂, S(O)_(f)(CR³R⁴)_(e)P(O)(OR²)₂, C(O)(CR³R⁴)_(d)R³, NR²C(O)(CR³R⁴)_(d)R³, OC(O)(CR³R⁴)_(d)N(R²)₂, C(O)(CR³R⁴)_(d)N(R²)₂, NR²C(O)(CR³R⁴)_(d)N(R²)₂, OC(O)(CR³R⁴)_(d)N(R²)₂, (CR³R⁴)_(d)R³, NR²(CR³R⁴)_(d)R³, O(CR³R⁴)_(d)R³, S(O)_(f)(CR³R⁴)_(d)R³, HNC(O)R², HN—C(O)OR², (CR³R⁴)_(d)N(R²)₂, NR²(CR³R⁴)_(e)N(R²)₂, O(CR³R⁴)_(e)N(R²)₂, S(O)_(f) (CR³R⁴)_(d)N(R²)₂, OP(O)(OR²)₂, OC(O)OR², OCH₂O, HN—CH═CH, —N(COR²)CH₂CH₂, HC═N—NH, N═CH—S, (CR³R⁴)_(d)C═C(CR³R⁴)_(d)R², (CR³R⁴)_(d)C═C(CR³R⁴)_(d)OR², (CR³R⁴)_(d)C═C(CR³R⁴)_(d)N(R²)₂, (CR³R⁴)_(d)CC(CR³R⁴)_(d)R², (CR³R⁴)_(d)CC(CR³R⁴)_(e)OR², (CR³R⁴)_(d)CC(CR³R⁴)_(e)N(R²)₂, (CR³R⁴)_(d)C(O)(CR³R⁴)_(d)R², (CR³R⁴)_(d)C(O)(CR³R⁴)_(d)OR² and (CR³R⁴)_(d)C(O)(CR³R⁴)_(d)N(R²)₂; R³ and R⁴ may be selected from the group consisting of H, F, hydroxy, and C₁-C₄ alkyl or CR³R⁴ may represent a carbocyclic or heterocyclic ring of from 3 to 6 carbons or alternatively, (CR³R⁴)_(d) and (CR³R⁴)_(e) may form a 3-7 membered carbocyclic or heterocyclic ring, preferably R³ and R⁴ are H, F, CH₃ or hydroxy; R⁵ is Ar—R¹ _(b) wherein Ar is 5-7 membered carbocyclic aryl or 5-7 membered heterocyclic aryl; R⁶ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, hydroxylmethyl and phenyl; R⁷ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, (R²CCR²)aCN and aryl; a is 0 or an integer of from 1 to 3; b is 0 or an integer of from 1 to 2; c is an integer of from 1 to 2; d is 0 or an integer of from 1 to 5; e is an integer of from 1 to 4; f is 0 or an integer of from 1 to 2; g is an integer of from 2 to 5, and further provided said alkyl or aryl radicals may be substituted with one or two halo, hydroxy, lower alkyloxy, lower alkyl amino or cycloalkylamino radicals wherein the cycloalkyl ring can include an enchained oxygen, sulfur or additional nitrogen atom and may be substituted with one or two halo or lower alkyl radicals; and pharmaceutically acceptable salts thereof.
 2. The compound of claim 1 wherein A is a carbocyclic aryl group.
 3. The compound of claim 1 wherein A is a heterocyclic aryl group.
 4. The compound of claim 1 wherein R¹ is a carbocyclic aryl group.
 5. The compound of claim 1 wherein R¹ is a heterocyclic aryl group.
 6. The compound of claim 1 wherein N(R²) is selected from the group consisting of pyrrolidine, 3-fluoropyrrolidine, piperidine, 4-fluoropiperidine, N-methylpiperazine, morpholine, 2,6-dimethylmorpholine, thiomorpholine wherein said heterocyclic ring may be substituted with one or more of R³.
 7. A method for treating diseases related to unregulated tyrosine kinase signal transduction, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim
 1. 8. The method of claim 7 wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
 9. The method of claim 8 wherein the blood vessel proliferative disorder is selected from the group consisting of diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, arthritis and restenosis.
 10. The method of claim 7 wherein the fibrotic disorder is selected from the group consisting of hepatic cirrhosis and atherosclerosis.
 11. The method of claim 7 wherein the mesangial cell proliferative disorder is selected from the group consisting of glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection and glomerulopathies.
 12. The method of claim 7 wherein the metabolic disorder is selected from the group consisting of psoriasis, diabetes mellitus, wound healing, inflammation and neurodegenerative diseases.
 13. The compound of claim 1 selected from the group consisting of (3E)-6-fluoro-3-{4-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, 6-Fluoro-3-[4-[4-(3-hydroxy-pyrrolidine-1-carbonyl)-phenyl]-5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one, 4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-N-(2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl)benzamide methyl (3E)-3-{5,5-dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carboxylate, methyl (3E)-3-{5,5-dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-6-carboxylate, (3E)-3-{5,5-dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-N-methyl-2-oxoindoline-6-carboxamide, methyl (3E)-3-{5,5-dimethyl-4-[4-(pyrrolidin-1-ylcarbonyl)phenyl]furan-2(5H)-ylidene}-5-fluoro-2-oxoindoline-6-carboxylate, methyl (3E)-3-[4-(4-{[(2,3-dihydroxypropyl)(methyl)amino]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-5-fluoro-2-oxoindoline-6-carboxylate, 4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-N-(2,3-dihydroxypropyl)-N-methylbenzamide, ethyl (2S)-2-({4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoyl}amino)-4-(methylthio)butanoate, (3E)-6-fluoro-3-[4-(4-{[3-(hydroxymethyl)piperidin-1-yl]carbonyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, ethyl 3-({4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoyl}amino)propanoate, methyl (2S)-2-({4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoyl}amino)-3-hydroxypropanoate, N-(2,3-dihydroxypropyl)-4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-N-methylbenzamide, methyl 1-{4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoyl}piperidine-4-carboxylate, methyl (3E)-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-6-carboxylate, (3E)-3-{5,5-dimethyl-4-[4-(morpholin-4-ylmethyl)phenyl]furan-2(5H)-ylidene}-2-oxoindoline-5-carboxylic acid, (3E)-3-[4-(4-{[4-(hydroxymethyl)piperidin-1-yl]methyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-2-oxoindoline-5-carboxylic acid, methyl 1-{4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzyl}piperidine-4-carboxylate, 1-{4-[(5E)-5-(5,6-difluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzyl}piperidine-4-carboxylic acid, (3E)-6-fluoro-3-[4-{4-[(3-hydroxypiperidin-1-yl)methyl]phenyl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-(4-{[3-(2-hydroxyethyl)piperidin-1-yl]methyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, methyl 1-{4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzyl}-4-hydroxypyrrolidine-2-carboxylate (3E)-3-[5,5-dimethyl-4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]methyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-5-fluoro-3-[4-(4-{[3-(hydroxymethyl)piperidin-1-yl]methyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-5-fluoro-3-{4-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}methyl)phenyl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one, (3E)-3-[4-(4-{[(2,3-dihydroxypropyl)(methyl)amino]methyl}phenyl)-5,5-dimethylfuran-2(5H)-ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-3-[5,5-dimethyl-4-(4-{[(2S,3R,4S,5R)-3,4,5-trihydroxy-2-methylpiperidin-1-yl]methyl}phenyl)furan-2(5H)-ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one, 1-{4-[(5E)-5-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzyl}piperidine-4-carboxylic acid, (3E)-3-{5,5-dimethyl-4-[6-(2-morpholin-4-ylethyl)pyridin-3-yl]furan-2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-(6-{2-[3-(hydroxymethyl)piperidin-1-yl]ethyl}pyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-{6-[2-(4-hydroxypiperidin-1-yl)ethyl]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-(6-{4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}pyridin-3-yl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-{6-[2-(hydroxymethyl)morpholin-4-yl]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-3-[4-{6-[(1,1-dioxidotetrahydro-3-thienyl)(methyl)amino]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-{6-[4-(hydroxymethyl)piperidin-1-yl]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-{6-[(2-hydroxyethyl)(2-pyridin-4-ylethyl)amino]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-{6-[4-(2-hydroxyethyl)piperazin-1-yl]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (4-{5-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]pyridin-2-yl}piperazin-1-yl)acetic acid, 6-Fluoro-3-[4-{6-[(2-hydroxy-ethyl)-(2-pyridin-4-yl-ethyl)-amino]-pyridin-3-yl}-5,5-dimethyl-5H-furan-(2E)-ylidene]-1,3-dihydro-indol-2-one, ethyl (4-{5-[(5E)-5-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]pyridin-2-yl}piperazin-1-yl)acetate, (3E)-3-[4-{6-[(2,3-dihydroxypropyl)(methyl)amino]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-5-fluoro-3-[4-{6-[(2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl)amino]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, 1-{5-[(5E)-5-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]pyridin-2-yl}piperidine-4-carboxylic acid, (3E)-3-[4-{6-[(2,3-dihydroxypropyl)(methyl)amino]pyridin-3-yl}-5,5-dimethylfuran-2(5H)-ylidene]-5,6-difluoro-1,3-dihydro-2H-indol-2-one, ethyl (2S)-2-({4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]pyridin-2-yl}amino)-4-(methylthio)butanoate, (3E)-6-fluoro-3-[4-{2-[4-(hydroxymethyl)piperidin-1-yl]pyridin-4-yl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-{2-[(2-hydroxyethyl)(2-pyridin-4-ylethyl)amino]pyridin-4-yl}-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, methyl [({4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-2-thienyl}methyl)amino]acetate, (3E)-3-{5,5-dimethyl-4-[5-(morpholin-4-ylmethyl)-3-thienyl]furan-2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]methyl}-3-thienyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-3-[4-(5-{[ethyl(2-pyridin-2-ylethyl)amino]methyl}-3-thienyl)-5,5-dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-3-[4-(5-{[bis(2-methoxyethyl)amino]methyl}-3-thienyl)-5,5-dimethylfuran-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-{4-[4-(2-hydroxyethyl)piperazin-1-yl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one, (3E)-3-{4-[(2,4-dimethoxybenzyl)amino]-5,5-dimethylfuran-2(5H)-ylidene}-6-fluoro-1,3-dihydro-2H-indol-2-one, N-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]-6-[4-(2-hydroxyethyl)piperazin-1-yl]nicotinamide, (3E)-6-(4-methoxyphenyl)-3-[4-(4-methoxyphenyl)-5,5-dimethylfuran-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-6-bromo-3-(5,5-dimethyl-4-morpholin-4-ylfuran-2(5H)-ylidene)-1,3-dihydro-2H-indol-2-one, 6-Fluoro-3-(4-{4-[2-(2-hydroxy-ethoxy)-ethyl]-piperazin-1-yl}-5H-furan-2-ylidene)-1,3-dihydro-indol-2-one, 3-{4-[4-(2-Diethylamino-ethoxy)-phenylamino]-5H-furan-2-ylidene}-6-flu(3E)-3-(3,3′-bifuran-5(2H)-ylidene)-6-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-(1H-pyrrol-3-yl)furan-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-[4-(3-thienyl)furan-2(5H)-ylidene]-1,3-dihydro-2H-indol-2-one oro-1,3-dihydro-indol-2-one, 3-{4-[5-(6-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidene)-2,5-dihydro-furan-3-yl]-phenyl}-propionic acid, 6-Fluoro-3-{4-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-5H-furan-2-ylidene}-1,3-dihydro-indol-2-one, (3E)-3-[5,5-dimethyl-4-(3-thienyl)furan-2(5H)-ylidene]-6-fluoro-1,3-dihydro-2H-indol-2-one, (3E)-6-fluoro-3-{4-[4-(3-hydroxypropyl)phenyl]-5,5-dimethylfuran-2(5H)-ylidene}-1,3-dihydro-2H-indol-2-one, methyl ({4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]benzoyl}amino)acetate, ethyl 3-{4-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]phenyl}propanoate, and N-{3-[(5E)-5-(6-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,2-dimethyl-2,5-dihydrofuran-3-yl]phenyl}acetamide. 